<SEC-DOCUMENT>0001437749-24-027977.txt : 20240829
<SEC-HEADER>0001437749-24-027977.hdr.sgml : 20240829
<ACCEPTANCE-DATETIME>20240829060251
ACCESSION NUMBER:		0001437749-24-027977
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20240829
DATE AS OF CHANGE:		20240829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioCardia, Inc.
		CENTRAL INDEX KEY:			0000925741
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				232753988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281448
		FILM NUMBER:		241258306

	BUSINESS ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		650-226-0123

	MAIL ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiger X Medical, Inc.
		DATE OF NAME CHANGE:	20110616

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardo Medical, Inc.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLICKNSETTLE COM INC
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>bcda20240827_s1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:bcda="http://www.bcda.com/20240829"><head>
	<title>bcda20240827_s1a.htm</title>

	<!-- Generated by ThunderDome Portal - 8/29/2024 6:54:32 AM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>

<ix:nonNumeric contextRef="d2024S1A" name="dei:AmendmentFlag" id="ixv-3822">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d2024S1A" name="dei:EntityCentralIndexKey" id="ixv-3823">0000925741</ix:nonNumeric>
<ix:nonNumeric contextRef="d2024S1A" id="DT" name="dei:DocumentType">S-1/A</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcda-20240829.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d2024S1A">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-08-29</xbrli:startDate>
<xbrli:endDate>2024-08-29</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>As filed with the Securities and Exchange Commission on August 29, 2024.</b></div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: right;"><b>Registration No.</b>&#160;<b>333-281448</b>&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family: Times New Roman; font-size: 16pt; margin: 0pt; text-align: center;"><b>UNITED STATES</b><br/>
<b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family: Times New Roman; font-size: 12pt; margin: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<div style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>AMENDMENT NO. 1 TO</b></div>

<div style="font-family: Times New Roman; font-size: 16pt; margin: 0pt; text-align: center;"><b>FORM</b>&#160;<b><span style="-sec-ix-hidden:DT">S-1</span></b></div>

<div style="font-family: Times New Roman; font-size: 16pt; margin: 0pt; text-align: center;"><b>REGISTRATION STATEMENT</b></div>

<div style="font-family: Times New Roman; font-size: 12pt; margin: 0pt; text-align: center;"><i>Under</i></div>

<div style="font-family: Times New Roman; font-size: 12pt; margin: 0pt; text-align: center;"><i>THE SECURITIES ACT OF 1933</i></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin: 0pt; text-align: center;"><ix:nonNumeric contextRef="d2024S1A" name="dei:EntityRegistrantName" id="ixv-42"><b>BioCardia, Inc.</b></ix:nonNumeric></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Exact name of Registrant as specified in its charter)</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d2024S1A" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-53"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2836</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d2024S1A" name="dei:EntityTaxIdentificationNumber" id="ixv-60"><b>23-2753988</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(State or other jurisdiction of</b><br/>
			<b>incorporation or organization)</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Primary Standard Industrial</b><br/>
			<b>Classification Code Number)</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(I.R.S. Employer</b><br/>
			<b>Identification Number)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d2024S1A" name="dei:EntityAddressAddressLine1" id="ixv-85"><b>320 Soquel Way</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d2024S1A" name="dei:EntityAddressCityOrTown" id="ixv-89"><b>Sunnyvale</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d2024S1A" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-91"><b>California</b></ix:nonNumeric> <ix:nonNumeric contextRef="d2024S1A" name="dei:EntityAddressPostalZipCode" id="ixv-93"><b>94085</b></ix:nonNumeric></b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(650) 226-0120</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:99.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Peter Altman</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>President and Chief Executive Officer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>320 Soquel Way</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sunnyvale, California 94085</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(650) 226-0120</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:99.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><i>Copies to:</i></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Michael J. Danaher</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Austin D. March</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Wilson Sonsini Goodrich &amp; Rosati,</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Professional Corporation</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>650 Page Mill Road</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Palo Alto, CA 94304</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(650) 493-9300</b></div>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Ron Ben-Bassat</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Eric Victorson</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sullivan &amp; Worcester LLP</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>1251 Avenue of the Americas</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>New York, NY 10020</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(212) 660-3000</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;"><b>Approximate date of commencement of proposed sale to the public:</b>&#160;As soon as practicable after this Registration Statement becomes effective.</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, or Securities Act, check the following box. &#9746;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221;&#160;&#8220;accelerated filer,&#8221;&#160;&#8220;smaller reporting company,&#8221;&#160;and &#8220;emerging growth company&#8221;&#160;in Rule&#160;12b-2 of the Securities Exchange Act of 1934, or the Exchange Act.</div>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt;">Large accelerated filer</div>
			</td>
			<td style="vertical-align: top; width: 30%;">&#9744;</td>
			<td colspan="1" style="vertical-align: top; width: 20%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accelerated filer</div>
			</td>
			<td style="vertical-align: top; width: 20%;">&#9744;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt;"><ix:nonNumeric contextRef="d2024S1A" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-3834">Non-accelerated filer</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top; width: 30%;">&#9746;</td>
			<td colspan="1" style="vertical-align: top; width: 20%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Smaller reporting company</div>
			</td>
			<td style="vertical-align: top; width: 20%;"><ix:nonNumeric contextRef="d2024S1A" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-3835">&#9746;</ix:nonNumeric></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">&#160;</td>
			<td colspan="1" style="vertical-align: top; width: 20%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company</div>
			</td>
			<td style="vertical-align: top; width: 20%;"><ix:nonNumeric contextRef="d2024S1A" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-3836">&#9744;</ix:nonNumeric></td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; vertical-align: top; text-indent: 36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; vertical-align: top; text-indent: 36pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;"><ix:nonNumeric contextRef="d2024S1A" name="dei:AmendmentDescription" id="ixv-208"><b>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section</b>&#160;<b>8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section</b>&#160;<b>8(a), may determine.</b></ix:nonNumeric></div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#ff0000;"><b>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ff0000;"><b>Preliminary Prospectus subject to completion dated August 29, 2024</b></span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to&#160;2,439,024&#160;Shares of Common Stock</b><br/>
<b>Up to</b>&#160;<b>2,439,024</b> <b>Pre-Funded Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b> <b>Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b> <b>Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants</b><br/>
<b>Up to</b>&#160;<b>2,439,024</b> <b>Shares of Common Stock issuable upon exercise of the Warrants</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="logo01.jpg" src="logo01.jpg"/></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are offering, on a best efforts basis, up to&#160;2,439,024 shares of our common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), together with up to&#160;2,439,024 common warrants each of which is exercisable for one share of Common Stock (the &#8220;Common Warrants&#8221;). Each share of our Common Stock or each pre-funded warrant to purchase a share of Common Stock (a &#8220;Pre-Funded Warrant&#8221;) in lieu thereof, is being sold together with one Common Warrant. The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering but must be purchased together in this offering.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We have assumed a combined public offering price of $2.46&#160;per share of Common Stock and accompanying Common Warrant. The Common Warrants will be exercisable immediately, have an assumed exercise price equal to 110% of the combined public offering price per share of Common Stock and accompanying Common Warrant in this offering (or $2.71&#160;per share at such assumed combined public offering price) and will expire five years from the date of issuance. The actual combined public offering price will be determined between us, A.G.P./Alliance Global Partners (&#8220;AGP&#8221; or the &#8220;Placement Agent&#8221;) and the investors in the offering at pricing and may be at a discount to the current market price of our Common Stock. Therefore, the assumed combined public offering price used throughout this prospectus may not be indicative of the final offering price.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are also offering Pre-Funded Warrants to purchase up to 2,439,024 shares of Common Stock to those purchasers whose purchase of shares of Common Stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, in lieu of shares of Common Stock that would result in beneficial ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock. Each Pre-Funded Warrant is exercisable for one share of our Common Stock and has an exercise price of $0.001 per share. Each Pre-Funded Warrant is being offered together with one Common Warrant. The Pre-Funded Warrants and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. For each Pre-Funded Warrant that we sell, the number of shares of Common Stock we are offering will be reduced on a one-for-one basis.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to this prospectus, we are also offering the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants and Common Warrants offered hereby. These securities are being sold in this offering to certain purchasers under a securities purchase agreement dated&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 between us and the purchasers.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have engaged the Placement Agent in connection with the securities offered by this prospectus. The Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of securities but has agreed to use its best efforts to sell the securities offered by this prospectus. We have agreed to pay the Placement Agent a fee based upon the aggregate gross proceeds raised in this offering as set forth in the table below.</div>

<div style="margin: 0pt; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, certain members of our Board of Directors and non-director executive officers have indicated their preliminary interest in purchasing a portion of our Common Stock and accompanying Common Warrants in this offering. Because this indication of preliminary interest is not a binding agreement or commitment to purchase, such persons could determine to purchase more, fewer or no securities in this offering, or we could determine to sell more, fewer or no securities to them.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The shares of our Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants being offered will be sold in a single closing. The shares issuable upon exercise of the Pre-Funded Warrants or Common Warrants will be issued upon the exercise thereof. Because there is no minimum number of securities or minimum aggregate amount of proceeds for this offering to close, we may sell fewer than all of the securities offered hereby, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus. Because there is no escrow account and there is no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Also, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. The offering of the shares of our Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants will terminate no later than September 27, 2024; however, the shares of our Common Stock underlying the Pre-Funded Warrants and the Common Warrants will be offered on a continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our Common Stock is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BCDA.&#8221; On August 27, 2024, the last reported closing sale price of our Common Stock on Nasdaq was $2.46&#160;per share. There is no established trading market for any of the Common Warrants and we do not expect a market to develop. We do not intend to apply for a listing for the Pre-Funded Warrants or Common Warrants on any national securities exchange.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share and</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Per Pre-Funded</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Warrant and</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Common</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Public offering price</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement Agent Fees(1)</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds, before expenses, to us(2)</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upon the closing of this offering, we will pay the Placement Agent a cash placement commission equal to 7.0% of the aggregate gross proceeds to us from the sale of the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, together with the accompanying Common Warrants, sold in this offering (the &#8220;Base Fee&#8221;); provided, however, (i) that such commission percentage will be reduced to a fee of up to 3.5% for any proceeds to us from sales to our directors, our executive officers or certain other identified purchasers and any other purchaser brought to the offering by the Company (each such identified purchaser, an &#8220;Identified Purchaser&#8221;) (collectively, the &#8220;Cash Fee&#8221;), (ii) that such commission percentage shall be 5.0% for the first $3,000,000 of any sale of the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, together with the accompanying Common Warrants, purchased by any of the persons pursuant to which the Company is required to pay a tail fee to a prior placement agent (the &#8220;Tail Investors&#8221;) and (iii) that such commission percentage shall be 4.0% for amounts invested in excess of the first $3,000,000 of any sale of the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, together with the accompanying Common Warrants, purchased by the Tail Investors. No Cash Fee will be payable in respect of any Pre-Funded Warrant or Common Warrant exercises that may occur in the future. We have also agreed to reimburse the Placement Agent at closing (i) for legal and other expenses incurred by it in connection with the offering in an aggregate amount of up to $50,000, and (ii) non-accountable expenses payable to the Placement Agent of up to $10,000. See &#8220;Plan of Distribution&#8221; for a complete description of compensation payable to the Placement Agent.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The amount of proceeds, before expenses, to us does not give effect to any exercise of the Pre-Funded Warrants or Common Warrants.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investing in our securities involves a high degree of risk. See </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page 5</b><b>&#160;of this prospectus to read about the factors you should consider before buying our securities.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Delivery of the Common Stock, or Pre-Funded Warrants in lieu thereof, and Common Warrants to purchasers is expected to be made on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Sole Placement Agent</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>A.G.P.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b> </b>, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 95%;">&#160;</td>
			<td style="vertical-align: top; width: 5%; text-align: right;"><span style="text-decoration: underline;"><b>Page</b></span></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 95%;">&#160;</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PROSPECTUS SUMMARY</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">1</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">RISK FACTORS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">5</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">9</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MARKET, INDUSTRY AND OTHER DATA</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">10</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">USE OF PROCEEDS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">11</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DIVIDEND POLICY</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">12</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAPITALIZATION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">13</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DILUTION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">14</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DESCRIPTION OF SECURITIES</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">15</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK, PRE-FUNDED WARRANTS AND COMMON WARRANTS</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">18</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PLAN OF DISTRIBUTION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">25</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LEGAL MATTERS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXPERTS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">WHERE YOU CAN FIND MORE INFORMATION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Neither we nor the Placement Agent have authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained or incorporated by reference in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of securities.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For investors outside the United States, neither we nor the Placement Agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required. Persons outside the United States who come into possession of this prospectus and any free writing prospectus related to this offering are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">-i-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS SUMMARY</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>This summary highlights certain information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. Before investing in our securities, you should read this entire prospectus and the documents incorporated by reference carefully, including the </i>&#8220;<i>Risk Factors,</i>&#8221;<i> and the financial statements and accompanying notes and other information included and incorporated by reference in this prospectus. Unless otherwise indicated or the context otherwise requires, references in this prospectus to </i>&#8220;<i>BioCardia,</i>&#8221;<i> the </i>&#8220;<i>Company,</i>&#8221;&#160;&#8220;<i>we,</i>&#8221;&#160;&#8220;<i>us</i>&#8221;<i> and </i>&#8220;<i>our</i>&#8221;<i> refer to BioCardia, Inc. and its subsidiaries taken as a whole.</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our Business</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">We are a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. We are advancing two cell therapy platforms derived from the bone marrow in clinical trials today. Our CardiAMP&#174; autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Our immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as an &#8220;off the shelf&#8221; cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO&#8482;), which is actively enrolling, and acute respiratory distress syndrome (ARDS).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Our autologous CardiAMP and our allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by our Helix&#8482; minimally invasive intramyocardial therapeutic delivery platform. We partner this therapeutic delivery platform and provide development services selectively with others seeking to develop biotherapeutic interventions for local delivery to the heart.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Associated with Our Business</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. See &#8220;Risk Factors&#8221; below. The principal factors and uncertainties that make investing in our company risky include, among others:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Business, Financial Condition and Capital Requirements</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We will require substantial additional financing to achieve our goals, and our failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have a history of operating losses, and we may not be able to achieve or sustain profitability.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our existing and any future contractual arrangement that we expect will provide us access to capital may provide less capital than expected and on a delayed basis.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Development and Commercialization</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our success depends in large part on our ability to obtain approval for, and successfully commercialize, the CardiAMP Cell Therapy System. Because the CardiAMP Cell Therapy System is, to our knowledge, the first cardiac cell-based therapy with an accepted pivotal trial that is to be regulated by the FDA via the premarket approval pathway, the approval process for the CardiAMP Cell Therapy System is uncertain.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our cell therapy systems and other therapeutic candidates are based on novel technology, which makes it difficult to accurately and reliably predict the time and cost of product development and subsequently obtaining regulatory approval. At the moment, no cell-based therapies have been approved in the United States for a cardiac indication.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have encountered, and may in the future encounter, substantial delays in our clinical studies.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our therapeutic candidates.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We rely on third parties to conduct some or all aspects of our product manufacturing, diagnostic protocol development, research, and preclinical and clinical testing, and these third parties may not perform satisfactorily.</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-1-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We rely on third parties to conduct, supervise and monitor our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We depend on third-party vendors to manufacture some of our components and sub-assemblies, which could make us vulnerable to supply shortages and price fluctuations that could harm our business.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our future commercial success depends upon attaining significant market acceptance of our therapeutic candidates, if approved, among physicians, patients and healthcare payors.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our ability to compete is highly dependent on demonstrating the benefits of CardiAMP to physicians, hospitals and patients.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than we do.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our therapeutic candidates, if approved, we may be unable to generate any revenues.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have limited experience manufacturing our therapeutic candidates or products in commercial quantities, which could harm our business.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we fail to obtain and sustain an adequate level of reimbursement for our products by third-party payors, sales and profitability would be adversely affected.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Relating to Government Regulation, Compliance and Litigation</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Even if we obtain regulatory approval for a product candidate, including our cell therapy systems and other therapeutic candidates, these products or therapies, along with our other regulated products, will be subject to ongoing regulatory scrutiny.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory agencies.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our therapeutic candidates or products, or if clearances or approvals for our therapeutic candidates or products in additional indications are delayed or not issued, our commercial operations would be harmed.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our therapeutic candidates or products or limit the scope of any approved indication or market acceptance.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our therapeutic candidates are intended to treat patients who are extremely ill, and patient deaths that occur in our clinical trials could negatively impact our business even if they are not shown to be related to our therapeutic candidates.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we or our suppliers fail to comply with the FDA's QSRs, or QMSR, when it goes into effect in 2026, our manufacturing operations could be delayed or shut down and product sales could suffer.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The requirements to obtain regulatory approval of the FDA and regulators in other jurisdictions can be costly, time-consuming, and unpredictable. If we are unable to obtain timely regulatory approval for our therapeutic candidates, our business may be substantially harmed.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Even if we obtain and maintain approval for our therapeutic candidates or products from the FDA, we may never obtain approval for our therapeutic candidates or products outside of the United States, which would limit our market opportunities and adversely affect our business.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may face competition from biosimilars due to changes in the regulatory environment.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A recall of any of our commercialized products, or the discovery of serious safety issues, could have a significant negative impact on us.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Modifications to our products may require reclassifications, new regulatory approvals or clearances, or may require us to cease marketing or recall the modified products until new CE marking is obtained.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our employees, principal investigators, consultants and collaboration partners may engage in misconduct or other improper activities, including noncompliance with laws and regulatory standards and requirements and insider trading.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our therapeutic candidates or product.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to the Operation of Our Business</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our therapeutic candidates, conduct our clinical trials and commercialize our therapeutic candidates.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-2-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our business and operations would suffer in the event of system failures.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Relating to Our Intellectual Property</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may not be able to protect our proprietary technology in the marketplace.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The patent protection of biotherapeutics is complex and uncertain.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may be forced to litigate to enforce or defend our intellectual property rights, and/or the intellectual property rights of our licensors.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Intellectual property disputes could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Patent reform legislation and recent court decisions could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If third parties claim that our therapeutic candidates or other products infringe upon their intellectual property, commercialization of our therapeutic candidates or products and our operating profits could be adversely affected.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity of our therapeutic candidates or products, our business may be materially harmed.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Securities</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we do not regain compliance with or continue to satisfy the Nasdaq continued listing requirements, our securities could be delisted from the Nasdaq.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may be exposed to additional risks as a result of our reverse merger transaction.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our annual and quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Raising additional funds through debt or equity financing could be dilutive and may cause the market price of our Common Stock to decline.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Future sales and issuances of our Common Stock or rights to purchase our Common Stock, including pursuant to the HCW Sales Agreement or under our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General Risks</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We are at risk of securities class action litigation.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Implications of Being a Smaller Reporting Company</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our Common Stock held by non-affiliates exceeds $250 million as of the prior June&#160;30 or (ii)&#160;our annual revenue exceeded $100 million during such completed fiscal year and the market value of our Common Stock held by non-affiliates exceeds $700 million as of the prior June&#160;30.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Information</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085. Our telephone number is (650) 226-0120. Our website address is www.biocardia.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available free of charge on our investor relations website as soon as reasonably practicable after we electronically file or furnish such material to the Securities and Exchange Commission (&#8220;SEC&#8221;). The SEC also maintains a website that contains these reports and our other electronic SEC filings. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-3-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>THE OFFERING</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock offered</b>:</div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2,439,024&#160;shares.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;"><b>Pre-Funded Warrants offered:</b></td>
			<td style="vertical-align: bottom; width: 75%;">We are also offering to those purchasers whose purchase of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the closing of this offering, in lieu of purchasing Common Stock, Pre-Funded Warrants to purchase up to an aggregate of 2,439,024 shares of our Common Stock. Each Pre-Funded Warrant is exercisable for one share of our Common Stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of Common Stock is being sold to the public in this offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. This offering also relates to the shares of Common Stock issuable upon exercise of any Pre-Funded Warrants sold in this offering. For each Pre-Funded Warrant that we sell, the number of shares of Common Stock that we are offering will be reduced on a one-for-one basis.</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Warrants offered:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">Every share of our Common Stock, or Pre-Funded Warrant in lieu thereof, is being sold together with one Common Warrant. Each Common Warrant will be exercisable immediately for one share of our Common Stock, have an assumed initial exercise price equal to 110% of the combined public offering price per share of Common Stock and accompanying Common Warrant in this offering (or $2.71 per share at such assumed combined public offering price), and will expire five years from the date of issuance. The shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and Common Warrants are immediately separable and will be issued separately in this offering, but must initially be purchased together in this offering.</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock to be&#160;</b><b>outstanding </b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>after this&#160;</b><b>offering:</b></div>
			</td>
			<td style="vertical-align: top; width: 75%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4,562,900 shares.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of proceeds:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">We estimate that the net proceeds from the offering will be approximately $5.3 million, based on an assumed combined public offering price of $2.46, after deducting Placement Agent fees and offering expenses payable by us. We have assumed throughout this prospectus that we will pay the Placement Agent the Base Fee on all securities sold in this offering.</div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">We intend to use the net proceeds from this offering for working capital and general corporate purposes, which include, but are not limited to, advancing our investigational biotherapeutic candidates and our biotherapeutic delivery partnering business. See &#8220;Use of Proceeds.&#8221;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Current market for the</b><br/>
			<b>securities:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;BCDA.&#8221; There is no established trading market for the Pre-Funded Warrants or Common Warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Pre-Funded Warrants or Common Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Pre-Funded Warrants and Common Warrants will be limited.</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Affiliate share purchases:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">In addition, certain members of our Board of Directors and non-director executive officers have indicated their preliminary interest in purchasing a portion of our Common Stock and accompanying Common Warrants in this offering.</div>

			<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

			<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Because this indication of preliminary interest is not a binding agreement or commitment to purchase, such persons could determine to purchase more, fewer or no securities in this offering, or we could determine to sell more, fewer or no securities to them.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;"><b>Best efforts offering:</b></td>
			<td style="vertical-align: bottom; width: 75%;">We have agreed to offer and sell the securities offered hereby to the purchasers through the Placement Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;Plan of Distribution&#8221; on page 25 of this prospectus.&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk Factors:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">You should carefully read &#8220;Risk Factors&#8221;&#160;beginning on page 5 and other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our securities.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The number of shares of Common Stock to be outstanding after the offering is based on 2,123,876 shares of Common Stock outstanding as of July 31, 2024, and excludes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2,439,024&#160;shares of Common Stock issuable upon exercise of the Pre-Funded Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2,439,024&#160;shares of Common Stock issuable upon exercise of the Common Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">153,290 shares of Common Stock issuable upon exercise of stock options outstanding under our equity incentive plans, with a weighted-average exercise price of $52.43 per share&#894;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">208,993 shares of Common Stock issuable upon exercise of our other outstanding warrants to purchase Common Stock, with a weighted average exercise price of $66.30 per share; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99,675 shares of Common Stock available for future issuance under our 2016 Equity Incentive Plan.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Unless expressly indicated or the context requires otherwise, all information in this prospectus is as of July 31, 2024, assumes no exercise of any outstanding warrants or options described above.&#160;Also, except as otherwise indicated, all information in this prospectus assumes no exercise of any Pre-Funded Warrants or Common Warrants.</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-4-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RISK FACTORS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i>Investing in our securities involves a high degree of risk.</i>&#160;<i>Before making an investment decision, you should carefully consider the risks described below, and those discussed under the headings </i>&#8220;<i>Risk Factors</i>&#8221;<i> contained in our Quarterly Reports on Form</i>&#160;<i>10-Q for the quarters ended March 31, 2024 and June 30, 2024, and our Annual Report on Form</i>&#160;<i>10-K for the year ended December</i>&#160;<i>31, 2023, which are incorporated by reference into this prospectus, together with the other information contained in this prospectus and the documents incorporated by reference herein.</i>&#160;<i>If any of these risks is realized, our business, financial condition, results of operations and prospects could be materially and adversely affected.</i>&#160;<i>In that event, the trading price of our securities could decline and you could lose part or all of your investment.</i>&#160;<i>Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we do not regain compliance with or continue to satisfy the Nasdaq continued listing requirements, our Common Stock could be delisted from the Nasdaq.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The listing of our Common Stock on the Nasdaq is contingent on our compliance with the Nasdaq&#8217;s conditions for continued listing. We are currently not in compliance with Nasdaq listing requirements, specifically the requirement to maintain a minimum market value of listed securities of at least $35.0 million (&#8220;MVLS Requirements&#8221;), and we were previously not in compliance with the Nasdaq listing requirement&#160;to maintain a minimum $1.00 per share closing bid price for our Common Stock (&#8220;Minimum Bid Price Requirement&#8221;). On March 6, 2024, and March 12, 2024, we received delisting determination letters from the Nasdaq advising us that we did not regain compliance with the MVLS Requirement and the Minimum Bid Price Requirement, respectively, by the initial compliance dates afforded by the Nasdaq. As a result, trading of our securities on the Nasdaq was subject to suspension at the opening of business on March 15, 2024, and a Form 25-NSE would have been filed with the SEC to remove our securities from listing and registration on the Nasdaq unless we requested an appeal of these determinations to a Nasdaq Hearings Panel (&#8220;Panel&#8221;). On March 12, 2024, we submitted a hearing request to the Panel to appeal the delisting determinations. Our request for a hearing stayed the suspension of our securities and the filing of a Form 25-NSE pending the Panel&#8217;s decision. Following our hearing with the Panel, on May 13, 2024, the Panel granted our request for continued listing on Nasdaq subject to, among other things, (i) us maintaining compliance with the Minimum Bid Price Requirement for ten consecutive trading days on or before June 24, 2024, which occurred following a reverse stock split, and (ii) us demonstrating compliance with minimum stockholders&#8217; equity continued listing requirements under Nasdaq rules on or before September 2, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we fail to demonstrate our compliance with the requirements of the Panel&#8217;s order, our Common Stock will be subject to delisting by the Nasdaq. In the event our Common Stock is no longer listed for trading on Nasdaq, our trading volume and share price may decrease and we may experience further difficulties in raising capital, which could materially affect our operations and financial results. Further, delisting from the Nasdaq could also have other negative effects, including potential loss of confidence by partners, lenders, suppliers and employees and could also trigger various defaults under our financing arrangements and other outstanding agreements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Management will have broad discretion as to the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our management will have broad discretion over the use of proceeds from this offering, including for any of the purposes described in the section of this prospectus entitled &#8220;Use of Proceeds,&#8221; and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our Common Stock. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply the net proceeds from the sale of our shares in this offering could effectively have a material adverse effect on our business, delay the development of our products, compromise our ability to pursue our business strategy, and cause the price of our Common Stock to decline, and we might not be able to yield a significant return, if any, on our investment of these net proceeds.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-5-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>You will experience immediate dilution in the book value per share of the Common Stock you purchase.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">You will incur immediate and substantial dilution as a result of this offering.&#160;The assumed combined public offering price per share of Common Stock and accompanying Common Warrant of $2.46&#160;and assumed combined public offering price per Pre-Funded Warrant and accompanying Common Warrant of $2.459 are substantially higher than the as adjusted net tangible book value per share of our Common Stock.&#160;If you purchase Common Stock in this offering, you will incur immediate and substantial dilution of $1.97&#160;per share in the as adjusted net tangible book value of shares of our Common Stock, based on the assumed offering price per share of Common Stock and accompanying Common Warrant of $2.46.&#160;In addition, the purchase of Common Warrants in this offering will not result in the immediate acquisition of shares of our Common Stock unless and until you exercise the purchased Common Warrants.&#160;As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of liquidation. In addition, to the extent outstanding options and warrants are ultimately exercised, there will be further dilution of the securities sold in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we raise additional capital through the sale of shares of our Common Stock, convertible securities or debt in the future, your ownership in us could be diluted and restrictions could be imposed on our business. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We may issue shares of our Common Stock or securities convertible into our Common Stock to raise additional capital in the future. While this offering may not be consummated due to a variety of reasons, including the SEC not declaring the registration statement effective, poor market conditions or a decline in the trading price of our Common Stock, to the extent we issue such securities, our stockholders may experience substantial dilution and the trading price of our Common Stock could decline. If we obtain funds through a credit facility or through the issuance of debt or preferred securities, such debt or preferred securities could have rights senior to your rights as a common shareholder, which could impair the value of our Common Stock.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Sales of a substantial number of shares of our Common Stock in the public market or raising additional funds through debt or equity financing could cause our stock price to fall. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic collaborations or partnerships, or marketing, distribution or licensing arrangements with third parties, we may be required to limit valuable rights to our intellectual property, technologies, therapeutic candidates or future revenue streams, or grant licenses or other rights on terms that are not favorable to us. Furthermore, any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our therapeutic candidates.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Sales of a substantial number of shares of our Common Stock in the public market or the perception that these sales might occur, could depress the market price of our Common Stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our Common Stock. A substantial number of shares of Common Stock are being offered by this prospectus supplement. We cannot predict the number of these shares that might be sold nor the effect that future sales of the shares of our Common Stock would have on the market price of our Common Stock.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our stock. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have never paid dividends and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if our stock price appreciates and you sell our Common Stock thereafter.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The market price and trading volume of our Common Stock may be volatile and may be affected by economic conditions beyond our control.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The market price of our Common Stock is likely to be volatile. Some specific factors that could negatively affect the price of our Common Stock or result in fluctuations in its price and trading volume include:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results of clinical trials of our therapeutic candidates;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-6-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results of clinical trials of our competitors&#8217;&#160;products;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory actions with respect to our therapeutic candidates or products or our competitors&#8217;&#160;products;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated fluctuations in our quarterly operating results or those of our competitors;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">publication of research reports by securities analysts about us or our competitors in the industry;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our failure or the failure of our competitors to meet analysts&#8217;&#160;projections or guidance that we or our competitors may give to the market;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our liquidity positions;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">issuances by us of debt or equity securities;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">litigation involving our company, including stockholder litigation, investigations or audits by regulators into the operations of our company, or proceedings initiated by our competitors or clients;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the passage of legislation or other regulatory developments affecting us or our industry, fluctuations in the valuation of companies perceived by investors to be comparable to us;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">trading volume of our Common Stock and warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sales or perceived potential sales of our Common Stock and/or warrants by us, our directors, senior management or our stockholders in the future;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">short selling or other market manipulation activities;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">announcement or expectation of additional financing efforts;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">terrorist acts, acts of war or periods of widespread civil unrest;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">natural disasters, pandemics and other calamities;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in market conditions for biopharmaceutical stocks; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">conditions in the U.S. financial markets or changes in general economic conditions, including as a result of inflation and changes in interest rates.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our Common Stock, the price and trading volume of our securities could decline.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts commence coverage of us, the trading price for our Common Stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, the price of our Common Stock would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause the price or trading volume of our Common Stock to decline.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-7-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Participation in this offering by certain of our affiliates would reduce the available public float of our Common Stock. </i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Certain members of our Board of Directors and non-director executive officers have indicated an interest in purchasing up a portion of our Common Stock and accompanying Common Warrants in this offering. However, because indications of interest are not binding agreements or commitments to purchase, and such potential purchasers could determine to purchase no securities in this offering. Moreover, no guarantee will be or has been given by us or the Placement Agent as to the final allocation to any of the aforementioned persons or other persons, that any allocation will be made to them, or as to the size of any such allocation. To the extent such members of the Board of Directors and non-director executive officer participate in this offering, such purchases would reduce the non-affiliate public float for our Common Stock, meaning the number of shares of Common Stock that are not held by officers, directors and controlling shareholders. A reduction in the public float could reduce the number of shares of Common Stock that are available to be traded at any given time, thereby adversely impacting the liquidity of our Common Stock and depressing the price at which you may be able to sell Common Stock purchased in this offering.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Common Warrants are speculative in nature.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Common Warrants, which have an assumed initial exercise price of $2.71 per share of Common Stock, subject to adjustments, are exercisable beginning on the issuance date and will expire five years from the date of issuance. If the price of the Common Stock does not increase to an amount sufficiently above the exercise price of the Common Warrants during the period during which the Common Warrants are exercisable, you will be unable to recover any of your investment in the Common Warrants. In such event, the Common Warrants will not have any value.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There can be no assurance that the market price of the Common Stock will ever equal or exceed the exercise price of the Common Warrants, and consequently, whether it will ever be profitable for holders of the Common Warrants to exercise such Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>There is no public market for the Pre-Funded Warrants or Common Warrants.</b></i></div>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There is no established public trading market for the Pre-Funded Warrants or Common Warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Pre-Funded Warrants or Common Warrants on any securities exchange. Without an active market, the liquidity of such warrants will be limited.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Holders of Pre-Funded Warrants or Common Warrants will have no rights as a common stockholder until they acquire our Common Stock.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Until you acquire shares of our Common Stock upon exercise of your Pre-Funded Warrants or Common Warrants, you will have no rights with respect to shares of our Common Stock issuable upon exercise of your Pre-Funded Warrants or Common Warrants.&#160; Upon exercise of your Pre-Funded Warrants or Common Warrants, you will be entitled to exercise the rights of a holder of our Common Stock only as to matters for which the record date occurs after the exercise date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>The reasonable best efforts structure of this offering may have an adverse effect on our business plan.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Placement Agent is offering the shares of Common Stock, or Pre-Funded Warrants, and accompanying Common Warrants on a &#8220;reasonable best efforts&#8221; basis, and the Placement Agent is under no obligation to purchase any securities for its own account. The Placement Agent is not required to sell any specific number or dollar amount of shares of Common Stock, or Pre-Funded Warrants, and accompanying Common Warrants in this offering but will use its best efforts to sell the securities offered in this prospectus supplement. As a &#8220;reasonable best efforts&#8221; offering, there can be no assurance that the offering contemplated hereby will ultimately be consummated or will result in any proceeds being made available to us or, if consummated, the amount of proceeds to be received. The success of this offering will impact our ability to use the proceeds to execute our business plan. An adverse effect on the business may result from raising less than anticipated and from the fact that there is no minimum raise.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we do not maintain a current and effective registration statement relating to the Common Stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants being offered in this offering, holders will be able to exercise such warrants on a </i></b>&#8220;<b><i>cashless</i></b>&#8221;<b><i> basis and we may not receive any additional funds upon the exercise of such warrants.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If we do not maintain a current and effective registration statement relating to the Common Stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants being offered in this offering, such warrants may be exercised by way of a &#8220;cashless&#8221; exercise, meaning that the holder would not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of our Common Stock determined according to the formula set forth in the warrant. Accordingly, we may not receive any additional funds upon the exercise of such warrants.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-8-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus and the documents we have filed with the SEC that are incorporated by reference in this prospectus contain certain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements, including statements regarding (i) expectations concerning our ability to raise additional funding from equity or debt financings and to continue as a going concern; (ii) our ability to retain the listing of our securities on the Nasdaq Capital Market; (iii) the plans and objectives of management for future operations, including plans or objectives relating to the development of our cell therapy systems; (iv) the timing and conduct of the clinical trials for our products, including statements regarding the timing, progress and results of current and future preclinical studies and clinical trials as well as our research and development programs; (v) the timing or likelihood of regulatory filing, approvals and required licenses for our cell therapy systems; (vi) our ability to adequately protect our intellectual property rights and enforce such rights to avoid violation of the intellectual property rights of others; (vii) the timing, costs and other aspects of the commercial launch of our products; (viii) our estimates regarding the market opportunity, clinical utility, potential advantages and market acceptance of our products; (ix) the impact of government laws and regulations; (x) our ability to recruit and retain qualified clinical, regulatory and research and development personnel; (xi) the availability of reimbursement or other forms of funding for our products from government and commercial payors; (xii) difficulties in maintaining commercial scale manufacturing capacity and capability and our ability to generate growth; (xiii) uncertainty in industry demand; (xiv) general economic conditions and market conditions in our industry; (xv) the effects of pandemics on our business, preclinical studies and clinical trials; (xvi) the depth of the trading market in our securities; (xvii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (xviii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC; and (xix) the assumptions underlying or relating to any statement described in points (i)-(xix) above. These statements are not guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict. The words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;pro-forma,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;strategy,&#8221; &#8220;anticipate,&#8221; &#8220;attempt,&#8221; &#8220;develop,&#8221; &#8220;plan,&#8221; &#8220;help,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; and similar expressions (including the negative of any of the foregoing) are intended to identify forward-looking statements. Those statements appear in this prospectus and the documents we have filed with the SEC that are incorporated by reference in this prospectus, particularly in the sections captioned &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and include statements regarding the intent, belief or current expectations of our management that are subject to known and unknown risks, uncertainties and assumptions. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this prospectus or any free writing prospectus, as applicable, whether as a result of any new information, future events or otherwise.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus and the information incorporated by reference herein and therein include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus are the property of their respective owners.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-9-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MARKET, INDUSTRY AND OTHER DATA</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus and the documents incorporated by reference in this prospectus contain estimates and information concerning our industry, including market size and growth rates of the markets in which we participate, that are based on industry publications and reports. We relied on industry, market data, peer reviewed journals, formal presentations at medical society meetings and other sources. We also rely on our own research and estimates in this prospectus. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to these estimates. We have not independently verified the accuracy or completeness of the data contained in these industry publications and reports. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled &#8220;Risk Factors,&#8221; and in the &#8220;Risk Factors&#8221; section in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023 and our Quarterly Reports on Form&#160;10-Q for the quarters ended March 31, 2024 and June 30, 2024, which are incorporated by reference herein. These and other factors could cause results to differ materially from those expressed in these publications and reports.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-10-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>USE OF PROCEEDS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We estimate that the net proceeds to us from the issuance and sale of securities in this offering will be approximately $5.3 million, based on an assumed combined public offering price of $2.46&#160;per share of Common Stock and accompanying Common Warrant or an assumed combined public offering price of $2.459&#160;per Pre-Funded Warrant and accompanying Common Warrant, after deducting Placement Agent fees and offering expenses payable by us, assuming we pay the Placement Agent the Base Fee for all securities in this offering. This amount excludes the proceeds, if any, from the exercise of any Pre-Funded Warrants and the Common Warrants issued in this offering. If all of the Common Warrants sold in this offering were to be exercised in cash at an assumed exercise price of $2.71 per share, we would receive additional net proceeds of approximately $6.6 million. We cannot predict when or if these Common Warrants will be exercised. It is possible that the Common Warrants may expire and may never be exercised. Additionally, because this is a &#8220;best efforts&#8221; offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the Placement Agent&#8217;s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus. As a result, we may receive significantly less in net proceeds. Based on the assumed offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $3.9 million, $2.5 million, and $1.1 million, respectively, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us, and assuming we do not issue any Pre-Funded Warrants and that we pay the Placement Agent the Base Fee for all securities in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We intend to use the net proceeds from this offering for general corporate purposes, which may include working capital and other general corporate purposes, which include, but are not limited to, advancing our investigational biotherapeutic candidates and our biotherapeutic delivery partnering business.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The expected use of net proceeds of this offering represents our current intentions based on our present plans and business conditions. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering. Pending these uses, we plan to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-11-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIVIDEND POLICY</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have never declared or paid any cash dividend on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any determination to declare or pay dividends in the future will be at the discretion of our board of directors and will depend on a number of factors, including our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-12-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAPITALIZATION</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth our capitalization as of June 30, 2024 on:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an actual basis; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align: top; padding: 0pt;">an as adjusted basis, giving effect to the sale and issuance of securities by us in this offering, based on an assumed combined public offering price of $2.46 per share and accompanying Common Warrant, after deducting Placement Agent fees and estimated offering expenses payable by us, assuming we pay the Placement Agent the Base Fee for all securities in this offering. The as adjusted basis assumes no sale of Pre-Funded Warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis, and excludes the proceeds, if any, from the exercise of any Pre-Funded Warrants or Common Warrants.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You should read this table together with the section of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023 and our Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2024 entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included therein, each of which incorporated by reference in this prospectus.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>As of June 30, 2024</b></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Actual</b></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>As Adjusted</b><b><sup style="vertical-align:top;line-height:120%;">(1)</sup></b></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>(Unaudited, in thousands, except share and per share data)</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash, cash equivalents and short-term investments</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,890</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,193</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,851</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,851</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders&#8217; equity:</div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding, actual and as adjusted</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock, par value $0.001; 50,000,000 shares authorized, 2,123,876 shares issued and outstanding, actual; 50,000,000 shares authorized and 4,562,900 shares issued and outstanding, as adjusted</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Additional paid-in capital</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">154,125</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">159,426</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accumulated other comprehensive income</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accumulated deficit</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(156,088</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(156,088</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders&#8217; equity</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,961</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,342</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total capitalization</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,890</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,193</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</div>
			</td>
			<td style="width: auto; padding: 0pt; font-size: 10pt;">A $0.25 increase (decrease) in the assumed combined public offering price per share of Common Stock and accompanying Common Warrant of $ would increase (decrease) the as adjusted amount of additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $567,000 ($567,000) assuming that the number of shares of Common Stock offered by us as set forth on the cover page of this prospectus remains the same and after deducting estimated Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of Common Warrants or sale of Pre-Funded Warrants. An increase (decrease) of 250,000 in the number of shares of Common Stock and accompanying Common Warrants offered by us would increase (decrease) the as adjusted amount of additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $572,000 ($572,000), assuming no change in the assumed combined public offering price per share of Common Stock and accompanying Common Warrant, and after deducting estimated Placement Agent fees and estimated offering expenses payable by us. All information in this table &#160;assumes we pay the Placement Agent the Base Fee for all securities sold in this offering.</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The number of shares of Common Stock to be outstanding after the offering is based on 2,123,876 shares of Common Stock outstanding as of June 30, 2024, and excludes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2,439,024 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2,439,024&#160;shares of Common Stock issuable upon exercise of the Common Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">155,642 shares of Common Stock issuable upon exercise of stock options outstanding under our equity incentive plans, with a weighted-average exercise price of $52.85 per share;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">208,993 shares of Common Stock issuable upon exercise of our other outstanding warrants to purchase Common Stock, with a weighted average exercise price of $66.30 per share; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">97,323 shares of Common Stock available for future issuance under our 2016 Equity Incentive Plan.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-13-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DILUTION</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If you purchase our Common Stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the combined public offering price per share of Common Stock and accompanying Common Warrant and the net tangible book value per share of our Common Stock immediately after this offering.&#160;Net tangible book value per share is determined by dividing the number of shares of Common Stock outstanding as of June 30, 2024 into our total tangible assets less total liabilities.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our net tangible book value as of June 30, 2024 was approximately $(3.0) million, or $(1.43) per share, based on 2,123,876 shares of our Common Stock outstanding as of that date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">After giving effect to the sale of securities by us at the assumed combined public offering price of $2.46 per share of Common Stock and accompanying Common Warrant, and after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of Common Warrants in the offering and that we pay the Placement Agent the Base Fee for all securities in this offering, our as adjusted net tangible book value as of June 30, 2024 would have been approximately $2.3 million, or $0.49&#160;per share. This represents an immediate increase in net tangible book value of $1.93&#160;per share to existing stockholders and immediate dilution of $1.97&#160;per share to investors in this offering. The dilution figures assume no sale of Pre-Funded Warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis and excludes the proceeds, if any, from the exercise of any Pre-Funded Warrants or Common Warrants issued in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following table illustrates this dilution on a per share basis:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Assumed combined public offering price per share of Common Stock and accompanying Common Warrant</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2.46</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net tangible book value per share as of June 30, 2024</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.43</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Increase in net tangible book value per share attributable to investors participating in this offering</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1.93</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As adjusted net tangible book value per share after giving effect to this offering</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="color: #ff00ff;">0.49</span></td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilution per share to investors in this offering</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1.97</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Each $0.25 increase (decrease) in the assumed combined public offering price of $2.46 per share of Common Stock and accompanying Common Warrant would increase (decrease) the as adjusted net tangible book value by $0.12 per share and the dilution to investors participating in this offering by $0.13 per share, assuming the number of shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants offered by us as set forth on the cover page of this prospectus, remains the same, and after deducting estimated Placement Agent fees and estimated expenses payable by us. Similarly, an increase of 250,000 in the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants offered by us, as set forth on the cover page of this prospectus, would increase the as adjusted net tangible book value by $0.09 per share and decrease the dilution to investors participating in this offering by $0.09 per share, assuming the assumed combined public offering of $2.46 remains the same and after deducting estimated Placement Agent fees, assuming we pay the Placement Agent the Base Fee for all securities in this offering, and estimated offering expenses payable by us. Conversely, a decrease of 250,000 in the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants offered by us, as set forth on the cover page of this prospectus, would decrease the as adjusted net tangible book value by $0.10 per share and increase the dilution to investors participating in this offering by $0.10 per share, assuming the assumed combined public offering price of $2.46 per share of Common Stock and accompanying Common Warrant remains the same and after deducting estimated Placement Agent fees and estimated offering expenses payable by us. All information in this table assumes we pay the Placement Agent the Base Fee for all securities sold in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table and discussion above based on 2,123,876 shares of Common Stock outstanding as of June 30, 2024, and excludes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2,439,024 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2,439,024&#160;shares of Common Stock issuable upon exercise of the Common Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">155,642 shares of Common Stock issuable upon exercise of stock options outstanding under our equity incentive plans, with a weighted-average exercise price of $52.85 per share;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">208,993 shares of Common Stock issuable upon exercise of our other outstanding warrants to purchase Common Stock, with a weighted average exercise price of $66.30 per share; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">97,323 shares of Common Stock available for future issuance under our 2016 Equity Incentive Plan.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">To the extent that additional shares are issued pursuant to the foregoing, investors purchasing our Common Stock in this offering will experience further dilution. In addition, we may offer other securities in other offerings due to market conditions or strategic considerations. To the extent we issue such securities, you may experience further dilution.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-14-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DESCRIPTION OF SECURITIES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Capital Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The description of our capital stock is incorporated by reference to Exhibit 4.10 to our Annual Report on Form 10&#8209;K for the fiscal year ended December 31, 2023, filed with the SEC on March 27, 2024.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Pre-Funded Warrants</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following summary of certain terms and conditions of the Pre-Funded Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of Pre-Funded Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>General</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The term &#8220;pre-funded&#8221; refers to the fact that the purchase price of the Pre-Funded Warrants in this offering includes almost the entire exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.001 per share. The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding Common Stock following the consummation of this offering the opportunity to invest capital into the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of shares of our Common Stock, which would result in such ownership of more than 4.99% (or, at the election of the holder, 9.99%), and receiving the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at a nominal price at a later date.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Form</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Pre-Funded Warrants will be issued as individual warrant agreements to the investors. You should review the form of Pre-Funded Warrant, filed as an exhibit to the registration statement of which this prospectus forms a part, for a complete description of the terms and conditions applicable to the Pre-Funded Warrants.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercisability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Pre-Funded Warrants are exercisable at any time after their original issuance. The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full in immediately available funds for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as described below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s Pre-Funded Warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding Common Stock. No fractional shares of Common Stock will be issued in connection with the exercise of a Pre-Funded Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Duration and Exercise Price</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The exercise price per whole share of our Common Stock purchasable upon the exercise of the Pre-Funded Warrants is $0.001 per share of Common Stock. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price of the Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cashless Exercise</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If, at any time after the issuance of the Pre-Funded Warrants, the holder exercises its Pre-Funded Warrants and a registration statement registering the issuance of the shares of Common Stock underlying the Pre-Funded Warrants under the Securities Act is not then effective or available (or a prospectus is not available for the resale of shares of Common Stock underlying the Pre-Funded Warrants), then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants. Notwithstanding anything to the contrary, in the event we do not have or maintain an effective registration statement, there are no circumstances that would require us to make any cash payments or net cash settle the Pre-Funded Warrants to the holders.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Transferability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-15-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exchange Listing</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There is no established trading market for the Pre-Funded Warrants and we do not plan on applying to list the Pre-Funded Warrants on The Nasdaq Capital Market any other national securities exchange or any other nationally recognized trading system.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Rights as a Stockholder</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Except by virtue of such holder&#8217;s ownership of shares of our Common Stock, the holder of a Pre-Funded Warrant does not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises the Pre-Funded Warrant.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following summary of certain terms and provisions of the Common Warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the form of Common Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Common Warrant.&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Duration and Exercise Price</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Each Common Warrant offered hereby will have an assumed initial exercise price per share equal to $2.71&#160;(assuming an exercise price equal to 110% of the combined public offering price per share of Common Stock and accompanying Common Warrant in this offering). The Common Warrants will be immediately exercisable and will expire five years from the date of issuance. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercisability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Common Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Common Warrant to the extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding Common Stock immediately after exercise, except that upon notice from the holder to us, the holder may increase or decrease the beneficial ownership limitation up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants, provided that any change in such beneficial ownership limitation shall not be effective until 61 days following notice from the holder to us. No fractional shares of Common Stock will be issued in connection with the exercise of a Common Warrant. In lieu of fractional shares, we will, at our election, either pay a cash adjustment in respect of such fractional amount or round up to the next whole share.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cashless Exercise</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If, at the time a holder exercises its Common Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the Common Warrants under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Common Warrants.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Transferability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to applicable laws, the Common Warrants may be transferred at the election of the holder upon surrender of the Common Warrant to the Company together with the appropriate instruments of transfer.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exchange Listing</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There is no established public trading market for the Common Warrants, and we do not expect a market to develop. In addition, we do not intend to list the Common Warrants on any securities exchange or nationally recognized trading system.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Fundamental Transaction</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If, at any time while the Common Warrants are outstanding, we effect a Fundamental Transaction, then upon any subsequent exercise of Common Warrants, the holders thereof will have the right to receive the same amount and kind of securities, cash or property as they would have been entitled to receive upon the occurrence of such Fundamental Transaction if they had been, immediately prior to such Fundamental Transaction, the holder of the number of shares of Common Stock then issuable upon exercise of those Common Warrants, or any other consideration payable as part of the Fundamental Transaction.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-16-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Right as a Stockholder</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;Except as otherwise provided in the Common Warrants or by virtue of such holder&#8217;s ownership of shares of our Common Stock, the holders of the Common Warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they acquire shares of our Common Stock upon exercise of their Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Listing</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Our Common Stock is listed on Nasdaq under the symbol &#8220;BDCA.&#8221;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-17-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK, PRE-FUNDED WARRANTS AND COMMON WARRANTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following discussion describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our Common Stock, Pre-Funded Warrants and Common Warrants acquired in this Offering. This discussion is based on the current provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), existing and proposed U.S. Treasury regulations promulgated thereunder, and administrative rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive effect. No ruling has been or will be sought from the Internal Revenue Service (the &#8220;IRS&#8221;), with respect to the matters discussed below, and there can be no assurance the IRS will not take a contrary position regarding the tax consequences of the acquisition, ownership or disposition of our Common Stock, Pre-Funded Warrants and Common Warrants, or that any such contrary position would not be sustained by a court.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We assume in this discussion that the shares of our Common Stock, Pre-Funded Warrants and Common Warrants will be held as capital assets (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxes, does not discuss the potential application of the Medicare contribution tax on net investment income or the alternative minimum tax and does not deal with state or local taxes, U.S. federal gift and estate tax laws, except as specifically provided below with respect to non-U.S. holders, or any non- U.S. tax consequences that may be relevant to holders in light of their particular circumstances. This discussion also does not address the special tax rules applicable to particular holders, such as</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">financial institutions;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">brokers or dealers in securities or currencies or traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">tax-exempt organizations;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">pension plans;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">regulated investment companies, real estate investment trusts;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">owners that hold our Common Stock, Pre-Funded Warrants or Common Warrants as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">insurance companies;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">persons that own, or are deemed to own, more than 5% of our capital stock, Pre-Funded Warrants and/or Common Warrants (except to the extent specifically set forth below);</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">entities or arrangements treated as partnerships for U.S. federal income tax purposes and other pass-through entities (and partners or other investors therein);</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">controlled foreign corporations, passive foreign investment companies, or corporations that accumulate earnings to avoid U.S. federal income tax;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">persons subject to special tax accounting rules as a result of any item of gross income with respect to our Common Stock, Pre-Funded Warrants or Common Warrants being taken into account in an applicable financial statement;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">persons deemed to sell our Common Stock, Pre-Funded Warrants or Common Warrants under the constructive sale provisions of the Code; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">certain U.S. expatriates and certain former citizens or long-term residents of the United States.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-18-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In addition, this discussion does not address the tax treatment of partnerships or other pass-through entities or persons who hold our Common Stock, Pre-Funded Warrants or Common Warrants through partnerships or other entities which are pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our Common Stock, Pre-Funded Warrants or Common Warrants should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our Common Stock, Pre-Funded Warrants or Common Warrants through a partnership or other pass-through entity, as applicable.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">This discussion of U.S. federal income tax considerations is for general information purposes only and is not tax advice. Prospective investors should consult their own tax advisors regarding the U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding and disposing of our Common Stock, Pre-Funded Warrants and Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">For the purposes of this discussion, a &#8220;U.S. Holder&#8221; means a beneficial owner of our Common Stock, Pre-Funded Warrants or Common Warrants that is, (or other entity classified as a partnership for U.S. federal income tax purposes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">(a) an individual who is a citizen or resident of the United States, (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d) a trust if it (1) is subject to the primary supervision of a court within the United States and one or more U.S. persons (within the meaning of Section 7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">A &#8220;Non-U.S. Holder&#8221; is, for U.S. federal income tax purposes, a beneficial owner of our Common Stock, Pre-Funded Warrants or Common Warrants that is not a U.S. Holder or an entity or arrangement treated as a partnership for U.S. federal income tax purposes.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>General Treatment of Pre-Funded Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Although the law in this area is not completely settled, the Pre-Funded Warrants are generally expected to be treated as shares of our Common Stock for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Common Stock as described below, and not as a holder of a Common Warrant as described below. Accordingly, no gain or loss should be recognized upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the shares of Common Stock received. Similarly, the tax basis of a Pre-Funded Warrant should carry over to the shares of Common Stock received upon exercise, increased by the exercise price (if applicable). Holders should discuss with their tax advisor the consequences of the acquisition, ownership and disposition of the Pre-Funded Warrants, as well as the exercise of, certain adjustments to, and any payments in respect of the Pre-Funded Warrants (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Allocation of Purchase Price</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">For U.S. federal income tax purposes, the shares of Common Stock and Common Warrants or Pre-Funded Warrants and Common Warrants acquired in this Offering will be treated as an &#8220;investment unit&#8221; consisting of one share of Common Stock and one Common Warrant to acquire one share of our Common Stock or one Pre-Funded Warrant and one Common Warrant to acquire one share of our Common Stock. The purchase price for each investment unit will be allocated between these two components in proportion to their relative fair market values at the time the unit is purchased by the holder. This allocation of the purchase price for each unit will establish the holder&#8217;s initial tax basis for U.S. federal income tax purposes in the share of Common Stock or Pre-Funded Warrant and the Common Warrant included in each unit. The separation of the share of Common Stock or Pre-Funded Warrant and&#160;one Common Warrant included in each unit should not be a taxable event for U.S. federal income tax purposes. Each holder should consult his, her or its own tax advisor regarding the allocation of the purchase price for a unit.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-19-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Tax Considerations Applicable to U.S. Holders</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercise and Expiration of Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In general, a U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon exercise of a Common Warrant. The U.S. Holder will take a tax basis in the shares acquired on the exercise of a Common Warrant equal to the exercise price of the Common Warrant, increased by the U.S. Holder&#8217;s adjusted tax basis in the Common Warrant exercised (as determined pursuant to the rules discussed above). The U.S. Holder&#8217;s holding period in the shares of our Common Stock acquired on exercise of the Common Warrant will begin on the date of exercise of the Common Warrant, and will not include any period for which the U.S. Holder held the Common Warrant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In certain limited circumstances, a U.S. Holder may be permitted to undertake a cashless exercise of Common Warrants into our Common Stock. The U.S. federal income tax treatment of a cashless exercise of Common Warrants into our Common Stock is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a Common Warrant described in the preceding paragraph. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The lapse or expiration of a Common Warrant will be treated as if the U.S. Holder sold or exchanged the Common Warrant and recognized a capital loss equal to the U.S. Holder&#8217;s tax basis in the Common Warrant. The deductibility of capital losses is subject to limitations.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Certain Adjustments to and Distributions on Common Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Under Section 305 of the Code, an adjustment to the number of shares of Common Stock issued on the exercise of the Common Warrants or an adjustment to the exercise price of the Common Warrants may be treated as a constructive distribution to a U.S. Holder of the Common Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. Holder&#8217;s proportionate interest in our &#8220;earnings and profits&#8221; or assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders). An adjustment made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution should generally not be considered to result in a constructive distribution. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property to the holders of Common Warrants. In certain circumstances, if we were to make a distribution in cash or other property with respect to our Common Stock after the issuance of the Common Warrants, then we may make a corresponding distribution to the holders of the Common Warrants. The taxation of a distribution received with respect to a Common Warrant is unclear. It is possible such a distribution would be treated as a distribution (or constructive distribution), although other treatments are possible. For more information regarding the U.S. federal income tax considerations related to distributions, see the discussion below regarding &#8220;&#8212;Distributions.&#8221; U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to the Common Warrants and any distributions with respect to the Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Distributions</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">We have never declared or paid any cash dividend on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. In the event that we do make distributions on our Common Stock to a U.S. Holder, those distributions generally will constitute dividends for U.S. tax purposes to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or exchange of our Common Stock as described below under the section titled &#8220;&#8211;Disposition of Our Common Stock or Common Warrants.&#8221; Under current law, if certain requirements are met, a preferential U.S. federal income tax rate will apply to any dividends paid to the beneficial owner of our Common Stock who is an individual U.S. Holder and meets certain holding period requirements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Distributions constituting dividends for U.S. federal income tax purposes that are made to U.S. Holders that are corporate shareholders may qualify for the dividends received deduction (a &#8220;DRD&#8221;), which is generally available to corporate shareholders. No assurance can be given that we will have sufficient earnings and profits (as determined for U.S. federal income tax purposes) to cause any distributions to be eligible for a DRD. In addition, a DRD is available only if certain holding periods and other taxable income requirements are satisfied.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-20-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The taxation of a distribution received with respect to a Pre-Funded Warrant is unclear. It is possible such a distribution would be treated as a distribution as described in this section, although other treatments may also be possible. Holders should consult their tax advisors regarding the proper treatment of any payments in respect of the Pre-Funded Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Disposition of Our Common Stock or Common Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Upon a sale or other taxable disposition of our Common Stock or upon the sale, exchange (other than by exercise) or redemption of our Common Warrants, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in the Common Stock or Common Warrants. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock or Common Warrants exceeds one year. The deductibility of capital losses is subject to certain limitations. U.S. Holders who recognize losses with respect to a disposition of our Common Stock or Common Warrants should consult their own tax advisors regarding the tax treatment of such losses.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Information Reporting and Backup Withholding</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Information reporting requirements generally will apply to payments of dividends (including constructive dividends) on the Common Stock and Common Warrants and to the proceeds of a sale or other disposition of Common Stock and Common Warrants paid by us to a U.S. Holder unless such U.S. Holder is an exempt recipient, such as a corporation. Backup withholding will apply to those payments if the U.S. Holder fails to provide the holder&#8217;s taxpayer identification number, or certification of exempt status, or if the holder otherwise fails to comply with applicable requirements to establish an exemption.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against the U.S. Holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. U.S. Holders should consult their own tax advisors regarding their qualification for exemption from information reporting and backup withholding and the procedure for obtaining such exemption.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Tax Considerations Applicable to Non-U.S. Holders</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercise and Expiration of Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In general, a Non-U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon the exercise of Common Warrants into shares of Common Stock. The U.S. federal income tax treatment of a cashless exercise of Common Warrants into our Common Stock is unclear. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding the U.S. federal income tax consequences of a cashless exercise of Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The expiration of a Common Warrant will be treated as if the Non-U.S. Holder sold or exchanged the Common Warrant and recognized a capital loss equal to the Non-U.S. Holder&#8217;s tax basis in the Common Warrant. However, a Non-U.S. Holder will not be able to utilize a loss recognized upon expiration of a Common Warrant against the Non-U.S. Holder&#8217;s U.S. federal income tax liability unless the loss is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if an income tax treaty applies, is attributable to a permanent establishment or fixed base in the United States) or is treated as a U.S.-source loss and the Non-U.S. Holder is present 183 days or more in the taxable year of disposition and certain other conditions are met.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Certain Adjustments to and Distributions on Common Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As described under &#8220;&#8212;U.S. Holders &#8211;Certain Adjustments to and Distributions on Common Warrants,&#8221; an adjustment to the Common Warrants could result in a constructive distribution to a Non-U.S. Holder, which would be treated as described under &#8220;&#8212;Distributions&#8221; below, and the tax treatment of distributions on the Common Warrants is unclear. Any resulting withholding tax attributable to deemed dividends would be collected from other amounts payable or distributable to the Non-U.S. Holder. Non-U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to and distributions on the Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-21-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Distributions</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">We have never declared or paid any cash dividend on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. In the event that we do make distributions on our Common Stock to a Non-U.S. Holder, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as described in &#8220;&#8212;U.S. Holders &#8211; Distributions.&#8221;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Any distribution (including constructive distributions) on our Common Stock that is treated as a dividend paid to a Non-U.S. Holder that is not effectively connected with the holder&#8217;s conduct of a trade or business in the United States will generally be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and the Non-U.S. Holder&#8217;s country of residence. To obtain a reduced rate, of withholding under a treaty, a Non-U.S. Holder generally will be required to provide the applicable withholding agent with a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate form, certifying the Non-U.S. Holder&#8217;s entitlement to benefits under that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder&#8217;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#8217;s agent may then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We generally are not required to withhold tax on dividends paid (or constructive dividends deemed paid) to a Non-U.S. Holder that are effectively connected with the holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that the holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to the applicable withholding agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non- U.S. Holder&#8217;s effectively connected earnings and profits, subject to certain adjustments.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The taxation of a distribution received with respect to a Pre-Funded Warrant is unclear. It is possible such a distribution would be treated as a distribution as described in this section, although other treatments may also be possible. Non-U.S. Holders should consult their own tax advisors regarding the proper treatment of any payments in respect of the Pre-Funded Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">See also the sections below titled &#8220;&#8212;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;Foreign Accounts&#8221; for additional withholding rules that may apply to dividends paid to certain foreign financial institutions or non-financial foreign entities.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Disposition of Our Common Stock or Common Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to the discussions below under the sections titled &#8220;&#8212;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;Foreign Accounts&#8221; a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain realized on a sale or other taxable disposition of our Common Stock or Common Warrants unless:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business in the United States, and if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States; in these cases, the Non-U.S. Holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and if the Non-U.S. Holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income tax treaty, may also apply;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-22-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Non-U.S. Holder is a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other requirements are met, in which case the Non-U.S. Holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the Non- U.S. Holder, if any; or</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our Common Stock constitutes a U.S. real property interest because we are, or have been at any time during the five-year period preceding such disposition (or the Non-U.S. Holder&#8217;s holding period for the Common Stock or Common Warrants, if shorter), a &#8220;U.S. real property holding corporation,&#8221;&#160;unless our Common Stock is regularly traded on an established securities market and the Non-U.S. Holder held no more than 5% of our outstanding Common Stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the Non-U.S. Holder held our Common Stock. Special rules may apply to the determination of the 5% threshold in the case of a holder of a Common Warrant. Non-U.S. Holders are urged to consult their own tax advisors regarding the effect of holding our Common Warrants on the calculation of such 5% threshold. Generally, a corporation is a &#8220;U.S. real property holding corporation&#8221;&#160;if the fair market value of its &#8220;U.S. real property interests&#8221;&#160;(as defined in the Code and the applicable Treasury Regulations issued thereunder) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#8220;U.S. real property holding corporation&#8221;&#160;for U.S. federal income tax purposes. No assurance can be provided that our Common Stock will be regularly traded on an established securities market for purposes of the rules described above. Special rules may apply to non-U.S. holders of Pre-Funded Warrants, who should consult their tax advisors. Non-U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax considerations that could result if we are, or become, a &#8220;U.S. real property holding corporation.&#8221;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Backup Withholding and Information Reporting</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We must report annually to the IRS and to each Non-U.S. Holder the gross amount of the distributions (including constructive distributions) on our Common Stock or Common Warrants paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. Holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate, currently 24%, with respect to dividends (or constructive dividends) on our Common Stock or Common Warrants. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E (or other applicable IRS Form W-8) or otherwise meets documentary evidence requirements for establishing that it is a Non-U.S. Holder, or otherwise establishes an exemption. Dividends paid to Non-U.S. Holders subject to withholding of U.S. federal income tax, as described above under the heading &#8220;&#8212;Distributions,&#8221; will generally be exempt from U.S. backup withholding.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Information reporting and backup withholding generally will apply to the proceeds of a disposition of our Common Stock or Common Warrants by a Non-U.S. Holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a Non-U.S. Holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. Holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Copies of information returns may be made available to the tax authorities of the country in which the Non-U.S. Holder resides or is incorporated under the provisions of a specific treaty or agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-23-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a Non-U.S. Holder can be refunded or credited against the Non-U.S. Holder&#8217;s U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Foreign Accounts</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Code Sections 1471-1474, commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, and the Treasury Regulations issued thereunder generally impose a U.S. federal withholding tax of 30% on dividends on, and, subject to the proposed Treasury Regulations discussed below, the gross proceeds from a sale or other disposition of, our Common Stock or Common Warrants such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which include certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on, and, subject to the proposed Treasury Regulations discussed below, the gross proceeds from a sale or other disposition of, our Common Stock or Common Warrants paid to a &#8220;non-financial foreign entity&#8221; (as defined under these rules) unless such entity provides the withholding agent with a certification identifying the direct and indirect U.S. owners of the entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. The withholding obligations under FATCA generally apply to dividends on our Common Stock or Common Warrants. The U.S. Department of the Treasury has issued proposed Treasury Regulations providing that, if finalized in their present form, the withholding obligations under FATCA would not apply with respect to payment of gross proceeds from a sale or other disposition of Common Stock or Common Warrants. The proposed Treasury Regulations may be relied upon until final Treasury Regulations are issued. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of taxes withheld under FATCA. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our Common Stock or Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><b>The preceding discussion of material U.S. federal tax considerations is for information only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our Common Stock, Pre-Funded Warrants or Common Warrants, including the consequences of any proposed changes in applicable laws.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-24-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PLAN OF DISTRIBUTION </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Placement Agent has agreed to act as our exclusive placement agent in connection with this offering. The Placement Agent is not purchasing or selling any of the securities offered by this prospectus, nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities but has agreed to use its reasonable best efforts to arrange for the sale of all of the securities offered hereby. Therefore, we may not sell the entire number of securities offered pursuant to this prospectus. We will enter into a securities purchase agreement directly with certain investors, at the investor&#8217;s option, who purchases our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will deliver the securities being issued to the investors upon receipt of such investor&#8217;s funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have agreed to indemnify the Placement Agent and specified other persons against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the Placement Agent may be required to make in respect thereof.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, certain members of our Board of Directors and non-director executive officers have indicated their preliminary interest in purchasing a portion of our Common Stock and accompanying Common Warrants in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fees and Expenses </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have engaged AGP as our exclusive placement agent in connection with this offering. This offering is being conducted on a &#8220;best efforts&#8221; basis and the Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay the Placement Agent a fee based on the aggregate proceeds as set forth in the table below:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share<br/>
			and<br/>
			Common<br/>
			Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%; border-bottom: 1px solid black;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Per Pre-Funded</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Warrant and</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Common </b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Public offering price</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement Agent Fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds,&#160;before expenses, to us<sup style="vertical-align:top;line-height:120%;">(1)</sup></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">The amount of proceeds, before expenses, to us does not give effect to any exercise of the Pre-Funded Warrants or Common Warrants.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have agreed to pay the Placement Agent the Cash Fee equal to 7.0% of the aggregate gross proceeds from the sale of the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, together with the accompanying Common Warrants, sold in this offering; provided, however, (i) the Placement Agent shall receive 3.50% of the aggregate purchase price paid by any of the Company&#8217;s executive officer or director or their affiliates or the Identified Purchasers, (ii) the Cash Fee shall be 5.0% for the first $3,000,000 of any Securities purchased by Tail Investors and (iii) the Cash Fee shall be 4.0% for amounts invested in excess of the first $3,000,000 of any Securities purchased by Tail Investors. Because there is no minimum offering amount required as a condition to closing in this offering, the actual aggregate Cash Fee, if any, is not presently determinable and may be substantially less than the maximum amount set forth above. No Cash Fee will be payable in respect of any Pre-Funded Warrant or Common Warrant exercises that may occur in the future. We have also agreed to reimburse the Placement Agent at closing (i) for legal and other expenses incurred by it in connection with the offering in an aggregate amount of up to $50,000, and (ii) non-accountable expenses payable to the Placement Agent of up to $10,000. We estimate the total expenses payable by us for this offering, excluding the Placement Agent fees and expenses, will be approximately $0.2 million.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As discussed above, we have agreed to pay an investment banking firm that we engaged in a prior financing a cash fee of up to seven percent (7.0%) of the gross proceeds received by us from of the Tail Investors in this offering (the &#8220;Fee Tail&#8221;). To the extent Tail Investors represent one-half of the gross proceeds received in this offering, we would be obligated to pay to such investment banking firm, and our net proceeds in this offering would be reduced by, approximately $0.2 million.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-25-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Regulation M</i></b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">may not engage in any stabilization activity in connection with our securities; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Lock-Up Agreements</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our directors and officers have entered into lock-up agreements. Under these agreements, these individuals agreed, subject to specified exceptions, not to sell or transfer any shares of Common Stock or securities convertible into, or exchangeable or exercisable for, Common Stock during a period ending 60&#160;days after the completion of this offering, without first obtaining the written consent of the Placement Agent. Specifically, these individuals agreed, in part, subject to certain exceptions, not to:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of Common Stock; or</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any of our securities.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>No Sales of Similar Securities</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have agreed, subject to certain exceptions, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments or supplements thereto (other than the prospectus supplement, registration statement or amendment to the registration statement relating to the securities offered hereunder and a registration statement on Form S-8), until 60&#160;days after the completion of this offering.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Discretionary Accounts</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Placement Agent does not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary authority.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Listing </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;BCDA.&#8221; We do not plan to list the Pre-Funded Warrants or Common Warrants on the Nasdaq or any other securities exchange or trading market.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-26-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LEGAL MATTERS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The validity of the securities offered hereby will be passed upon for us by Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation, Palo Alto, California. Certain members of, and investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich &amp; Rosati, P.C., own an interest representing less than one percent of the outstanding shares of Common Stock. The Placement Agent is being represented by Sullivan &amp; Worcester LLP, New York, New York in connection with this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPERTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2023 have been so incorporated in reliance on the report of PKF San Diego, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WHERE YOU CAN FIND MORE INFORMATION</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have filed with the SEC a registration statement on Form&#160;S-1 under the Securities Act with respect to the securities offered by this prospectus.&#160; This prospectus, which constitutes a part of the registration statement, does not include all of the information contained in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC.&#160; You should refer to the registration statement and its exhibits for additional information.&#160; Whenever we make references in this prospectus to any of our contracts, agreements or other documents, such references are not necessarily complete and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You can read our SEC filings, including the registration statement and its exhibits, over the Internet at the SEC&#8217;s web site at www.sec.gov.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are subject to the information reporting requirements of the Exchange Act, and we will file annual, quarterly and special reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the website of the SEC referred to above. We also maintain a website at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated by reference in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished rather than filed), until the offering of the securities under the registration statement of which this prospectus forms a part is terminated or completed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Annual Report on Form&#8239;10-K for the year ended December&#160;31, 2023, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924009587/bcda20231231_10k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">March&#160;</span><span style="text-decoration: underline;">27, 2024</span></a>;</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our Quarterly Reports on Form&#8239;10-Q for the quarters ended March&#160;31, 2024 and June 30, 2024, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924016611/bcda20240331_10q.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">May 14, 2024</span></a>&#160;and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/925741/000143774924026310/bcda20240630_10q.htm" style="-sec-extract:exhibit;">August&#160;13, 2024</a>, respectively;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-27-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the portions of our Definitive Proxy Statement on Schedule&#160;14A (other than information furnished rather than filed therein) filed on <a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924012080/bcda20240410_def14a.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">April&#160;</span><span style="text-decoration: underline;">15, 2024</span></a>;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Current Reports on Form&#8239;8-K filed on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924002611/bcda20240130_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">January&#160;</span><span style="text-decoration: underline;">31, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924003561/bcda20240208_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">February 9, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924007371/bcda20240312_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">March 12, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924007467/bcda20240312c_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">March 12, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924017856/bcda20240520_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">May 21, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924018654/bcda20240530_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">May 30, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924019535/bcda20240607_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">June 7, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924019813/bcda20240610_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">June&#160;</span><span style="text-decoration: underline;">10, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924022861/bcda20240716_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">July 17, 2024</span></a>,&#160;<a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924023823/bcda20240730_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">July 30, 2024</span></a>, and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924027952/bcda20240827_8k.htm" style="-sec-extract:exhibit;">August 28, 2024</a>; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the description of our Common Stock contained in the Registration Statements on Form&#8239;8-A relating thereto, filed on <a href="http://www.sec.gov/Archives/edgar/data/925741/000143774919014460/bcda20190723_8a12b.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">July 23, 2019</span></a>, including any amendment or report filed for the purpose of updating such description.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. Any such request may be made by writing or telephoning us at the following address or phone number:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">BioCardia, Inc.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">320 Soquel Way</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Sunnyvale, California 94085</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Attn: Investor Relations</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(650) 226-0120</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We will not, however, send exhibits to those documents, unless the exhibits are specifically incorporated by reference in those documents.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We make available free of charge on our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. You may access these filings on our website at <i>www.biocardia.com</i>. We do not incorporate the information on our website into this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any statement contained in a document incorporated in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference therein. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-28-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="logo01.jpg" src="logo01.jpg"/></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Prospectus</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b>&#160;<b>Shares of Common Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b>&#160;<b>Pre-Funded Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b> <b>Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b>&#160;<b>Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;<b>2,439,024</b>&#160;<b>Shares of Common Stock issuable upon exercise of the Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Sole Placement Agent</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>A.G.P.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>, 2024</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 13. Other Expenses of Issuance and Distribution</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following table sets forth all expenses, other than the selling commissions, payable by the registrant in connection with the securities being registered. All the amounts shown are estimates except the SEC registration fee, the Nasdaq Stock Market and the FINRA filing fee.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SEC registration fee</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,862</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FINRA filing fee</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,392</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal fees and expenses</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">200,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting fees and expenses</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Miscellaneous</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,458</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,712</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 14. Indemnification of Directors and Officers</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except for breaches of the director&#8217;s duty of loyalty to the corporation or its stockholders, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of a law, authorizations of the payments of a dividend or approval of a stock repurchase or redemption in violation of Delaware corporate law or for any transactions from which the director derived an improper personal benefit.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with a threatened, pending, or completed action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, indemnification is limited to expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with defense or settlement of such action or suit and no indemnification shall be made with respect to any claim, issue, or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. In addition, to the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit, or proceeding described above (or claim, issue, or matter therein), such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith. Expenses (including attorneys&#8217; fees) incurred by an officer or director in defending any civil, criminal, administrative, or investigative action, suit, or proceeding may be advanced by the corporation upon receipt of an undertaking by such person to repay such amount if it is ultimately determined that such person is not entitled to indemnification by the corporation under Section 145 of the General Corporation Law of the State of Delaware.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 174 of the General Corporation Law of the State of Delaware provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-1
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our amended and restated certificate of incorporation provides for the indemnification of our directors to the fullest extent permissible under Delaware General Corporation Law. Our amended and restated bylaws provide for the indemnification of our directors and officers to the maximum extent permitted by the Delaware General Corporation Law. In addition, we have entered into indemnification agreements with our directors and officers, and we maintain insurance policies insuring our directors and officers against certain liabilities that they may incur in their capacity as officers and directors of our company.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">These indemnification provisions and the indemnification agreements entered into between us and our officers and directors may be sufficiently broad to permit indemnification of our officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 15. Recent Sales of Unregistered Securities</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following is a summary of all securities that we have sold during the past three years without registration under the Securities Act. On May 30, 2024, we executed a 1-for-15 reverse stock split of our Common Stock. Unless otherwise indicated, all per share amounts included in the summary below for transactions that occurred prior to such respective reverse stock splits are presented without giving effect to such reverse stock splits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 9, 2024, we entered into a Securities Purchase and Registration Rights Agreement (the &#8220;2024 Purchase Agreement&#8221;) relating to a private placement (the &#8220;2024 Private Placement&#8221;) with certain qualified institutional buyers and institutional accredited investors, as well as Peter Altman, our President and Chief Executive Officer (each, a &#8220;2024 Investor&#8221;&#160;and, collectively, the &#8220;2024 Investors&#8221;). Pursuant to the 2024 Purchase Agreement, the Company sold to the 2024 Investors (i) an aggregate of 2,012,978 shares of the Company&#8217;s Common Stock (the &#8220;2024 Shares&#8221;), at an offering price of $0.4331 per 2024 Share, other than Dr. Altman, who paid $0.4625 per 2024 Share in compliance with Nasdaq rules, and (ii) warrants to purchase an aggregate of 1,006,488 shares of Common Stock (the &#8220;2024 Warrants&#8221;; the shares of Common Stock issuable upon exercise of or otherwise pursuant to the 2024 Warrants collectively are referred to herein as the &#8220;2024 Warrant Shares&#8221;; the 2024 Warrant Shares, together with the 2024 Shares and the 2024 Warrants, as applicable, the &#8220;2024 Securities&#8221;). Of the 2024 Securities, Dr. Altman purchased (i) 108,108 2024 Shares and (ii) a 2024 Warrant to purchase 54,054 2024 Warrant Shares.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December 14, 2022, we entered into a Securities Purchase and Registration Rights Agreement (the &#8220;2022 Purchase Agreement&#8221;) relating to a private placement (the &#8220;2022 Private Placement&#8221;) with certain qualified institutional buyers and institutional accredited investors, as well as certain directors and officers of the Company (each, a &#8220;2022 Investor&#8221;&#160;and, collectively, the &#8220;2022 Investors&#8221;). Pursuant to the 2022 Purchase Agreement, the Company agreed to sell to the 2022 Investors an aggregate of 2,122,017 shares of the Company&#8217;s Common Stock (the &#8220;2022 Shares&#8221;), at an offering price of $1.68 per 2022 Share. Certain of the Company&#8217;s directors and executive officers purchased an aggregate of 499,997 of the 2022 Shares.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act because the issuance of securities to the recipients did not involve a public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-2
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Item 16. Exhibits and Financial Statement Schedules</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(a)</b>&#160;<b>Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">See the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form&#160;S-1, which Exhibit Index is incorporated by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(b)</b>&#160;<b>Financial Statement Schedules</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 17. Undertakings</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The undersigned registrant hereby undertakes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To include any prospectus required by section 10(a)(3) of the Securities Act;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221;&#160;table in the effective registration statement.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; <i>provided, however</i>, that paragraphs&#160;(i), (ii)&#160;and (iii)&#160;above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act that are incorporated by reference in this Registration Statement or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the Registration Statement.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-3
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iv.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to section&#160;13(a) or section&#160;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section&#160;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the purpose of determining any liability under the Securities Act of 1933, each post&#8209;effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i>&#160;offering thereof.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to section&#160;13(a) or section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit Index</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b><br/>
			<b><span style="text-decoration: underline;">Number</span></b></div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline;">Description</span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1*#</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_719066.htm" style="-sec-extract:exhibit;">Form of Placement Agency Agreement</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1(1)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000119312516691114/d242455dex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Agreement and Plan of Merger dated August 22, 2016</span>&#160;</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.2(2)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex2-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">First Amendment to Agreement and Plan of Merger dated October 21, 2016 </span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1**</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924025899/ex_711385.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation, as amended May 29, 2024, as currently in effect</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.2(3)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924018654/ex_681330.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Certificate of Amendment of Amended and Restated Certificate of Incorporation as filed on May 29, 2024 with the State of Delaware</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.3(4)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774923011915/ex_508441.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Amended and Restated Bylaws </span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1(5)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Specimen common stock certificate</span></a>&#160;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2(6)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">BioCardia 2002 Stock Plan, as amended</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.3(7)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917001935/ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Stock Option Agreement under BioCardia 2002 Stock Plan</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.4**</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924025899/ex_711393.htm" style="-sec-extract:exhibit;">BioCardia 2016 Equity Incentive Plan, as amended</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.5(8)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917001935/ex4-7.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Stock Option Agreement under BioCardia 2016 Equity Incentive Plan</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.6(9)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917001935/ex4-8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Restricted Stock Unit Agreement under BioCardia 2016 Equity Inventive Plan</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; text-align: center;">4.7*</td>
			<td style="vertical-align: top; width: 90%;"><a href="ex_718768.htm" style="-sec-extract:exhibit;">Form of Pre-Funded Warrant in connection with this offering</a></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.8*</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_718769.htm" style="-sec-extract:exhibit;">Form of Common Warrant in connection with this offering</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.9(10)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774920010860/ex_186905.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Director Restricted Stock Unit Agreement under the BioCardia 2016 Equity Incentive Plan</span></a></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-4
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 10%;"><b>Exhibit</b><br/>
			<b><span style="text-decoration: underline;">Number</span></b></td>
			<td style="vertical-align: bottom; width: 90%;"><b><span style="text-decoration: underline;">Description</span></b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.10(11)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774922029106/ex_456742.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Securities Purchase and Registration Rights Agreement, dated December 14, 2022, between the Company and certain qualified institutional buyers and institutional accredited investors</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.11(12)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924003561/ex_624462.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Securities Purchase and Registration Rights Agreement, dated February 9, 2024, by and among the Company and certain qualified institutional buyers and institutional accredited investors (including the Form of Warrant attached as Exhibit A thereto)</span></a>&#160;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5.1*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_719273.htm" style="-sec-extract:exhibit;">Opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C.</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1(13)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Indemnification Agreement for directors and executive officers</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2(14)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917005643/ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Change of Control and Severance Agreement with each executive officer</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.3(15)***</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex10-8.htm" style="-sec-extract:exhibit;">License and Distribution Agreement, dated October 30, 2012, by and between the Company and Biomet Biologics, LLC, as amended</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.4(16)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774923008312/ex_492010.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Second Amendment to License and Distribution Agreement, dated September 22, 2022, by and between Biomet Biologics, LLC</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.5(17)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774920007637/ex_181285.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Litigation Funding Agreement dated April 9, 2020, between BSLF, LLC and the Company</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.6(18)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774922007544/ex_340237.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Lease agreement, dated December 14, 2021 between the Company and the Irvine Company LLC</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.7(19)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774922008717/ex_356846.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Controlled Equity Offering Sales Agreement dated April 12, 2022 between the Company and Cantor Fitzgerald &amp; Co.</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.8(20)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774923033718/ex_602831.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">At The Market Offering Agreement, dated December 6, 2023, by and between BioCardia, Inc. and H.C. Wainwright &amp; Co., LLC</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.9*#</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_718770.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.10**</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924025899/ex_711394.htm" style="-sec-extract:exhibit;">Amendment to Change of Control and Severance Agreement, dated May 30, 2024, by and between BioCardia, Inc. and Peter Altman</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.11**</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924025899/ex_711395.htm" style="-sec-extract:exhibit;">Amendment to Change of Control and Severance Agreement, dated May 30, 2024, by and between BioCardia, Inc. and David McClung</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">21.1(21)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924009587/ex_642178.htm" style="-sec-extract:exhibit;">Subsidiaries of the Company</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23.1*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_718762.htm" style="-sec-extract:exhibit;">Consent of PKF San Diego, LLP, Independent Registered Public Accounting Firm</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23.2*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_719273.htm" style="-sec-extract:exhibit;">Consent of Wilson Sonsini Goodrich &amp; Rosati, P.C. (included in the opinion filed as Exhibit&#8239;5.1 to this registration statement)</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">24.1</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of attorney (included on signature page of this report)</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_718763.htm" style="-sec-extract:exhibit;">Filing Fee Table</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; text-align: center;">**</td>
			<td style="vertical-align: bottom; width: 90%;">Previously Filed</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">***</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Confidential Treatment portions of this exhibit have been omitted as permitted by applicable regulations.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8224;</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To be filed by amendment.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</div>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-5
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(1)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 2.1 to the Current Report on Form 8-K filed by us on August 25, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 2.2 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(3)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 3.1 to the Current Report on Form 8-K filed by us on May 30, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(4)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 3.1 to the Current Report on Form 8-K filed by us on May 1, 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(5)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(6)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(7)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.3 to the registration statement on Form S-8 filed by us on February 8, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(8)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.7 to the registration statement on Form S-8 filed by us on February 8, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(9)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.8 to the registration statement on Form S-8 filed by us on February 8, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(10)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on May 15, 2020.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(11)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on December 15, 2022.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(12)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on February 9, 2024.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(13)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.4 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(14)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.2 to the Annual Report on Form 10-K filed by us on March 30, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(15)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.8 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(16)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.4 to the Annual Report on 10-K filed by us on March 29, 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(17)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed by us on April 14, 2020.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(18)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.14 to the Annual Report on 10-K filed by us on March 29, 2022.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(19)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 1.1 to the Current Report on Form 8-K filed by us on April 12, 2022.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(20)</div>
			</td>
			<td style="vertical-align: middle; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 1.1 to the Current Report on Form 8-K filed by us on December 6, 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(21)</div>
			</td>
			<td style="vertical-align: middle; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously Filed as Exhibit 21.1 to the Annual Report on Form 10-K filed on March 27, 2024</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-6
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#8239;S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on August 29, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td colspan="2" rowspan="1" style="width: 5%;"><b>BIOCARDIA,</b>&#8239;<b>INC.</b></td>
			<td style="width: 55%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&#160;</td>
			<td style="width: 40%;">&#160;</td>
			<td style="width: 55%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 5%;">By:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 40%;">/s/ Peter Altman, Ph.D.</td>
			<td style="width: 55%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&#160;</td>
			<td style="width: 40%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Peter Altman, Ph.D.</div>

			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">President and Chief Executive Officer</div>
			</td>
			<td style="width: 55%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Signature</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Date</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ Peter Altman, Ph.D.</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer and Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Peter Altman, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ David McClung</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">David McClung</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; text-align: center;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">*</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Andrew Blank</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">*</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jim Allen</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">*</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bill Facteau</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">*</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Richard Krasno, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%; text-align: center;">*</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">August 29, 2024</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jay M. Moyes</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%; text-align: center;">*</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 29, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Simon Stertzer, M.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">*Pursuant to power of attorney</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">By:&#160; &#160;<span style="text-decoration: underline;">/s/ Peter Altman</span></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Peter Altman, Ph.D.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><i>Attorney-in-fact</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
II-7
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex_719066.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html><head>
	<title>ex_719066.htm</title>

	<!-- Generated by ThunderDome Portal - 8/29/2024 6:10:02 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 1.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>A.G.P./Alliance Global Partners</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>590 Madison Avenue, 28th Floor</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>New York, NY 10022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August [__], 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">BioCardia, Inc.<br>
			Attention:&nbsp;&nbsp;Peter Altman, Chief Executive Officer<br>
			320 Soquel Way</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sunnyvale, CA 94085</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Placement Agency Agreement</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dear Mr. Altman:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Subject to the terms and conditions of this letter agreement (the &#8220;<b>Agreement</b>&#8221;) between A.G.P./Alliance Global Partners, as the sole placement agent (&#8220;<b>A.G.P.</b>&#8221;) (A.G.P. is also referred to herein as the &#8220;<b>Placement</b>&nbsp;<b>Agent</b>&#8221;), and BioCardia, Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a &#8220;reasonable best efforts&#8221; basis, in connection with the proposed placement (the &#8220;<b>Placement</b>&#8221;) of registered securities of the Company, consisting of: (i)&nbsp;shares of common stock, par value $0.001 per share (&#8220;<b>Common Stock</b>&#8221;), (ii) pre-funded warrants to purchase Common Stock (the &#8220;<b>Pre-Funded Warrants</b>&#8221;), and (iii) warrants to purchase Common Stock (the &#8220;<b>Common Warrants</b>&#8221; and collectively with the Pre-Funded Warrants, the &#8220;<b>Warrants</b>&#8221;).&nbsp; The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the &#8220;<b>Placement Agent Securities</b>.&#8221;&nbsp; The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warrants shall be offered and sold under the Company&#8217;s registration statement on Form S-1 (File No. 333-281448), which was declared effective by the Securities and Exchange Commission (the &#8220;<b>Commission</b>&#8221;) on August [__], 2024.&nbsp; The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the &#8220;<b>Purchase</b>&nbsp;<b>Agreement</b>&#8221;), shall be collectively referred to herein as the &#8220;<b>Transaction Documents</b>.&#8221;&nbsp; The terms of the Placement shall be mutually agreed upon by the Company and the purchasers listed in the Purchase Agreement (each, a &#8220;<b>Purchaser</b>&#8221; and collectively, the &#8220;<b>Purchasers</b>&#8221;), and nothing herein constitutes that the Placement Agent would have the power or authority to bind the Company or any Purchaser, or an obligation for the Company to issue any Placement Agent Securities or complete the Placement.&nbsp; The Company expressly acknowledges and agrees that the Placement Agent&#8217;s obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement Agent to purchase the Placement Agent Securities and does not ensure the successful placement of the Placement Agent Securities or any portion thereof or the success of the Placement Agent with respect to securing any other financing on behalf of the Company.&nbsp; The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement.&nbsp; Certain affiliates of the Placement Agent may participate in the Placement by purchasing some of the Placement Agent Securities.&nbsp; The sale of Placement Agent Securities to any Purchaser will be evidenced by the Purchase Agreement between the Company and such Purchaser, in a form reasonably acceptable to the Company and the Purchaser. Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement.&nbsp; Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries from prospective Purchasers. The Company retains the right, in its sole discretion, to approve or reject any potential investor in the Placement and to approve or disapprove, in its sole discretion, the final terms and conditions of the placement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 8%;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>SECTION 1.</u></p>
			</td>
			<td style="width: 89%;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td rowspan="1" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Representations of the Company</u>.&nbsp;&nbsp;With respect to the Placement Agent Securities, each of the representations and warranties (together with any related disclosure schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is hereby incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the Closing Date, hereby made to, and in favor of, the Placement Agent.&nbsp;&nbsp;In addition to the foregoing, the Company represents and warrants that there are no affiliations with any Financial Industry Regulatory Authority (&#8220;<b>FINRA</b>&#8221;) member firm participating in the Placement among the Company&#8217;s officers or directors.</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">B.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Covenants of the Company</u>.&nbsp;&nbsp;Furthermore, for sixty (60) days after the Closing Date, the Company shall not, without the prior written consent of the Placement Agent, (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or (ii) file any registration statement or amendment or supplement thereto, other than the Preliminary Prospectus, the Prospectus or a registration statement on Form S-8 in connection with any employee benefit plan; provided, however, such restrictions shall not apply with respect to an Exempt Issuance.&nbsp;&nbsp;In addition, for one hundred and eighty (180) days after the Closing Date, other than as set forth in the Purchase Agreement, the Company shall not effect or enter into an agreement to effect any issuance of Placement Agent Securities or shares of Common Stock involving a Variable Rate Transaction except such restriction shall not apply with respect to an Exempt Issuance, <u>provided</u>, <u>however</u>, that, following the 60<sup style="vertical-align:top;line-height:120%;">th</sup>&nbsp;day after the Closing Date, the Company may enter into and/or issue shares of Common Stock in an &#8220;at the market&#8221;&nbsp;offering.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>SECTION 2.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>REPRESENTATIONS OF THE PLACEMENT AGENT</u>.&nbsp; The Placement Agent represents and warrants that it (i) is a member in good standing of the FINRA, (ii) is registered as a broker/dealer under the Securities Exchange Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;), (iii)&nbsp;is licensed as a broker/dealer under the laws of the United States of America, applicable to the offers and sales of the Placement Agent Securities by the Placement Agent, (iv) is and will be a corporate body validly existing under the laws of its place of incorporation, (v) has full power and authority to enter into and perform its obligations under this Agreement and (vi) has taken all reasonable and appropriate measures to ensure that the Placement constitutes a &#8220;public offering&#8221; for purposes of Nasdaq Rule 5635 and will provide any documentation reasonably requested by the Company to substantiate such determination.&nbsp; The Placement Agent will immediately notify the Company in writing of any change in its status with respect to subsections (i) through (vi) above.&nbsp; The Placement Agent covenants that it will use its reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>SECTION 3.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>COMPENSATION</u>.&nbsp; In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agent and/or its respective designees a cash fee of 7.0% of the aggregate purchase price paid by any and all Purchasers at the Closing (the &#8220;<b>Cash Fee</b>&#8221;); provided, however, (i) that the Placement Agent shall receive 3.50% of the aggregate purchase price paid by any of the Company&#8217;s executive officer or director or their affiliates or those investors listed on Exhibit A hereto and any other Purchaser brought to the Placement by the Company, (ii) that the Cash Fee shall be 5.0% for the first $3,000,000 of any Securities purchased by any of the persons pursuant to which the Company is required to pay a tail fee to a prior placement agent (the &#8220;<b>Tail Investors</b>&#8221;) and (iii) that the Cash Fee shall be 4.0% for amounts invested in excess of the first $3,000,000 of any Securities purchased&nbsp; by Tail Investors.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 4.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>EXPENSES</u>.&nbsp; The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Placement Agent Securities (including all printing and engraving costs); (ii) all fees and expenses of the transfer agent; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Placement Agent Securities; (iv)&nbsp;all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Preliminary Prospectus and the Prospectus, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys&#8217; fees and expenses incurred by the Company in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Placement Agent Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country; (vii) the fees and expenses associated with including the Placement Agent Securities on the Trading Market; (viii) up to $50,000 for accountable expenses related to legal fees of counsel to the Placement Agent; and (ix) non-accountable expenses, including IPREO software related expenses, background check expenses, tombstones and marketing related expenses, including road show expenses, and any other non-accountable expenses incurred by the Placement Agent in connection with the Placement, provided, however, that such reimbursement for non-accountable expenses shall not exceed $10,000.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>SECTION 5.</u></p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>INDEMNIFICATION</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To the extent permitted by law, with respect to the Placement Agent Securities, the Company shall indemnify and hold harmless the Placement Agent and its affiliates, agents, stockholders, directors, officers, employees, members and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) (each such entity or person, an &#8220;<b>Indemnified Person</b>&#8221;) from and against all claims, actions, suits, proceedings (including those of stockholders), damages, costs and liabilities (collectively, &#8220;<b>Claims</b>&#8221;), and shall reimburse each Indemnified Person for all reasonable out-of-pocket fees and expenses (including the reasonable fees and expenses of counsel) (collectively, the &#8220;<b>Expenses</b>&#8221;) as they are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any Claim, whether or not an Indemnified Person is a party thereto, that is caused by, arises out of, or is based upon (i) any untrue statements made or any statements omitted to be made in the Registration Statement, the Preliminary Prospectus or the Prospectus, or by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged untrue statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or on behalf of an Indemnified Person expressly for use in the Registration Statement, Preliminary Prospectus or any Prospectus) or (ii) any other actions taken or omitted to be taken by the Company or any Indemnified Person in connection with this Agreement; provided, however, the Company will not be responsible for any Claims or Expenses of any Indemnified Person that are judicially determined to have resulted primarily from an Indemnified Person&#8217;s (x) willful misconduct, violation of law or gross negligence in connection with any of the action, inaction or the services described herein, or (y) use of any offering materials or information concerning the Company in connection with the offer or sale of the Placement Agent&#8217;s Securities in the Placement, which were not authorized for such use by the Company and which use constitutes gross negligence, violation of law or willful misconduct.</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">B.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Promptly after receipt by the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which any Indemnified Person is entitled to indemnity hereunder, the Placement Agent will notify the Company in writing of such claim or of the commencement of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses.&nbsp;&nbsp;If the Company so elects or is requested by the Placement Agent, the Company will assume the defense of such action or proceeding and will employ counsel reasonably satisfactory to the Placement Agent and will pay the reasonable fees and expenses of such counsel.&nbsp;&nbsp;Notwithstanding the preceding sentence, the Placement Agent will be entitled to employ its own counsel separate from counsel for the Company and from any other party in such action if counsel for the Placement Agent reasonably determines that it would be inappropriate under the applicable rules of professional responsibility for the same counsel to represent both the Company and the Placement Agent.&nbsp;&nbsp;In such event, the reasonable out-of-pocket fees and disbursements of no more than one such separate counsel will be paid by the Company, in addition to reasonable fees of local counsel.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">C.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company may not settle, compromise or consent to the entry of any judgment in any pending or threatened Claim, in which indemnification may be sought hereunder (whether or not any Indemnified Person is an actual or potential party thereto), without the prior written consent of the Placement Agent (which will not be unreasonably delayed or withheld) unless such settlement, compromise or consent provides for an unconditional and irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">D.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company agrees to notify the Placement Agent promptly of the assertion against it or any other person of any Claim or the commencement of any action or proceeding relating to a transaction contemplated by this Agreement.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">E.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If for any reason the foregoing indemnity is unavailable to the Placement Agent or insufficient to hold the Placement Agent harmless, then the Company shall contribute to the amount paid or payable by the Placement Agent as a result of such Claim or Expenses in such proportion as is appropriate to reflect (a) the relative benefits to the Company on the one hand, and the Placement Agent on the other hand, in connection with the Placement, (b) the relative fault of the parties, and (c) other equitable considerations; provided, however, that in no event shall the amount to be contributed by the Placement Agent exceed the fees actually received by the Placement Agent under this Agreement.&nbsp;&nbsp;Notwithstanding the immediately preceding sentence, to the extent the exception to indemnification contemplated by Paragraph A of this Section applies with respect to the Placement Agent, the Company shall contribute to the amount paid or payable by the Placement Agent as a result of such Claim or Expenses in such proportion as is appropriate to reflect the relative fault of the Company, on the one hand, and the Placement Agent, on the other hand, in connection with the matters contemplated by the Agreement; provided, however, that in no event shall the amount to be contributed by Placement Agent exceed the fees actually received by Placement Agent under the Agreement.&nbsp;&nbsp;The Company agrees that for the purposes of this paragraph the relative benefits to the Company and the Placement Agent of the contemplated transaction (whether or not such transaction is consummated) shall be deemed to be in the same proportion that the aggregate cash consideration payable (or contemplated to be payable) in such transaction bears to the fees paid or payable to the Placement Agent under the Agreement.</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">F.</td>
			<td style="width: 89%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These indemnification provisions shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed, survive the termination of this Agreement, and be in addition to any liability that the Company might otherwise have to any Indemnified Person.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 6.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>ENGAGEMENT TERM</u>.&nbsp; The Placement Agent&#8217;s engagement hereunder will be until the earlier of the Closing Date and August 25, 2024.&nbsp; The date of termination of this Agreement is referred to herein as the &#8220;<b>Termination Date</b>.&#8221;&nbsp; In the event, however, in the course of the Placement Agent&#8217;s performance of due diligence it deems, it necessary to terminate the engagement, the Placement Agent may do so prior to the Termination Date.&nbsp; The Company may elect to terminate the engagement hereunder for any reason prior to the Termination Date but will remain responsible for fees pursuant to Section 3 hereof with respect to the Placement Agent Securities if sold in the Placement.&nbsp; Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein, as well as provisions in Sections 10 &#8211; 14 hereof will survive any expiration or termination of this Agreement.&nbsp; If this Agreement is terminated prior to the completion of the Placement, all fees and expenses due to the Placement Agent as set forth in Section 3 and Section 4 (except for the $10,000 non-accountable expense allowance) shall be paid by the Company to the Placement Agent on or before the Termination Date (in the event such fees are earned or owed as of the Termination Date).&nbsp; The Placement Agent agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes other than those contemplated under this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 7.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>PLACEMENT AGENT INFORMATION</u>.&nbsp; The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement is for the confidential use of the Company only in its evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent&#8217;s prior written consent; provided, however, that the Company may disclose a copy of this Agreement (i) to its employees, officers, managers and members and (ii) to any investor or prospective investor in the Placement, any acquiror or prospective acquiror of the Company or any underwriter or prospective underwriter, in each case provided that the Company takes reasonable measures to ensure that the recipient of such information treats such information as confidential.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 32pt; text-align: justify;"><u>SECTION 8.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>NO FIDUCIARY RELATIONSHIP</u>.&nbsp; This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof.&nbsp; The Company acknowledges and agrees that the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agent hereunder, all of which are hereby expressly waived.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 9.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>CLOSING</u>.&nbsp; The obligations of the Placement Agent, and the closing of the sale of the Placement Agent Securities hereunder are subject to the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects), of the representations and warranties on the part of the Company contained herein and in the Purchase Agreement (except to the extent a representation or warranty speaks as of a specific date, in which case such representation or warranty shall be accurate as of such date), to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agent:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Placement Agent Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Placement Agent Securities shall be reasonably satisfactory in all material respects to the Placement Agent.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Placement Agent shall have received from the Company&#8217;s counsel, Wilson Sonsini Goodrich &amp; Rosati LLP, such counsel&#8217;s written opinion and negative assurance letter with respect to the Placement Agent Securities, addressed to the Placement Agent and dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement Agent.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">C.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Placement Agent shall have received an executed FINRA questionnaire from each of the Company and the Company&#8217;s executive officers and directors as well as executed Lock-Up Agreements from the Company&#8217;s executive officers and directors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">D.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Shares of Common Stock sold in the Placement, including shares of Common Stock issuable upon the exercise of the Warrants, must be registered under the Exchange Act.&nbsp;&nbsp;The Company shall have taken no action designed to terminate the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the Commission or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing, except as disclosed in the Registration Statement, the Preliminary Prospectus and the Prospectus.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">E.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would, as of the Closing Date, prevent the issuance or sale of the Placement Agent Securities.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">F.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company shall have entered into a Purchase Agreement with each of the Purchasers of the Placement Agent Securities and such agreements shall be in full force and effect and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">FINRA shall have raised no objection to the fairness and reasonableness of the terms and arrangements of this Agreement.&nbsp;&nbsp;In addition, the Company shall, if requested by the Placement Agent, make or authorize Placement Agent&#8217;s counsel to make on the Company&#8217;s behalf, any filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all filing fees required in connection therewith.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">[Reserved]</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Placement Agent shall have received customary certificates of the Company&#8217;s executive officers, as to the accuracy of the representations and warranties contained in the Purchase Agreement, and a certificate of the Company&#8217;s secretary certifying (i) that the Company&#8217;s charter documents are true and complete, have not been modified and are in full force and effect; (ii)&nbsp;that the resolutions of the Company&#8217;s Board of Directors relating to the Placement are in full force and effect and have not been modified; and (iii) as to the incumbency of the officers of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If any of the conditions specified in this Section 9 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agent hereunder may be cancelled by the Placement Agent at, or at any time prior to, the Closing Date.&nbsp; Notice of such cancellation shall be given to the Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 10.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>GOVERNING LAW</u>.&nbsp; This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed entirely in such State, without regard to principles of conflicts of law.&nbsp; This Agreement may not be assigned by either party without the prior written consent of the other party.&nbsp; This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns.&nbsp; Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or conduct in connection herewith is waived.&nbsp; Any dispute arising under this Agreement may be brought into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts.&nbsp; Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. &nbsp;Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 11.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>ENTIRE AGREEMENT/MISCELLANEOUS</u>.&nbsp; This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes all prior agreements and understandings, relating to the subject matter hereof, including the terms of engagement, dated June 26, 2024, by and between the Company and the Placement Agent, which engagement letter shall be terminated and of no further effect upon the execution of this agreement. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision of this Agreement, which will remain in full force and effect.&nbsp; This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by both the Placement Agent and the Company.&nbsp; The representations, warranties, agreements and covenants contained herein shall survive the Closing Date of the Placement and delivery of the Placement Agent Securities for the applicable statute of limitations.&nbsp; This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.&nbsp; In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 12.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>NOTICES</u>.&nbsp; Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following the date of mailing, if sent by an internationally recognized air courier service, or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given.&nbsp; The address for such notices and communications shall be as set forth on the signature pages hereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 13.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>PRESS ANNOUNCEMENTS</u>.&nbsp; The Company agrees that the Placement Agent shall, on and after the Closing Date, have the right to reference the Placement and the Placement Agent&#8217;s role in connection therewith in the Placement Agent&#8217;s marketing materials and on its website and to place advertisements in financial and other newspapers and journals, in each case at its own expense.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>SECTION 14.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>PAYMENTS</u>.&nbsp; All payments made or deemed to be made by the Company to the Placement Agent, its affiliates, stockholders, directors, officers, employees, members and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) (each, a &#8220;<b>Payee</b>&#8221;), if any, will be made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income or similar taxes) imposed or levied by or on behalf of the United States or any political subdivision or any taxing authority thereof or therein unless the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges.&nbsp; In such event, the Company will pay such additional amounts as will result, after such withholding or deduction, in the receipt by the Payee of the amounts that would otherwise have been receivable in respect thereof.&nbsp; For the avoidance of doubt, all sums payable, paid or deemed payable under this Agreement shall be considered exclusive of value added tax, sales tax or other similar taxes which shall be borne by, paid, collected and remitted by the Company in accordance with applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Please confirm that the foregoing correctly sets forth our agreement by signing and returning to the Placement Agent the enclosed copy of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>[The remainder of this page has been intentionally left blank.]</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The foregoing Agreement is hereby accepted and agreed to as of the date first written above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>A.G.P./ALLIANCE GLOBAL PARTNERS</b></td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 3%;">By:</td>
			<td colspan="4" rowspan="1" style="width: 35%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 17%;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 51%;">&nbsp;</td>
			<td style="width: 5%;">Name:</td>
			<td colspan="3" rowspan="1" style="width: 44%;">Thomas J. Higgins</td>
		</tr>
		<tr>
			<td style="width: 51%;">&nbsp;</td>
			<td style="width: 5%;">Title:</td>
			<td colspan="3" style="width: 44%;">Managing Director</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 40%;">&nbsp;</td>
			<td style="width: 60%;">Address for Notice:<br>
			590 Madison Avenue, 28<sup style="vertical-align:top;line-height:120%;">th</sup> Floor<br>
			New York, NY&nbsp; 10022<br>
			Attn:&nbsp; Thomas J. Higgins<br>
			Email:&nbsp; thiggins@allianceg.com</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">Accepted and agreed to as of the date first written above:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b>BIOCARDIA, </b>&nbsp;<b>INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 3%;">By:</td>
			<td style="width: 35%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 62%;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 5%;">Name:</td>
			<td style="width: 95%;">Dr. Peter A. Altman, Ph.D</td>
		</tr>
		<tr>
			<td style="width: 5%;">Title:</td>
			<td style="width: 95%;">Chief Executive Officer</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;"><u>Address for Notice</u>:</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">320 Soquel Way Sunnyvale, California 94085</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">Attn: Chief Financial Officer</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">Email: CEO@BioCardia.com</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">CFO@BioCardia.com&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">dmcclung@biocardia.com paltman@biocardia.com&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><i>[Signature Page to Placement Agency Agreement]</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>3
<FILENAME>ex_718768.htm
<DESCRIPTION>EXHIBIT 4.7
<TEXT>
<html><head>
	<title>ex_718768.htm</title>

	<!-- Generated by ThunderDome Portal - 8/27/2024 7:59:18 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.7</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PRE-FUNDED WARRANT</b><br>
<b>TO PURCHASE SHARES OF COMMON STOCK</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BIOCARDIA, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:51.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Warrant Shares: ________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:51.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Original Issuance Date: August [__], 2024</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) until this Warrant is exercised in full (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from BioCardia, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares of Common Stock, par value $0.001 per share (the &#8220;<u>Common Stock</u>&#8221;), of the Company (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;).&nbsp; The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section 1.&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated August [__], 2024, among the Company and the purchasers signatory thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section 2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. &nbsp;Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as <b>Exhibit A</b> (the &#8220;<u>Notice of Exercise</u>&#8221;).&nbsp; Within the earlier of (i) two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.&nbsp; No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.&nbsp; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. &nbsp;Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder are permitted, <i>provided however</i> that any such partial exercise must relate to a number of Warrant Shares equal to the lesser of fifty thousand (50,000) and all of the Warrant Shares available for purchase under this Warrant.&nbsp; The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.&nbsp; The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice.&nbsp; Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00&nbsp;p.m. (New York City time) on the Initial Exercise Date, and the Initial Exercise Date shall be the Warrant Share Delivery Date (as defined below) for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.&nbsp; <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">For the avoidance of doubt, at any time during which there is no effective registration statement for the issuance of the Warrant Shares to the Holder, but only if this Warrant is exercised for cash, the Company may settle the exercise of the Warrant with unregistered shares of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>.&nbsp; The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.&nbsp; The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date.&nbsp; The remaining unpaid exercise price per Warrant Share under this Warrant shall be $0.001, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 63pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Cashless Exercise.&nbsp; Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration statement registering the issuance of the Warrant Shares to the Holder, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part otherwise in accordance with the terms of this Warrant, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(A) =</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(B)&nbsp;=</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Exercise Price, as adjusted hereunder; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(X) =</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp; The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Mechanics of Exercise.</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>.&nbsp; The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to, or resale of the Warrant Shares by, the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of the Warrant Shares, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company, and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;).&nbsp; Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.&nbsp; If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, without delivering an objection to the Notice of Exercise per Section 2(a), the Company shall pay to the Holder, at the Holder&#8217;s election either (A) in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until the earlier of such Warrant Shares being delivered or Holder rescinds such exercise or (B) the amount pursuant to a Buy-In pursuant to Section 2(d)(iv) hereof.&nbsp; The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.&nbsp; As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>.&nbsp; If this Warrant shall have been exercised in part in accordance with the limitations of Section 2(a), the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>.&nbsp; If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>.&nbsp; In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&nbsp; For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000.&nbsp; The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.&nbsp; Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>.&nbsp; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&nbsp; As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>.&nbsp; The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <b>Exhibit B </b>duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&nbsp; The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>.&nbsp; The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>.&nbsp; The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates, and (iii) any other Persons whose beneficial ownership of shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&nbsp; To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of Common Stock that was provided by the Company.&nbsp; In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&nbsp; For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written request of a Holder, the Company shall within one Trading Day confirm in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.&nbsp; The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, at the election of the Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant.&nbsp; The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.&nbsp; Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.&nbsp; The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.&nbsp; The limitations contained in this paragraph shall apply to a successor holder of this Warrant.&nbsp; If the Warrant is unexercisable solely as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section 3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>.&nbsp; If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged.&nbsp; Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>[RESERVED]</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>.&nbsp; In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>.&nbsp; During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>[RESERVED]</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>[RESERVED]</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be.&nbsp; For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>.&nbsp; Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>.&nbsp; If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a cash dividend on, or a redemption of, the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.&nbsp; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Adjustment By Company</u>.&nbsp; Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section 4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>.&nbsp; This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto as <b>Exhibit B</b>, duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&nbsp; Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&nbsp; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.&nbsp; The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>.&nbsp; This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&nbsp; Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice.&nbsp; All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>.&nbsp; The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time.&nbsp; The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section 5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Currency</u>.&nbsp; All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>.&nbsp; This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.&nbsp; Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>.&nbsp; The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. &nbsp;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.&nbsp; The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant upon the exercise of any purchase rights under this Warrant.&nbsp; The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&nbsp; The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&nbsp; The Company covenants that all Warrant Shares underlying this Warrant which may be issued and delivered upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 81pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.&nbsp; Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 81pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>.&nbsp; All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>.&nbsp; The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>.&nbsp; No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies.&nbsp; Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>.&nbsp; Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>.&nbsp; No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>.&nbsp; The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&nbsp; The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>.&nbsp; Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.&nbsp; The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>.&nbsp; This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>.&nbsp; Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:63pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>.&nbsp; The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Signature Page Follows)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>BIOCARDIA, INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:&nbsp;&nbsp;[__]</p>

			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:&nbsp;&nbsp;&nbsp;&nbsp;[__]</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO: BIOCARDIA, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">(2) Payment shall take the form of (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#9744; in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Symbol;font-size:10pt;width:72.9411764705882%;margin-left:0pt;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:104.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Investing Entity: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Signature of Authorized Signatory of Investing Entity</i>: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:104.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">A-1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ASSIGNMENT FORM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information.</i>&nbsp;<i> Do not use this form to exercise the Warrant to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 73.7418%; margin-left: 0pt; margin-right: auto;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Please Print)</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Please Print)</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Phone Number:</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Email Address:</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Dated:&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Holder&#8217;s Signature:&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Holder&#8217;s Address:&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">B-1</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>4
<FILENAME>ex_718769.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<html><head>
	<title>ex_718769.htm</title>

	<!-- Generated by ThunderDome Portal - 8/28/2024 7:02:47 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.8</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WARRANT TO PURCHASE SHARES OF COMMON STOCK</b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BIOCARDIA, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:51.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Warrant Shares: ________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:51.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Original Issuance Date: August [__], 2024</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on August [__], 2029 (the &#8220;<u>Termination Date</u>&#8221;), but not thereafter, to subscribe for and purchase from BioCardia, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares of Common Stock, par value $0.001 per share (the &#8220;<u>Common Stock</u>&#8221;), of the Company (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Section&nbsp;1.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated August [__], 2024, among the Company and the purchasers signatory thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Section&nbsp;2.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt; text-indent: 45pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and, on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as <b>Exhibit A </b>(the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder are permitted, <i>provided however</i> that any such partial exercise must relate to a number of Warrant Shares equal to the lesser of fifty thousand (50,000) and all of the Warrant Shares available for purchase under this Warrant. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date (as defined below) for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof</b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt; text-indent: 45pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price under this Warrant shall be $[__] per share of Common Stock, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt; text-indent: 45pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration statement registering the issuance of the Warrant Shares to the Holder, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(A) =</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;Bloomberg&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(B) =</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Exercise Price, as adjusted hereunder; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(X) =</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30&nbsp;a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt;">(d)&nbsp; &nbsp; &nbsp; &nbsp;<u>Mechanics of Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to, or resale of the Warrant Shares by, the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of the Warrant Shares, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, without delivering an objection to the Notice of Exercise per Section 2(a), the Company shall pay to the Holder, at the Holder&#8217;s election either (A) in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until the earlier of such Warrant Shares being delivered or Holder rescinds such exercise or (B) the amount pursuant to a Buy-In pursuant to Section 2(d)(iv) hereof. The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part in accordance with the limitations of Section 2(a), the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <b>Exhibit B</b>, duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates, and (iii) any other Persons whose beneficial ownership of shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of Common Stock that was provided by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder, the Company shall within one Trading Day confirm in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, at the election of the Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable solely as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section&nbsp;3.&nbsp; &nbsp; &nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(b)&nbsp; &nbsp; &nbsp; [RESERVED]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(c)&nbsp; &nbsp; &nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(d)&nbsp; &nbsp; &nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(e)&nbsp; &nbsp; &nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a reincorporation in a different state or a similar transaction pursuant to which the surviving company remains a public company), (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&#8217;s (including its Subsidiaries, taken as a whole) assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each, a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder, as described below, an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, or the consideration of the Fundamental Transaction is at least 70% equity securities, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such cash payment right shall not apply. &#8220;Black Scholes Value&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the five (5) Trading Days immediately prior to such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&#8217;s election and (ii) the effective date of consummation of the Fundamental Transaction. The Company shall cause, to the extent the Fundamental Transaction with within the Company&#8217;s control, any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>[</u>RESERVED<u>]</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(h)&nbsp; &nbsp; &nbsp; &nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a cash dividend on or a redemption of the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 63pt;text-indent:27pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section&nbsp;4.&nbsp; &nbsp; &nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto as <b>Exhibit B </b>duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(b)&nbsp; &nbsp; &nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(c)&nbsp; &nbsp; &nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">Section 5.&nbsp; &nbsp; &nbsp; &nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Currency</u>. All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(b)&nbsp; &nbsp; &nbsp; &nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(d)&nbsp; &nbsp; &nbsp; &nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Authorized Shares</u>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant, which may be issued and delivered upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(f)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(g)&nbsp; &nbsp; &nbsp; &nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">(h)&nbsp; &nbsp; &nbsp; &nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">******************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(<i>Signature Page Follows</i>)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">BIOCARDIA, INC.</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">By:&nbsp; &nbsp; &nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Name:&nbsp;&nbsp;[__]</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Title:&nbsp;&nbsp;&nbsp;&nbsp;[__]</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO: BIOCARDIA, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">(2) Payment shall take the form of (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 0pt;">&#9744; in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 0pt;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Symbol; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:105.6%;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:105.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Symbol; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:105.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Investing Entity: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:105.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Signature of Authorized Signatory of Investing Entity</i>: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:105.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:105.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:105.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ASSIGNMENT FORM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Symbol;font-size:10pt;width:46%;margin-left:0pt;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Address:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Phone Number:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Email Address:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Signature:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Address:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:68%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ex_719273.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_719273.htm</title>

	<!-- Generated by ThunderDome Portal - 8/29/2024 3:18:38 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 5.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 75%; vertical-align: top;">
			<div><img alt="wslogo01.jpg" src="wslogo01.jpg"></div>
			</td>
			<td style="width: 25%; vertical-align: top;">Wilson Sonsini Goodrich &amp; Rosati<br>
			Professional Corporation<br>
			650 Page Mill Road<br>
			Palo Alto, California 94304-1050<br>
			O: 650.493.9300<br>
			F: 650.493.6811</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">August 29, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BioCardia, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">320 Soquel Way</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sunnyvale, California 94085</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"><b>Re:</b> <b>Registration Statement on Form S-1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We have acted as counsel to BioCardia, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), in connection with the registration of the offer and sale of (i) up to 2,439,024 shares (the &#8220;<u>Shares</u>&#8221;) of the Company&#8217;s common stock, $0.001 par value per share (&#8220;<u>Common Stock</u>&#8221;), (ii) pre-funded warrants (the &#8220;<u>Pre-Funded Warrants</u>&#8221;) to purchase up to 2,439,024 shares of Common Stock (the &#8220;<u>Pre-Funded Warrant Shares</u>&#8221;), (iii) warrants (the &#8220;<u>Common Warrants</u>&#8221; and, together with the Pre-Funded Warrants, the &#8220;<u>Warrants</u>&#8221;) to purchase up to 2,439,024 shares of Common Stock (the &#8220;<u>Common Warrant Shares</u>&#8221; and, together with the Pre-Funded Warrant Shares, the &#8220;<u>Warrant Shares</u>&#8221;) and (iv) the Warrant Shares issuable upon exercise of the Warrants, each pursuant to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-281448) (as amended, the &#8220;<u>Registration Statement</u>&#8221;). The Shares, the Warrants and the Warrant Shares are collectively referred to herein as the &#8220;<u>Securities</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We understand that the Shares and the Warrants are to be sold to the purchasers as described in the Registration Statement and pursuant to a securities purchase agreement, substantially in the form filed as an exhibit to the Registration Statement, to be entered into by and among the Company and the purchasers named therein (the &#8220;<u>Purchase Agreement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In our capacity as counsel to the Company, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such instruments, documents, certificates and records that we have deemed relevant and necessary for the basis of our opinions hereinafter expressed. As to questions of fact material to this opinion, we have relied on certificates or comparable documents of public officials and of officers and representatives of the Company. In our examination, we have assumed: (a) the authenticity of original documents and the genuineness of all signatures; (b) the conformity to the originals of all documents submitted to us as copies; (c) the truth, accuracy and completeness of the information, representations and warranties contained in the instruments, documents, certificates and records we have reviewed; (d) the legal competence of all signatories to such documents; and (e) any certificates representing the Securities will be duly executed and delivered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Based upon and subject to the foregoing qualifications, assumptions and limitations and the further limitations set out below, we are of the opinion that:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Shares have been duly authorized and, when issued and delivered against payment therefor in the circumstances contemplated by the Purchase Agreement, will be validly issued, fully paid and non-assessable.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">When the Warrants have been duly executed and delivered by the Company and duly delivered to the purchasers thereof against payment therefor in the circumstances contemplated by the Purchase Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Warrant Shares, when issued and delivered against payment therefor upon the exercise of the applicable Warrant in accordance with the terms therein, will be duly authorized, validly issued, fully paid and non-assessable.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">AUSTIN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BEIJING&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BOSTON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BOULDER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BRUSSELS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HONG KONG&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LONDON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LOS ANGELES&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEW YORK&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PALO ALTO<br>
SALT LAKE CITY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SAN DIEGO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SAN FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEATTLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHANGHAI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WASHINGTON, DC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WILMINGTON, DE</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="wslogo02.jpg" src="wslogo02.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">August 29, 2024</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Page 2</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We express no opinion as to the laws of any other jurisdiction other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware and, solely as to the Warrants constituting valid and binding obligations of the Company, the laws of the State of New York.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Our opinion that any document constitutes a valid and binding obligation is qualified as to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights of creditors generally;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the effect of general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing, and the possible unavailability of specific performance or injunctive relief, whether considered in a proceeding in equity or at law.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">We hereby consent to the use of this opinion as an exhibit to the Registration Statement and to the use of our name under the caption &#8220;Legal Matters&#8221; in the prospectus contained therein. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Sections 7 and 11 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:26.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:26.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Very truly yours,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:26.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:26.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Wilson Sonsini Goodrich &amp; Rosati, P.C.&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:26.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">WILSON SONSINI GOODRICH &amp; ROSATI</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:26.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional Corporation</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>ex_718770.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<html><head>
	<title>ex_718770.htm</title>

	<!-- Generated by ThunderDome Portal - 8/28/2024 7:04:12 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.9</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SECURITIES PURCHASE AGREEMENT</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">This Securities Purchase Agreement (this &#8220;<u>Agreement</u>&#8221;) is dated as of August [__], 2024, between BioCardia, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221; and collectively the &#8220;<u>Purchasers</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below) as to the Shares and the Warrants (and the Warrant Shares underlying the Warrants), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin: 0pt 0pt 0pt 0pt;"><b>ARTICLE I.</b><br>
<b>DEFINITIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">1.1&nbsp; &nbsp; &nbsp;&nbsp;<u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section&nbsp;1.1:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Acquiring Person</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;4.4.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Action</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Auditor</u>&#8221; means PKF San Diego, LLP.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday, or other day on which the Federal Reserve Bank of New York is closed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&#8217; obligations to pay the Subscription Amount at the Closing and (ii)&nbsp;the Company&#8217;s obligations to deliver the Securities, in each case, at the Closing have been satisfied or waived, but in no event later than the first&nbsp;(1st) Trading Day following the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Common Stock</u>&#8221; means common stock of the Company, par value $0.001 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Common Warrants</u>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Common Warrants shall be exercisable immediately upon issuance and have a term of exercise equal to five (5) years from the initial exercise date, in substantially the form of Exhibit A attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Company Counsel</u>&#8221; means Wilson Sonsini Goodrich &amp; Rosati P.C. with offices located at 650 Page Mill Road, Palo Alto, CA 94304.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Disclosure Schedules</u>&#8221; means the Disclosure Schedules of the Company delivered concurrently herewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Disclosure Time</u>&#8221; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00&nbsp;a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01&nbsp;a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>DVP</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Environmental Laws</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(m).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Evaluation Date</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(s)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Exempt Issuance</u>&#8221; means the issuance of (a) shares of Common Stock, restricted stock units, options or other equity awards to employees, consultants, contractors, advisors, officers, or directors of the Company pursuant to any stock or option plan in existence as of the date hereof, provided that such issuances to consultants, contractors or advisors are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights, (b) shares of Common Stock upon the exercise or exchange of or conversion of any Securities issued hereunder or securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.9(a) herein, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (d) shares of Common Stock issued to consultants or vendors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights, and (e) shares of Common Stock issued to existing holders of the Company&#8217;s securities in compliance with the terms of agreements entered into with, or instruments issued to, such holders, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the 30-day period following the Closing Date provided that such agreements regarding such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and provided further that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>FCPA</u>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>FINRA</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>GAAP</u>&#8221; means generally accepted accounting principles in the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Hazardous Materials</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(m).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Indebtedness</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(aa).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>IT Systems and Data</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(jj).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Liens</u>&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Lock-Up Agreements</u>&#8221; means the Lock-Up Agreements, dated as of the date hereof, by and among the Company and each director and officer, in substantially the form of <u>Exhibit</u><u>&nbsp;</u><u>C</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Material Adverse Effect</u>&#8221; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>OFAC</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(kk).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Per Share Purchase Price</u>&#8221; equals $[__], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of shares of Common Stock that occur between the date hereof and the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Per Pre-Funded Warrant Purchase Price</u>&#8221; equals $[__], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions relating to shares of Common Stock that occur after the date of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Placement Agent</u>&#8221; means A.G.P./Alliance Global Partners.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Placement Agent Counsel</u>&#8221; means Sullivan &amp; Worcester LLP with offices located at 1251 Avenue of the Americas, New York, NY 10020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Pre-Funded Warrants</u>&#8221; means, collectively, the warrants delivered to the Purchasers at Closing in accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately upon issuance and shall expire in accordance with the terms thereof, in substantially the form of <u>Exhibit</u><u>&nbsp;</u><u>B</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Preliminary Prospectus</u>&#8221; means the preliminary prospectus included in the Registration Statement at the time the Registration Statement is declared effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Proceeding</u>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), pending or, to the Company&#8217;s knowledge, threatened in writing against or affecting the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Prospectus</u>&#8221; means the final prospectus filed pursuant to the Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Purchaser Party</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;4.7.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Registration Statement</u>&#8221; means the effective registration statement with the Commission on Form&nbsp;S-1 (File No. 333-281448), which registers the sale of the Securities and includes any Rule 462(b) Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Rule 462(b) Registration Statement</u>&#8221; means any registration statement prepared by the Company registering additional Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Securities</u>&#8221; means the Shares, the Warrants, the Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Shares</u>&#8221; means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Short Sales</u>&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Subscription Amount</u>&#8221; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Trading Day</u>&#8221; means a day on which the principal Trading Market is open for trading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the shares of Common Stock are listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Transaction Documents</u>&#8221; means this Agreement, the Warrants, the Lock-Up Agreements and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Transfer Agent</u>&#8221; means Continental Stock Transfer &amp; Trust Company,the current transfer agent of the Company, with a mailing address at 1 State Street, 30<sup style="vertical-align:top;line-height:120%;">th</sup> Floor, New York, NY 10004-1561, and an email address of hfarrell@continentalstock.com and any successor transfer agent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Variable Rate Transaction</u>&#8221; shall have the meaning ascribed to such term in Section&nbsp;4.9(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Warrants</u>&#8221; means the Common Warrants and the Pre-Funded Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#8220;<u>Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin: 0pt 0pt 0pt 0pt;"><b>ARTICLE II.</b><br>
<b>PURCHASE AND SALE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">2.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing</u>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, (i)&nbsp;the number of shares of Common Stock set forth under the heading &#8220;Subscription Amount&#8221; on the Purchaser&#8217;s signature page hereto, at the Per Share Purchase Price, and (ii) Common Warrants exercisable for shares of Common Stock as calculated pursuant to Section 2.2(a); provided, however, that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&#8217;s Affiliates, and any Person acting as a group together with such Purchaser or any of such Purchaser&#8217;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing shares of Common Stock, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of shares of Common Stock in such manner to result in the full Subscription Amount being paid by such Purchaser to the Company. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, at the election of the Purchaser prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock, in each case, outstanding immediately after giving effect to the issuance of the Securities on the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Each Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for Delivery Versus Payment (&#8220;<u>DVP</u>&#8221;) settlement with the Company or its designees. The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of the Placement Agent or such other location as the parties shall mutually agree. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser through the Closing (the &#8220;<u>Pre-Settlement Period</u>&#8221;), such Purchaser sells to any Person all, or any portion, of any Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<u>Pre-Settlement Shares</u>&#8221;), such Person shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be a Purchaser under this Agreement unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to such Person at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&#8217;s receipt of the Subscription Amount for such Pre-Settlement Shares hereunder; provided, further, that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not such Purchaser will elect to sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell any Shares will be made in the sole discretion of such Purchaser from time to time, including during the Pre-Settlement Period. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Warrants) for purposes hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.2</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Deliveries</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">this Agreement duly executed by the Company;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Company&#8217;s wire instructions, on Company letterhead and executed by the Company&#8217;s Chief Executive Officer or Chief Financial Officer;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">subject to the sixth sentence in Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system shares of Common Stock equal to the portion of such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(iv)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&#8217;s Subscription Amount applicable to Pre-Funded Warrants divided by the sum of the Per Pre-Funded Warrant Purchase Price plus the exercise price per Warrant Share underlying such Pre-Funded Warrants, subject to adjustment therein;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(v)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Preliminary Prospectus and the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(vi)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 50% of such Purchaser&#8217;s shares of Common Stock and Pre-Funded Warrants, as applicable, with an exercise price equal to $[__] per share, subject to adjustment therein;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(vii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the duly executed Lock-Up Agreements;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(viii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a certificate executed by the Chief Executive Officer and Chief Financial Officer of the Company, dated as of the date of the Closing Date, in form and substance reasonably acceptable to the Purchasers and Placement Agent;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(ix)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a certificate executed by the Secretary of the Company, dated as of the date of Closing, in form and substance reasonable acceptable to the Purchasers and Placement Agent; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(x)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a legal opinion of Company Counsel, in form reasonably acceptable to the Placement Agent and the Purchasers.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">At the time this Agreement is executed, the Placement Agent shall have received a cold comfort letter containing statements and information of the type customarily included in accountants&#8217;&nbsp;comfort letters with respect to the financial statements and certain financial information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus, addressed to the Representative and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">On the Closing Date, the Placement Agent shall have received from the Auditor a letter, dated as of the Closing Date, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 2.2(b).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">this Agreement duly executed by such Purchaser; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">such Purchaser&#8217;s Subscription Amount with respect to the Securities purchased by such Purchaser, which shall be made available for DVP settlement with the Company or its designees.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.3</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Closing Conditions</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iv)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(v)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or any Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred after the date of this Agreement any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin: 0pt 0pt 0pt 0pt;"><b>ARTICLE III.</b><br>
<b>REPRESENTATIONS AND WARRANTIES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">3.1&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Representations and Warranties of the Company</u>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein to the extent of the disclosures contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Subsidiaries</u>. All of the direct and indirect subsidiaries of the Company are set forth on <u>Schedule 3.1(a)</u>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary, free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing, and, if applicable under the laws of the jurisdiction in which they are formed, in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective memorandum of association, articles of association, certificate or articles of incorporation, bylaws, operating agreement, or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors, a committee of the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217;&nbsp;rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>No Conflicts</u>. Except as set forth in <u>Schedule</u><u>&nbsp;</u><u>3.1(d)</u>, the execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s memorandum of association, articles of association, certificate or articles of incorporation, bylaws, operating agreement, or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings required pursuant to Section 4.3 of this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) notices and/or application(s) to and approvals by each applicable Trading Market for the listing of the applicable Securities for trading thereon in the time and manner required thereby, and (iv) filings required by the Financial Industry Regulatory Authority (&#8220;<u>FINRA</u>&#8221;) (collectively, the &#8220;<u>Required Approvals</u>&#8221;) and (v) any such consents, waivers, authorizations that have been or prior to the Closing Date will be, obtained by the Company or as would not have or reasonably be expected to result in a Material Adverse Effect.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Issuance of the Securities; Registration</u>. The Shares and Warrant Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Warrants, when issued and paid for in accordance with the applicable Transaction Documents, will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217;&nbsp;rights generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited by federal or state securities laws or public policy considerations in respect thereof. The Warrant Shares are duly authorized and, when issued in accordance with this Agreement and the terms of the Warrants, will be duly and validly issued, fully paid and non-assessable, and free and clear of all Liens imposed by the Company. Prior to or in connection with the Closing, the Company will have reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which Registration Statement became effective on [__], 2024, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Preliminary Prospectus or the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective as determined under the Securities Act, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Preliminary Prospectus, the Prospectus or any amendment or supplement thereto was issued, in respect of the Prospectus, and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(g)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Capitalization</u>. The capitalization of the Company as of the date hereof is as set forth on <u>Schedule</u><u>&nbsp;</u><u>3.1(g)</u>, which <u>Schedule 3.1(g)</u>&nbsp;shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. &nbsp;The Company has not issued any shares since its most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on <u>Schedule</u><u>&nbsp;</u><u>3.1(g)</u>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock, Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any share appreciation rights or &#8220;phantom share&#8221;&nbsp;plans or agreements or any similar plan or agreement. All of the outstanding shares of the Company are duly authorized, validly issued, fully paid and non-assessable, have been issued in compliance with all federal and state securities laws where applicable, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s share capital to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(h)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>SEC Reports; Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such materials) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Preliminary Prospectus and the Prospectus, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. Since January 1, 2023, as of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. &nbsp;In addition, any further documents so filed and incorporated by reference to the Prospectus, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Material Changes; Undisclosed Events, Liabilities or Developments</u>. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on <u>Schedule 3.1(i)</u>, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and strategic acquisitions and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any of its shares and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company share option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on&nbsp;<u>Schedule</u><u>&nbsp;</u><u>3.1(i)</u>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one&nbsp;(1) Trading Day prior to the date that this representation is made.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(j)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Litigation</u>. Except as set forth on&nbsp;<u>Schedule 3.1(j)</u>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;). None of the Actions set forth on <u>Schedule 3.1(j):</u>&nbsp;(i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents; or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth on <u>Schedule</u><u>&nbsp;</u><u>3.1(j)</u>, neither the Company nor any Subsidiary, nor any officer thereof, is the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. Except as set forth on <u>Schedule</u><u>&nbsp;</u><u>3.1(j)</u>, no director of the Company or any Subsidiary is the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which would result in a Material Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(k)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217;&nbsp;employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(l)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Compliance</u>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of (i), (ii) and (iii) as would not have or reasonably be expected to result in a Material Adverse Effect.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(m)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Environmental Laws</u>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;Hazardous Materials&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;Environmental Laws&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(n)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such certificates, authorizations or permits would not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(o)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Title to Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(p)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Intellectual Property</u>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have would have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual Property Rights</u>&#8221;). Neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two&nbsp;(2) years from the date of this Agreement except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(q)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(r)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Transactions with Affiliates and Employees</u>. Except as set forth on <u>Schedule</u><u>&nbsp;</u><u>3.1(r)</u>, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a material interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company or a Subsidiary and (iii) other employee benefits, including share option agreements under any share option plan of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(s)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Sarbanes-Oxley; Internal Accounting Controls</u>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed Form 10-K under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;). The Company presented in its most recently filed Form&nbsp;10-K under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Except as set forth on <u>Schedule 3.1(s)</u>, since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(t)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Certain Fees</u>. Except as set forth in the Preliminary Prospectus and Prospectus, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents (for the avoidance of doubt, the foregoing shall not include any fees and/or commissions owed to the Transfer Agent). Other than for Persons engaged by any Purchaser, if any, the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(u)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Investment Company</u>. The Company is not, and immediately after receipt of payment for the Securities, will not be required to register as an &#8220;investment company&#8221;&nbsp;within the meaning of the Investment Company Act of 1940, as amended.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(v)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Registration Rights</u>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(w)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Listing and Maintenance Requirements</u>. The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth on <u>Schedule 3.1(w)</u>, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth on <u>Schedule 3.1(w), </u>the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through The Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to The Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(x)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Application of Takeover Protections</u>. The Company has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#8217;s articles of incorporation or the laws of its state of incorporation that is or would become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217;&nbsp;ownership of the Securities.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(y)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Disclosure</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that it has not provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Preliminary Prospectus or the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(z)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers&#8217;&nbsp;representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(aa)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Solvency</u>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <u>Schedule</u><u>&nbsp;</u><u>3.1(aa)</u>&nbsp;sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &#8220;<u>Indebtedness</u>&#8221;&nbsp;means (x) any liabilities for borrowed money or amounts owed by the Company in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others to third parties, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(bb)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Tax Compliance</u>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, or as set forth on <u>Schedule 3.1(bb)</u>, the Company and its Subsidiaries each (i) has made or filed all federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges, fines or penalties that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its financial statements provision reasonably adequate for the payment of all material tax liability of which has not been finally determined and all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(cc)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company, has in the past five (5) years (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(dd)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Accountants</u>. The Company&#8217;s independent registered public accounting firm is as set forth in the Preliminary Prospectus and Prospectus. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required &nbsp;by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ended December&nbsp;31, 2024.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(ee)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Acknowledgment Regarding Purchasers</u><u>&#8217;</u><u>&nbsp;Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217;&nbsp;purchase of the Securities. The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(ff)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Acknowledgment Regarding Purchaser</u><u>&#8217;</u><u>s Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections&nbsp;3.2(f) and 4.11 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser, other than any Purchaser who is a director or officer of the Company, agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221;&nbsp;securities based on securities issued by the Company or to hold the Shares for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221;&nbsp;transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221;&nbsp;transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#8220;short&#8221;&nbsp;position in the shares of Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221;&nbsp;transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the shares of Common Stock are outstanding, and (z) such hedging activities (if any) would reduce the value of the existing stockholders&#8217;&nbsp;equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(gg)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Regulation M Compliance</u>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the shares of Common Stock, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the shares of Common Stock, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&#8217;s placement agent in connection with the placement of the shares of Common Stock.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(hh)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>[RESERVED]</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Stock Option Plans</u>. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No outstanding stock option granted under the Company&#8217;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(jj)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Cybersecurity</u>. Except as would not, individually or in the aggregate, have a Material Adverse Effect, (i) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification,; (ii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iii) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with commercially reasonable industry standards and practices.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(kk)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company&#8217;s knowledge, any director, officer, agent or employee of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<u>OFAC</u>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(ll)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(mm)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Promotional Stock Activities</u>.&nbsp;&nbsp;Neither the Company nor any Subsidiary of the Company and none of their respective officers, directors, managers, affiliates or agents have engaged in any stock promotional activity that would give rise to a complaint, inquiry, or trading suspension by the SEC alleging (i) a violation of the anti-fraud provisions of the federal securities laws, (ii) violations of the anti-touting provisions, (iii) improper &#8220;gun-jumping; or (iv) promotion without proper disclosure of compensation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">3.2&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217;&nbsp;rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Understandings or Arrangements</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, it will be either (i) an &#8220;accredited investor&#8221;&nbsp;as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3), (a)(7), (a)(9), (a)(12) or (a)(13) under the Securities Act, or (ii) a &#8220;qualified institutional buyer&#8221;&nbsp;as defined in Rule&nbsp;144A(a) under the Securities Act.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms, which terms include definitive pricing terms, of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares order to effect Short Sales or similar transactions in the future.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(g)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>No Voting Agreements</u>. The Purchaser is not a party to any agreement or arrangement, whether written or oral, between the Purchaser and any other Purchaser and any of the Company&#8217;s stockholders as of the date hereof, regulating the management of the Company, the stockholders&#8217;&nbsp;rights in the Company, the transfer of shares in the Company, including any voting agreements, stockholder agreements or any other similar agreement even if its title is different or has any other relations or agreements with any of the Company&#8217;s stockholders, directors or officers.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(h)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>No Foreign Person</u>. Purchaser acknowledges that the Company must assess potential foreign ownership, control, or influence related to potential investments into the Company, and the Purchaser represents that it is not a &#8220;foreign person&#8221;&nbsp;within the meaning of Treasury Regulations Section 1.1445-2.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Brokers</u>. Except as set forth on <u>Schedule</u><u>&nbsp;</u><u>3.2(h)</u>&nbsp;or in the Preliminary Prospectus or Prospectus, no agent, broker, investment banker, person or firm acting in a similar capacity on behalf of or under the authority of the Purchaser is or will be entitled to any broker&#8217;s or finder&#8217;s fee or any other commission or similar fee, directly or indirectly, for which the Company or any of its Affiliates after the Closing could have any liabilities in connection with this Agreement, any of the transactions contemplated by this Agreement, or on account of any action taken by the Purchaser in connection with the transactions contemplated by this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(j)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Independent Advice</u>. Each Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The Company acknowledges and agrees that the representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, except as set forth in this Agreement, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin: 0pt 0pt 0pt 0pt;"><b>ARTICLE IV.</b><br>
<b>OTHER AGREEMENTS OF THE PARTIES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Legends</u>. The shares of Common Stock shall be issued free of legends.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.2&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.3&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries or Affiliates, or any of their respective officers, directors or employees, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees or Affiliates, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. Other than the press release referred to in the initial sentence of this Section 4.3, the Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser who is not a director, officer or greater than 5% stockholder of the Company, or include the name of any such Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission, and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause&nbsp;(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.4&nbsp;&nbsp;&nbsp;&nbsp;<u>Stockholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;Acquiring Person&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser would be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.5&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section&nbsp;4.3, the Company covenants and agrees that neither it, nor any of its officers, directors or employees, will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser in connection with the transactions contemplated by the Transaction Documents without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees or Affiliates, or a duty to the Company, and of its Subsidiaries or any of their respective officers, directors, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall, as soon as practicable following delivery of such notice, file or furnish such material non-public information with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.6&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and general corporate procedures, including the purchase of any pending or future acquisitions, and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business or repayment of obligations outstanding as of the date of this Agreement consistent with prior practices), (b) for the redemption of any shares of Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations or similar applicable regulations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.7&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members, partners, employees and Affiliates (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<u>Purchaser Party</u>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable and documented out-of-pocket attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against a Purchaser Party in any capacity (including a Purchaser Party&#8217;s status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder of the Company who is not an Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by the Transaction Documents. For the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct claims brought by the Company against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim, damage or liability to the extent it is finally judicially determined to be attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in any Transaction Document or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, except with respect to direct claims brought by the Company, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal counsel), a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed, or to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made. The indemnification and other payment obligations required by this Section 4.7 shall be made by periodic payments of the amount thereof during the course of the investigation, defense, collection, enforcement or action, as and when bills are received or are incurred; <i>provided</i>, that if any Purchaser Party is finally judicially determined not to be entitled to indemnification or payment under this Section 4.7, such Purchaser Party shall promptly reimburse the Company for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.8&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Listing of Common Stock</u>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the shares of Common Stock on each Trading Market on which each is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Markets and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Markets. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of the Common Stock on a Trading Market and will comply in all material respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company agrees to use commercially reasonable efforts to maintain the eligibility of the&nbsp;Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.9</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Subsequent Equity Sales</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From the date hereof until one hundred and eighty (180) days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of shares of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;<u>Variable Rate Transaction</u>&#8221;&nbsp;means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for shares of Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering&#8221;, whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled; <u>provided</u>, <u>however</u>, that, following the 60<sup style="vertical-align:top;line-height:120%;">th</sup>&nbsp;day after the Closing Date, the entry into and/or issuance of shares of Common Stock in an &#8220;at the market&#8221;&nbsp;offering shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p font-family:times="" new="" roman="" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Notwithstanding the foregoing, this Section 4.9 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance other than as explicitly permitted in (i), (ii) or (iii) of Section 4.9(b).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.10&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Equal Treatment of Purchasers</u>. No consideration (including any modification of the Transaction Documents) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of the shares of Common Stock or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.11&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.3. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.3, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.3, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.3 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section&nbsp;4.3. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.12&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Procedures</u>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.13&nbsp;&nbsp;&nbsp;&nbsp;<u>Reservations of Shares</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue shares of Common Stock pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">4.14&nbsp;&nbsp;&nbsp;&nbsp;<u>Lock-Up Agreements</u>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements, except to extend the term of the lock-up period, and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its commercially reasonable efforts to seek specific performance of the terms of such Lock-Up Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin: 0pt 0pt 0pt 0pt;"><b>ARTICLE V.</b><br>
<b>MISCELLANEOUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth&nbsp;(5th) Trading Day following the date hereof; <u>provided</u>,&nbsp;<u>however</u>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.2&nbsp;&nbsp;&nbsp;&nbsp;<u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.3&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus and the Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.4&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.5&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers who purchased at least 50.1% in interest of the sum of (i)&nbsp;the Shares and (ii) the Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser), or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; provided, that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted Purchaser (or 50.1% in interest of such Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.6&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.7&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.8&nbsp;&nbsp;&nbsp;&nbsp;<u>No Third-Party Beneficiaries</u>. The Placement Agent shall be the third-party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.7 and this Section&nbsp;5.8.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.9&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section&nbsp;4.7, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="33" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.10&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page was an original thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.11&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.12&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.13&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Nature of Purchasers</u><u>&#8217;</u><u> Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents or has elected not to be represented by counsel after having been advised of the desirability to engage such counsel. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through Placement Agent Counsel. Placement Agent Counsel does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="34" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.14&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.15&nbsp;&nbsp;&nbsp;&nbsp;<u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions relating to shares of Common Stock that occur after the date of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin: 0pt 0pt 0pt 0pt;">5.16<b>&nbsp;&nbsp;&nbsp;&nbsp;WAIVER OF JURY TRIAL.</b>&nbsp;<b>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Pages Follow)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="35" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">BIOCARDIA, INC.</p>
			</td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Address for Notice</u>:</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">320 Soquel Way</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sunnyvale, California 94085</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By:</p>
			</td>
			<td style="vertical-align:top;width:54.3%;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Attn: Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</p>
			</td>
			<td style="vertical-align:top;width:54.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dr. Peter A. Altman, Ph.D</p>
			</td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Email: <u>CEO@BioCardia.com</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title:</p>
			</td>
			<td style="vertical-align:top;width:54.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer</p>
			</td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>CFO@BioCardia.com&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>dmcclung@biocardia.com</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>paltman@biocardia.com&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">With a copy to (which shall not constitute notice):</p>
			</td>
			<td style="vertical-align:top;width:38.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Wilson Sonsini Goodrich &amp; Rosati LLP</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">650 Page Mill Rd.<br>
			Palo Alto, CA 94304</p>
			</td>
			<td style="vertical-align:top;width:38.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Email: <u>mdanaher@wsgr.com</u></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:61.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Attention: Michael Danaher</p>
			</td>
			<td style="vertical-align:top;width:38.1%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK<br>
SIGNATURE PAGE FOR PURCHASER FOLLOWS]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="36" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">36</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 7%; padding: 0px;">Name of Purchaser:</td>
			<td nowrap="true" style="width: 63%; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px;">&nbsp;</td>
			<td nowrap="true" style="width: 30%; padding: 0px;">&nbsp;</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="width: 15%; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Signature of Authorized Signatory of Purchaser</i>:</td>
			<td nowrap="true" style="border-bottom: 1px solid rgb(0, 0, 0); width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&nbsp;</td>
			<td nowrap="true" style="width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 10%; padding: 0px;">Name of Authorized Signatory:</td>
			<td nowrap="true" style="border-bottom: 1px solid rgb(0, 0, 0); width: 60%; padding: 0px;">&nbsp;</td>
			<td nowrap="true" style="width: 30%; padding: 0px;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 9%; padding: 0px;">Title of Authorized Signatory:</td>
			<td nowrap="true" style="border-bottom: 1px solid rgb(0, 0, 0); width: 61%; padding: 0px;">&nbsp;</td>
			<td nowrap="true" style="width: 30%; padding: 0px;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 13%; padding: 0px;">Email Address of Authorized Signatory:</td>
			<td nowrap="true" style="border-bottom: 1px solid rgb(0, 0, 0); width: 57%; padding: 0px;">&nbsp;</td>
			<td nowrap="true" style="width: 30%; padding: 0px;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 15%; padding: 0px;">Facsimile Number of Authorized Signatory:</td>
			<td nowrap="true" style="border-bottom: 1px solid rgb(0, 0, 0); width: 55%; padding: 0px;">&nbsp;</td>
			<td nowrap="true" style="width: 30%; padding: 0px;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Address for Notice to Purchaser:</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Address for Delivery of Warrant Shares to the Purchaser (if not same address for notice):</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">DWAC for Common Stock:</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Subscription Amount: $___________________</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Shares of Common Stock: ___________________</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Shares of Common Stock underlying the Pre-Funded Warrants: ________</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="padding-left: 45pt; width: 50%;">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares underlying the Common Warrants: ________</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="padding-left: 45pt; width: 50%;">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">EIN Number: ___________________</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the first (1st) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="37" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">37</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ex_718762.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_718762.htm</title>

	<!-- Generated by ThunderDome Portal - 8/29/2024 3:18:56 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board of Directors<br>
BioCardia, Inc.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We consent to the incorporation by reference in the Amendment No. 1 to the registration statement on Form S-1, of BioCardia, Inc. of our report dated March 27, 2024, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, with respect to the consolidated balance sheets of BioCardia, Inc. as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years ended December 31, 2023 and 2022, and the related notes, which report appears in the December 31, 2023 annual report on Form 10-K of BioCardia, Inc. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such registration statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/PKF San Diego, LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">San Diego, California</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 29, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>ex_718763.htm
<DESCRIPTION>EXHIBIT FILING FEES
<TEXT>
<html><head>
	<title>ex_718763.htm</title>

	<!-- Generated by ThunderDome Portal - 8/28/2024 7:09:39 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 107</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation of Filing Fee Table</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM S-1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registration Statement Under the Securities Act of 1933 </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Form Type)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BioCardia, Inc. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact Name of the Registrant as Specified in its Charter)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="9" style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 46.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 1: Newly </b><br>
			<b>Registered Securities</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 4.5%; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Security</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Type</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Security Class </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fee </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Rule</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Amount</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registered</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Proposed </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Maximum</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Offering</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Price Per</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unit</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Maximum</b><br>
			<b>aggregate</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>offering</b><br>
			<b>price</b>(1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fee Rate</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Amount of </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>registration </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>fee</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees to be Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common stock, par value $0.001 per share (&#8220;Common Stock&#8221;)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(o)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,439,024</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black; text-align: center;">$2.46</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$5,999,999.04(2)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.00014760</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$885.60</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees Previously Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(o)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$6,000,000(2)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.00014760</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$885.60</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Fees Previously Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Pre-Funded Warrants to purchase one share of Common Stock (&#8220;Pre-Funded Warrants&#8221;)(3)(4)(5)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Rule 457(g)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Fees Previously Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Common Stock,<br>
			issuable upon the exercise of the Pre-Funded Warrants (4)(5)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Rule 457(o)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Fees Previously Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Warrants to purchase one share of Common Stock (&#8220;Warrants&#8221;) (4)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Rule 457(g)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Fees to be Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Common Stock,<br>
			issuable upon the exercise of the Warrants(6)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Rule 457(o)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2,439,024</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">$2.71</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">$6,609,755.04(2)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">0.00014760</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">$975.60</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.5%; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Fees Previously Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.2%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Equity</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Common Stock,<br>
			issuable upon the exercise of the Warrants(6)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Rule 457(o)</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$3,000,000(2)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.00014760</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$442.80</p>
			</td>
		</tr>
		<tr>
			<td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.8%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Offering Amounts</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$12,609,754.08</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$1,861.20</p>
			</td>
		</tr>
		<tr>
			<td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.8%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Fees Previously Paid</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$9,000,000</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$1,328.40</p>
			</td>
		</tr>
		<tr>
			<td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.8%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Fee Offsets</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:7.8%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$0.00</p>
			</td>
		</tr>
		<tr>
			<td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.8%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net Fee Due</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.1%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:7.8%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 4.4%; border-right: 1px solid black; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$532.80</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pursuant to Rule 416, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The proposed maximum aggregate offering price of the shares of Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the Pre-Funded Warrants offered and sold in the offering (plus the aggregate exercise price of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants), and as such the proposed aggregate maximum offering price of the shares of Common Stock and Pre-Funded Warrants (including shares of Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $6,000,000.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">No separate registration fee required pursuant to Rule 457(g) under the Securities Act.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registrant may issue Pre-Funded Warrants to purchase shares of Common Stock in the offering. The purchase price of each Pre-Funded Warrant will equal the price per share at which shares of Common Stock are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the Pre-Funded Warrants will equal $0.001 per share of Common Stock.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(6)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registration fee is calculated in accordance with Rule 457(o) under the Securities Act, based on an estimate of the proposed maximum aggregate offering price, representing the assumed exercise&nbsp;price of the Common Stock included in the registration statement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bcda-20240829.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/29/2024 6:54:39 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:bcda="http://www.bcda.com/20240829" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bcda.com/20240829">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20240829_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20240829_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20240829_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.bcda.com/20240829/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="bcda_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bcda-20240829_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/29/2024 6:54:39 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.bcda.com/20240829/role/statement-document-and-entity-information" xlink:href="bcda-20240829.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.bcda.com/20240829/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bcda-20240829_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/29/2024 6:54:39 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Filer Category</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Small Business</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bcda-20240829_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/29/2024 6:54:39 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.bcda.com/20240829/role/statement-document-and-entity-information" xlink:href="bcda-20240829.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.bcda.com/20240829/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>logo01.jpg
<TEXT>
begin 644 logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! 5<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]2IE&YF([
M ?AUS7DK?M9?!VRFEBE\?:3#(K$,FYL@CL>*]>F_U<AQSM/\J_ [P?X6TGQ;
M^TGI6BZM9I=:;>:F(YX<E RDG/(H _9!OVOO@SC(^(>D<?[3G_V6K>C_ +4/
MPJ\0:E%8Z=XYTF\N64MY:R,#CUY6O.8_^"=OP :) / \08C(87LV3G&?XJ\E
M^-W_  3#\(S:/J.J_#J2XT/6+>%C%:I,V)2!PF[.0#04C[KT[4K75K=)[*>*
MYMW'RR1-D&K]?BW^R5^TMXS^ ?QFL_"NM:I/?Z1<7RZ1?V=Q(TGE3&0("I8G
M SZ5^T,4JR0I(IRK $?E0)DE%(O2EH$%%%% !1110!&V-QIH/7 ITG&34%PX
MCCRS;0%W?_7IW5KL=O(?(_EKECBLW4M>L-+C,MS/%".NYFQBOEC]H_\ ;,M?
M"-Q-X>\+#[?K7W6F4Y6,]./4UP'P[^!OQ#_:"FAU_P =:]J&GZ;(N$MH9#&9
M!Z[17&\0I/EBCZ.GD\H4E7Q3Y8O[SZOU;]H'X?Z3=/;7GB:RAG4<J26_E3])
M^/W@+5YA#;>([.:4] K;?YUY_8?L2_#2WMXQ?:0]_.H^:XGN)-Q^N&JCXG_8
M;^']_:%=(M9-%O%&4N8IG)_+=3=2=OA(C3RINW.SZ$T_6+'4,26UQ%*K<AE?
M.:U(^<\YK\XM4^$_Q7^ OCK3UT35[RYTR[F""]1FF6-01P48D DDU^B.AK,F
MFPK.[2RJH#2, "QQR<"JIU'/='+CL%3PMI49\R9H4445T'D!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -< CFJ6I:E;Z39375Y+%;01J6+R-A5
M [D^E3:E>1Z?8SW4S!(8$:5R?[J@D_RKXX\-MJW[:7CC6=6O]2N;3X/:)<-;
MVUA;LT+ZC*@^<EU()0$$8SVH ]LU;]K/X1Z3<26E_P".M-MYHSAU9)' /U"U
MZ+X9\9:+XRLX[K1-3M]0MW&0\#9!%?)?A?\ :+^#3:7=:?X>^$>O:W8:?/+9
MM/:^&TO TBD@YD8Y/([FLV[\-:4WAN?XR? F[N+75=,#RZGX<N)F\JX1.7B:
M+.V-L?W0.E 'W&F-O'2BN ^"OQ7L/C5\.M)\4Z:&A%U&//MS_P L90/G3\#D
M44 =Y-_JY/H?Y5^$?PK8C]K#PZ >/[74_J:_=R?_ %4GT/\ *OP-\*^*--\%
M_M(:7K>K3-;Z?9ZFLDSJA8A03DX%!<3][D4&W4Y;E0.#[4V::.&*1I6"J%+$
MGL .IKYA7_@I1\!%M5)\62 A>$^R2%F('3 %>&?%#]O+5_C]:7?@GX1V4=G+
M>*T$NJZA>16^8VX.T.PQQ0)'R3JWAU_B5^VG=6'AR%I%F\2!PD(SF))P7D_(
M$YK]R-.M5L[&"$9Q'&J\G/0 5\@_L4_L6Z;\$8AXQU;4[;Q!XJNQE+RU;S(X
M0P^9=PSD\D9K[%#?+QS0)F#XE\?>'/!KP+KOB#3-%,_^J&H7<<'F?[NXC-;%
MC=I>0B6*59XF 994(*L#W!'6OS;_ ."KX">)/ [#.[=G.3_>Q7Z#?#O_ $?P
M)H@ZJMI&??[M CI)695RHRV>!G%9.M^*-.\-PM-JFHVFG0#YO.O)EC3:.IR3
MV]Z^9/VR/VS#\&9+7P9X0MX]5\?ZH-EO%]X6Q/&2!WYZ50^"?['=WXEMX_%O
MQEUS4/$_B34$$G]F&<I:6RL,E-G?K0!] 0_'[X<S2JB_$+PHY9BJJNKP;B?3
M[_6NQTK6;;6;-;JSNX+N _\ +6V<,GYUP+?LQ?"LVYB'@714!&W<EL P]P?7
MWKY\^-_[+WBCX5VLWCGX+^(]3L=6TY6N)M#O)S+;7$:\D =N/:@#[,9]RLP(
M/'&.E?/G[8WQ@F^&7P_:"PEV:EJ1-K"R]5)!)/Y UG?L@_M>6/[2'A^>QOX%
MTKQCIZC[;8L< KT+#/?(/'M7SY_P4 UJ:[^(FBV!=E2"U:0KV#E@ 1^!-<.,
MDXTM#ZGAO!QQN/A&6J1S_P"R#\)4^*?Q(N=5UA/MEA9D3L\G.9L\ ^O?BOTK
MTO3X+*%5AC5$4;54#@ >E?,G[ OANWL?A6E]&FV6[D+N?<9 _G7U3''MV\\B
MJPL4J:9MQ+B95,;.DGI'2PGDK@\?E2):QIT'/KGFI#3@*[;L^0MI8K3:;:W#
M R0HQW!N1W'>IEC$>=O&3DU)3';!%3;L.[>XV20HA/8=:SAXALO[06P%Y";X
MC<;?>-X7UQ2ZY?1Z=IMS=3,J10J7+,>. :^!-:^(^N>$_CYH'Q"OV:+P]K4_
MV3#9 2)7,9/_ ([G\:QJ5.0]/ X%XQ2=[6/T*+/P.])YC=,XXJEH^J1ZII]O
M<0MN21 ZGU!%3W&54D'G.X_CVK5.ZN>;*#4^1G.:E\5?"NBW;6E_XBTRSN4.
M&AN+I$8?4$Y%4S\:/!7./&.A #DG[='^76OB?4]-MM=_;2^PZA;QWEE(YW12
MKD'@5]C7GP%\ 75F4?PKII+(06\GG!]ZQC4E.]EL>[C,#2P?L^9OWE<[72?%
M6F:XL;Z??V]XCC<K02*X/Y5H^8SQ[PVU<'/'0U^?'Q?M[[]F#XMZ!=^%=0ND
MT.Z;,VGRRED&2!@>W-?>>@ZLVL:%8W97:US"DN!VW*#_ %IPJ<U[F&+P'U>$
M*D7>,C.U?XF^&]!N/L^IZ]IVGW("EH;BY16&>AP3[U3;XU^!/^AST(?]Q&'_
M .*KX5_:,LX[[]K[3+:=%FAFO+!)8Y!E64NF1BOMFQ^!_@:6%6E\+Z:<C_G@
M*5.3G>W0VQ&!I8:E"I)_$:5O\9O!-S(J0^,-$E8\86_B)/\ X]736NL6^I*'
ML[B.>,C(>-@P/XBO+O&'[,OP^\06@C_X1^WLW'W);,>6P/KD5\T>(=2\7_LB
M?$"PG.K76L>"]0EV&*[<GR,=@?IS0ZLH?$M#.A@J>+BU3E[Q]W--(JJQ.1WZ
M#-8VH^/M"TO4HM/NM:L8+^8A4M6G7S"3T &>31X/\46WC+PW9:K9R[[>XC$J
M,O<&OB3]HIL?M8>#V4D#[5"2 >O)IU*RIQ3[DX'+I8BHZ,W9Q3/OD3%QE3\O
M!!]14BL36?I638H-W1 !^56I91&I)QCIUK?I<\F47&3B4+[7;:QNX;>:[BAF
MF?9%'(0"YQR!^GYUH1S%E)#9&>#7P9^U-XTU_5/&>F^+M&FE_P"$<\-W9C=H
M\C;,"-Y/KG@?A7V5\,_&5KXW\'Z5JMLZM'=6Z2\'H2.E<ZK7J<IZN*RZ6'H1
MKIWYOP,#]I;4;W3?@/XVN;$M]J33FV;1R,D _H37(_L>V-II_P"RGX1%H5>$
MV5Q(S( !([22%B??.1^%>S:_I%OXDT.]TN[53!=PO"X;D<C'_P!?\*^2_@'X
MRN/V;_$VH?!;QS*;/2Y))9/#VMS?):R1RLS>66/"D,QZGO70>0>)?LU_M(>*
M_@KX9O;6+P8-3\+:GXBN8H];DNPJ0NTS ;QG"@5]D_ /X'Z=\+?"6N+-?)J5
MWXBFDOM0N  (R) <!0.#C)KFOV?_ -FJ/PW\*/$OA3Q3-;Z_I.MZA/=X@92I
M21RPVD$X(R.17E^M>,_$/[.7AW5/AAH^IQ^/K_52]OX=@M7WSZ8&RN)R,G"Y
M'/M0!TG_  3UDDM]+^(VFPR-)H]KX@N!;'L#O(('M@#BBO8/V7?@JWP3^$]C
MHMW*L^KW+M>:A*@X,[\L,]^:* /7)_\ 5R?0_P J_!GX?Z79ZU^U%HMCJ%K%
M>V5QJ:QRP3 E6!)XX-?O-/\ ZN3Z'^5?A%\+/^3L/#I[?VLO/XF@TB?L'#^R
M?\(FC1A\/]%!V\$0G/(YYS7C/Q:_X)G_  X\;:7=R: +KPYK#*[1/;R+Y6[L
M& 7<5SZ,#[U]?V[#R4Y'W1_*G38,;#?LXQN'44$'XJ^!_CY\3_V-_B\?#.L:
MM<7^EV,PAN-/NF+0M >C1J,%3CU)K]C/!7BZT\<>$]*UVP/^CW\"S1^N".AK
M\@O^"H5Q:2?M2:B;8(\BZ?;+-MQP?+&[/N*_37]CW3;G2/V=_!D-X=TOV,."
MW7:>10(^/?\ @K%_R,7@<^__ +-7W_X/N5M/ASI=PS;!#8!]WIA*^ /^"L7_
M ",'@C'(R/\ T*OOCPK:_;OAGI]MU,NG; .W*=: /RY_9-MY/VBOVY]6UW7=
M\[6+W%^#G(S%(J)C/LQXK]<E'[P$?*">1^@K\G_^"?#O\-OVQ/%.BZPOV:::
MVO(41AM8,TZ%>#[ U^L*@!ASDCB@JQ/522$.I5E#HWR%3R"#U%6MP]:@GGCM
MU:21PD2(7)SV'4T$GY)6=T_P5_X*+3'3LQV-SJ3-);1'"LCG[GT'/YUZE^W]
MI,D/Q0TB["L8+BS(!]"K#BO)=-CD^-'_  40EETQ6GL+?46=YXQN144CYB1P
M!D'FOM+]N+X5W7C#P#%JNG)OOM+/G$*N69<8(KBQ4/:4O=Z'UW"^+A@\Q@Y/
M<L?L#ZQ!??"&VMDD#2V\C(ZC^$YKZ>$JG)!Z5^;G[#/Q<MO!?CBZ\/Z@ZV]E
MJ87RRS 8F!Z?B"?RK]&H9DDC#*1C. P/6GA:BG!(GB?#2P^/G4>TM461,&[4
M_<*K([9(*\?2I(Y/7BNWE9\DD^I+N'6F22*.#S]!1N#=*IZA<):Q&9VVQJ"7
M/^R.>/QJ;HJ*<G9'C_[16NR7]CI_@RR=S>:[<)#-Y)^>"W!W-)^84?\  JYG
M]HSX,V_B3X)W%A:IB;285FM]B_.QC'W1_O8S^-87A[P?>_M"^.M5\9V_B#4?
M#]O;.UEIUSII&9(<_-DGCJHKM[S]G37)(1&?BCXIEC8$,CNF#]:YY+F3N?04
MZL<+.$4]>ID?L<_%H^./A\EG?MNU73&6VFAQRO\ =KZ'NN(R3W '\Z_/_P &
M-<_LU_M+/HUW=7-QHVL.BBXF. [.,9S]37W[)();,.#D$ @_A44)OE<65FV'
M5*O&K':>I^?FH:I;Z/\ MI"\N7\N&-\,QZ#..M?5GB;]ISP!X9@3[7K<#RN"
M1#&=S-@= !7RI>:?!JW[:\=I<P^="\F&B8<-]:G_ &AO@?=_!/QM:^/_  Y:
M-<Z<LWF75IC(C]QG@#%<L93IJ3CW/JL1AL)BY4*=;22B7O\ A&->_:\^*NFZ
MY+ITVE>$+ MLFF!1I5## VD=3_2ONK3=/73;.WM(\+';QK$ONH4 ?RKS_P"!
M?Q/T3XH>$;35M+D0.T8$UN6&Z)_0@<"O2SC;DC)]:ZZ45RN2W/C,RQ,ZDXT&
MK*&Q^=?[0&5_;,T;/_/]I_\ Z&E?HA9G=:Q_05^=_P ??WG[96B=_P#3[#/_
M 'VE?H=8KMM8^>U1A[MRL>GG27U?#W[$YC/ XP:^;_VY?#L>H?".>Z>-9#:R
M!AD?WCMS^1KZ2+CID9KYB_;J\4)HOPLDLY& ^W2",<^G/]*VQ#Y8'G9)%RQU
M-1VN+^PCXCGUKX/_ &620R?8)6MTW=E'2O'/VA@W_#57@\'J+F#/_?1KV[]A
M[PK)X=^#MG<21-&^H,9R&7!QZUXI^T9\G[5OA#'_ #\P?^A&N*?P)GU>%Y99
MGB53VLS[NTEA]C0=]O\ 2N%^-_CB+P3X'O)E;9>WG^AVH7EC+("JX'MUKMM-
MD"V,1) ^49_+BOG+QYHQ_:$^*TOAZUU6[TO3O"NVXEN+%L;KE\[1GU&TUZ$I
M6BDCXBE3YJTIO9,ZVS^#]G<?!-_#]]#Y]U<VYDN3UWSLO)_.O(?V)/&UQX?U
M;6_AMK$H%UIKL+96;)P#C ^G7Z5ZU_PSKKK0\?%3Q2.=V2ZD_3GWKYF^+_@?
M4OV;OC!X>\:0ZI>:K#<R[)KB^VARQ'SCCU3/XURU(\C4T?28&4,93JX1O5ZH
M_0CYKA"(V$<F 0Q&<5SGCSX7^'OB9H<FE>(]+@U*U8Y D'S(?56ZBM/PCK,'
MB#1K6_MW62&:-71E.001FMO-=R?,KGQ]2#IR<'T/G=OV,=-C!BL?B+XYTJR4
M_N[.QU"%(D'H 82<?C7=_#?]GOPA\+;MM0TG3OM&M2+MFU:]<R74WNS'C\A7
MIU%,S&QKL0#K13J* (KC_5M_NG^5?@Q\/=8LM!_:=T2_U&YBL[*'4PTEQ,2%
M09// -?O#<1K)(ZMERZ%=F2.*^<M1_X)X_ S6=0N+R]\)M+/,Y9F-[*,GZ!A
MB@I.QVJ?M7_"!;=$;XA:-C:!D3-GC'^S7CGQZ_X*,> /ASIMU;>%KI_%7B!H
MB+=[50UN&QQN)(_E72'_ ()N_L_QX8># <=OMLW_ ,572^"?V*/@S\.Y-^C>
M#[0.9!)FZ9IR&'LY/Y4$GYU?L^_LX>.?VMOC"?'7BNWGM?#IO/M5S<W8_P!:
MF=WEIZ@=*_7_ $;2[70]+M=.LH1#:VL8BBC'90!4NGZ;:Z5:I:V5K#9VT8Q'
M##&$0?10,5=QTSUH _-3_@K$-NO>" .F1_Z%7Z ^ 5SX'T'(_P"76,C'K@?I
M7+_&#]F_P)\<KS3KGQAHYU*737#VS+.T>WOR >>:]&T?3K;2-/@L;1 EM;H(
MXUR3@ =,F@#X0_;(_9;\1Z/\2++XT_#* 7&LV,J3W>GQ?\MMN<D =>/YU[K\
M!?VP/!OQBTFU@OKQ= \51J!>:3J(\J191PQ7/49KZ#:-=N J^F,<5YOXZ_9U
M\ _$1GEU?P[:BZ=2C7-DHMYB#U^=,-^M [G>S:M:6\+32W4"1*N\R&48 ]:^
M/_VIOVOH)=,NO 'PKCD\7>,-55[=VT]"Z6JG@DD=*])7]AGX6QLA\C7I AR(
MY-?NRK>Q'F<BO4? ?PD\)?#>,KH&A6>GRMP;E85\X_5\;C^= CYV_88_9!;X
M!Z'<>(O$+BY\8ZP@:X)Y$.>< _C7U1?65OJ5G+;W 6:%P5=6'#*>U:BX*\\_
MA2%%X^4?E1U&FXOFCN?GQ^T;^QWJVA:]+XB\#HTT#OYWV.([9$?KN6M/X,_M
MF7W@H0Z!\0].N87MU$*WF,L.V'']:^\)H8Y%^9<]NE<;XF^$?A?Q8KC4=!LI
MR_WW:)0S_4@9KB]ARR<H,^NCG<,30CA\=#FMUZG+Z3^TY\/-8L8[@>([2%6&
M?+F^5JH>+OVLOA]X9L1,FMQWSD?+':_,QK*NOV*?A=<32RMH"YD.2%GD 'T^
M:MGPO^RG\.O",ADLO#MJ&!R#.QEQ_P!]$U4O:;)GGK^S(SY];=CQFQ_:*\<?
M&WQMIVG^#='NK'PZDX-SJ$Z[2P[BO2OVJ_B1/X"^'*:=;NS:QK!%E;+&?FW$
M<M^AKVS2O#NG:+#LL;*"V48^6",(#^5<SXV^#OAGQYXATS5]8LY+F]T[FW8R
ML$0YS]WIFMHP:C9LRGBJ$JR=*%HHC^!_@V/P)\-]$TE0-\-LID8=2[?,Q/YU
MWLD@"YVY([4VWC6!5C50N!@!>G%3'Y5SC-:6/*JU'4FY'Q[^WI\/Y)/"MAXN
MLG,=QI,B@L@^;:6 #?@<5ZW^S5\3$^)WPQL;O=FYMU^SSJQYW@"O1?&O@O3?
M'>AW.E:K;"ZL+A=KQYQ7-_#/X'^&_A/'=KX=LI+2.Y.7C>=G&?4 GK7(J;4V
MT>W+&TZN#C1G\4=F?(<&(?VY("!@"0U]R>)/#MEXITJ>SOX%N+>9&5T<9!4]
M?QKCU^ OA!?B(OC)=+$GB!1Q<M*WIUVYQ7I<:#R0 =PSG-:4Z7*FGU)Q^8?6
M'2G#24%8_.RXCUO]C/XOGRY)+GPAJ$A*@G"JC$$_B,#]:^]?"'BVQ\::#::K
MI\Z7%K<(&61#P,C[OUK+^)7PE\/?%32X].\0:?'?6JR"15)VD, 1P1SW/%1_
M#GX4>'OA5I+6&A0RVMONR8Y)GD4?0$X%$:;IMI/0>.QM'%482DK36Y\._'G*
M_ME:/D[%^W:?@G_?2OT,M[Z);= 7 X_O5YCXZ_9E\"?$#Q-)K^K::\^J%1F9
M;AXRN.A&TC!%9W_#)_@P]]6_\'-U_P#%U%.#IMON:8S%T,;2IQ;MRJQW7C;X
MI^'? MC/<:KJ<%JL2;RK-\Y^GK7R3K5GK'[8?Q,TR>*VN+'P)I;^9YMPN!<G
ML1[8KZ-T/]F?P/HLSS?V8^H2DC']H74ESC\)&->GZ7H=EH]LL%I:PVT"C"Q0
MH%4?0"M)0<_BV.6CB:6#5Z7Q=RMX?T&V\-Z+:Z?:1K%;P1B-$4= !7PS^T@I
M;]JOPB!R3<P?^A&OOR0@C X/:O-O$WP&\'^+O&5GXFU+31<:O9NKQ3><ZA&'
M0X!J:E-3BHK0O+<P6%JSJSU;3'?%;X@6OPR^%NH:[-(JM;VY, ;_ ):/M^4?
MGBN-_9)\+W.F_#LZWJR[M8UR5KNXD/4J3E/T)KT#XB?"?P_\4=%&D:_:_;-/
M1AMMTD9!Q[@UU.BZ1;:#IUO96D7EVT*A$7L !@"M>35,Y95X*A*,=V[E[(\L
M'M7BO[67PY7Q[\*=26*!9;ZW"S6Y/565@21^ (KVM0-HS575+&'4K5[:9?,A
MF4QNAZ8-.I'FC8YL)B/J]:-6+U1\N?L%_%23Q-X/D\+W\PDU/1_DQG):(' ;
M\Z^LLC<1WKR3X>_LY^!OASXBFU;0=-:RU"?=YDT4\GS D':03C&:]80'<2>#
MG]*5.+C&S.C'UJ=>NZE)63):***T/."BBB@"-O\ 7)]#4-CUF_WJ** ++=OK
M0W2BB@!&[?6G444 1G_EI_GM2Q?ZM:** 'TP?>-%%  WWEJ)_P#CX%%% %BF
MM110 E0S_>C_ -ZBBCH/H1+]YJ>OWC116:W.-[DR]:9)]UOK116S-Z>Y)_RS
M6A>E%%24OB*Z_P"N:FQ_\?1HHJ?M$Q)8?]<?I4D/0?C113ZFC(YNJ?[U/NO]
M4WTHHJF0]@/^K;_=HHHJ62]D/'04T=Z**I[#8QOO#ZT^3[K?2BBH"'41_P#4
JTK_ZJBBJ*^P,_A% ^^M%%-[&"W)8_NBAOOBBBHCL=(^BBBJ **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>wslogo01.jpg
<TEXT>
begin 644 wslogo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MC#%YTNG^&/"VA6>I^(]?NH8RDEU_9FF7$-A$Z7&H36MN?.'Q[^S/_P %M?\
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MY/\ [1__  7@_P"":7[,7Q%U3X4^-OC;?^*_&_A[4)])\5:?\+O!VO>/-/\
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MQ'UCVU\/#%+ \BHNO:*_Y=OVB3,/_@N5_P $L_@U^QG\*_"__!0S]@[3;O\
M9H^)7P5^(?A!_$VC?#G4M1TS0+FTUO58M.T7Q7X<L&N9U\,ZYH6ORZ=;WMGI
M;V_A_6-$U"]CO=*,T):Z_HI_8<_:@O?VQ/\ @G[\(OVD=7M[6T\2?$+X0ZE<
M^+[:Q3RK*+QIX>BU?PSXN-E%MC$5G/XAT74;FTA556&WFCB7A*_FB_X+3?\
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MKD6$S3 Y97EA,NXDBGE688>OAL+3Q'M)MI8>M3:A[&I[TIMRY825*;7[I_\
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MG+X>?$S7[6WCLX/%5[9ZAH'C)+.+'E61\9>$=0T#Q3)918'EV<FKO;(  L0
MHHK*E6K4)JI0JU*-1:*I2G*G-7WM*#4E?R9T8G"87&T98?&8;#XNA)IRH8FC
M3KT9-;.5.K&<&UTO'0N?LT_L!?L:_L>27=U^S;^SS\/?A=JU_;FSO?$NF6-Y
MK/C&ZLF)+6,_C3Q1?:YXKEL6)):R;63:L>3$37UM?65KJ5E=Z=?0K<65_:W%
ME>6[[@D]K=1/!<0N5*L%EBD=&VLK88X(/-%%%6M6KU'5K5:E:J[7J59RJ5';
M:\YMR=NEWH&&PF%P=&.&PF&P^%P\;\M##4:="C&^_+2I1C!7ZVCKU/FK]FO]
MB_\ 9>_8^@\9VW[-7P>\.?"6#XAWFDZAXSC\/7.N7(U^\T)-2CTF>[.M:MJA
M1K%-8U)8A;&!#]KEWJY";9/VE?V,_P!E[]L/2O#6B_M,?!CPC\7;#P=?WFI>
M%U\1IJ,%WH=WJ,"6U^UAJ6C7^F:E%!?110"[L_M9L[E[:UFF@>:UMY(RBK^M
M8GVWUGZQ7^L;^W]K4]M\/)_%YN?X/=^+X?=VT,_[.R_ZI_9_U'!_4+6^I?5:
M'U2SJ>UM]6Y/8V]K^\MR?Q/?^+4]V\'>#_#7@#P?X6\ >#M(MM"\'>"?#6B>
M#_"V@VIF>ST;PSX;TNUT70](MC<R3SO;:=I=E:V4)N)II6BA4RR2.68_G/\
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MG<HMQ=T[$?P1^!_PH_9P^&'ACX,?!#P5I?P[^%_@W^VO^$8\':-)?S:;H_\
MPD/B'5O%>M?9I-3N[^^;^T/$.N:MJDWGW<N+B^E$>R(1QH445G.<ZDI3G*4Y
MSDYSG-N4IRDVY2E)MN4I-MMMMMMMNYO2ITZ-.G1HTX4J-*$*5*E2A&G3ITZ<
45&%.G"*480A%*,(12C&*2221_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>wslogo02.jpg
<TEXT>
begin 644 wslogo02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M_#AT?Q9K?@FXT+PO9^#KN'6['6M^A>-/"WB_0].L[+QGH=^T-KK(M;=O.A6
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=3<I4YU<-A:5&I*FYQA-PE.#<7*$9.+3E&+NE_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #PP'5DD'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( #PP'5EED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001437749-24-027977-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-027977-xbrl.zip
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ME$EN BXI;&F&-4&6_1<^_P)02P,$%     @ /# =6?3C_E$;!   :B$  !4
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M>WC/(B2S1)9*\(P(?1?L88%^%+3:0:?56(O8/R0.\8@S H\P\W:7/QY'QYG
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MOO2>;!EY6K"7X#A4E]_YA*W,A[01>0E^V5K[SA\X>\);HV E:8!?@ND#4T4
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M3<J]K(NN^A4G%D/L(JBN=8C53>=L6_B+-A7VYX?#<_VA_\973_X'4$L#!!0
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MW5<4,CFOD(E(!9 2F=49V]X+#%;\HQB.59PEI?_-,%XR">;HO8_%$-@]EK[
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MO7.DQ5>X_L/;91Z_R G(E"C_YY,HN4BZO<Y_IA>@ *7#T@?/-X:-W1M,YO5
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MTITFVDDR*T. !F>E#_ G"WY<N_"SI "A"8\64:Y)V0Q<54$P+!&,1C*2',(
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M ;7%8#BGUH4A6N/#N5<_T8ZW#[-(Q1245%3;-4*&PIO*4RJJ1GH#)6EBL-1
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MS6]4RK K+@A+(Q4#,-\2G $7:- ,#.^G2:F;87/EQ-4P*C),-YJO?VV:JT/
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MZ<08-#[)C!R5]P$M4"^2HL!OU NKP_I>T_&Z/M=B2E%64+,N+C ?(*<#,-?
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M2O#6,8\E0T3E^5M$1N6>4\]HL]LZIH"QJVI=5?_&52$CW:5>-?U"\0L3DPJ
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M?I@I3+T?;0\BTU(:XBBX3%+M]2QL*([A<=#37-E_S<0TQ F%$A&4CV-]3L1
M>YA!<H3!?"M/MK"W&0&)J6MFNR?7B+Y"<LIIK/SX8-2E&$ $7L+1SL;M>B02
MJ8$1WH5PRG6SU"F;J0IF--,-8=E-3MD-OE%ZJ,Z%?KJRV["-P"AMHG+"?-F7
M\6Z'$!4;=V!!=')>$6MBGJ*R-52]'9BH:%%J.8&*82CO!B:^!9P3LVHI'6]_
MY;:7EYX*A5^^&.*'0\^"(SA_X$;$>#W=1=CWJ'/AMW'LDDX',PT2Z@.5UI8]
M<KO[:N-Z,9DX"5IJAU9NR^.X;EH!U%A6= KH03'BR5PAS+9$LBYC/2+I,4\L
M/ZZM;/B%[SIB_4H\SXDG*=EB 57K*GC&%/GH=3]S')A)53T0YQ#P3F)S0 2K
M#>8EM<(<!(BV3 @N?E2&\CF=YUQ'\>QOR#\%C Z#QLJO(8(TYIPSS:W*&;Z-
MI0^VP,&F@&A<)'*6:+S#T. =<I*.F& W#W%)C0U*B>DE*G/L7$,VR)N-%C)0
M6'[!XM Q+Y9:G1*?1UVR:FT@G+08VO8[5#*$@:ZZFP+]>P0R],@XPWF5&9(5
M4$ZX:F*IZEC@"=!+5>\"]9DN:4'!((!JD@EIL<9%,A#S1*4'8*)?FD0;%_*Z
M?6MO':V"\("_HM[( %=Z<SO>60+'8+#^2A!DK(;HU#&K<RY/'4A2)[8PB@K4
MX/ETX&\$ 5Q(#,K0^MXPL.ZHF']E<_:VF+\^*R<%"1V-^&[,0@PBH[TUVT";
M"1&TT0DJ+]H$E8U+4&D9V8_#R#!A0.12XY/V7BI\4ITDN)DLK:70QT.A%P4H
MD4DZU[YM=OVJ.CSMQUWLHM6$ZJEJQI:@6X)^2((..-9 V?;:.1+6+!BDU#\-
MRD8=1X!<BHE%3'.HNB7@EH#ODH Y5F%:3Z#WCFIM4P4%,YB7*UR#:)ZAHVV
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MD=N+F%S'R7='L1-1WW2U->0@UU[51B19<CQ1= 6#&WY#IZ:U>AK!BC@6IK:
M=%G0B+#P<PLS"AQLWML,\#1V4M@87G1?"L*_;=X%I^E3BH4J0[C@(A-3@:DS
MM)1A<O<96JL3M-2X97VEFI1VAQ6;;HI;V<:JU'Q1,3FG'KJIYRH7'JO_&6?#
MN'/73E2]?W?KM06ELD=@<\[QI\WV57.:P!H9!CZW':%T?SFJY YTP8*JB5IG
M0K]QB]\GBV35(,GS9'+SR517]:0J'&]OX,4ZPIV^ VQ0..OXGT]>+&U!>UMS
M:+##F1*W^*C@L>D5BB0)E^YB\!28 O[?LQ6JT#=-J3FAI6D7ZHBN@[?[=9.+
MC5)CF"[0JVYM_NKNNCM8.VLE%/_27I\[NC[]]OK<[/J0<;F!-Z8EH>^&A#)O
M7QE!1$/P?UDQ76)A8_OX+>6D[?5!>WGR]FGOV2_/X5=O-Y 27=Y]3XRZP4N-
MM-#O[H"$VWX%_[6[^^SNV+GV;;^DL[EGLJN1V-,O<5"$DAJ"D *?%%E *%V"
MH0^L:\$Z&C#K_=G]$=+]<*]?!N8UN+#V5>TA/>BK-H@S[NX24[QKSOC W/ @
MR,8^!_(QO'P91,9%PGE &$5WTGJRY=Q/>Q!^OKWS67;'[N!U=6WJR=N?EKV[
M_W-9L:'P\]W.I^^_VNLVS2E.9FDP?>WE:>&$L.]X=^[U>%IJJ,WGE=_;V]Y0
M:M@@?GY/FNX#\_/S!%.%(LF(P%(\>GZ]SNL>X%+N^*]V>QMZ*3?@1%H":+GR
M#Z1EG]DFY9F*>:K^&:\?DS>A?4?[CKM_QP9QKQ] IS3_H?RU<C!_:X]]"$E,
M!X!9"%-*C<!"@8P;7__4[72[/2Q[\BZ#"$5>?]?O=KOX'YV(%!2(- FS"GU*
M<^)/56DWIW+D6$H;<H,8SE[D0DN3+=7JN:SFW&%4J:Y!/:'NGKU^XZPV0-'9
M@#-I2:#5=7\<77<M:4%9GDH\&+F@!,4;;[>[3#ST_5Y_VW_U\L5Z4F+Y</2K
M'7_W1=_?L]\O'+$5-@_M]]Y0'K,!I_'X#W]G0P]_@P1,:X[@Y"PT$54J;Q&
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MLF/0 _;V?O:>)JFO0<A$)(;NA6=$*=_;PR>?&5>:XT0K&:X.)A EDL3$U^V
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M=.SWH=EW?$DI05/.NJMH,A@P:'.);V!H4Q&+&\LD(:,\WG@\3L77Q&#ETIF
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M7.7MKH\E+L-$.+M)Q"K&!4T%OC(!X\%M3UU=/AOKCJ.J4HGC6\P;):ODB#'
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M3_^+#V=_3>X/RC8<E 4L<)SOQB"SRC8_F07Y0;S$"^F$GYNH'&^?I@R\:[R
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M)Y$_-W8==DY,P<OR!!B(R5#@W04>RNW?S4[[=+L.O-#KC0[\!Z(6_>#[SE>
M'V_]3FWZ-GU E0A8-, )U', KZ[LZZ^-BKXJ%^)+XM\%<9Z&<P?'O8WRL/'^
MG;AS@6DV0N+9KXGO9>AU<<O%5.E2/K3.K7?G4S<:R7T/S/:J(Q/X6HI &*[7
M/*1VRJN5M<5KLK!4IJ;*1JZ1PXM47SVA1!OLB6Y5E]R-VN"O1I=?V!WI6#]I
M0S13O2K5>,YC];!X*B_Y.L=K'RF&&[-[R2>'P'XI0(-SR-Y($[3^8$%W!^&[
M)",,<B"PZUH=*.?F\!_.E;!7G9-VI^4=M(X/CC!8KU(]$!3!UXSS) K26R?-
MQ<E$ ]<+PSEVB)IA&W3@HY8O731:BZP;_JX(NZ$X,TBA71IUK8 '0)]I/UT@
M9R]--+_!]7''^_JX?7W<.NOCSI;>H<6Q/N;>_.ZG!],/6U'([C.-TK TBT$#
MIRO#!4++$96FT,+8WP#P19 ".Q.:6-VO>0J_EV3 QT3;NCKCY]GV[4EE3INQ
M;]V'[YOBVSW=VHU[4OG&)FQ<[S$'SLSX;-^>/:E$8JOWK$. D2T\9P^E\=RX
M/>L_9L]V0$$^">"_"1L'P(%7N7-/PL5OPL[UCWIRXVHZ3\D-O#D\*VZ@*GH^
MPPVLZK.YZ1OX).#Y9FS@Z:O>P"?Q]VW&!IZ]Z@U\&J/89NS@8TW-8RKWV<9=
MV_HHRJ-V35?4T-9UMW'KMCZ0\JBM*S*T;./.;7TD!0J:7Z6C\#3.B0W9.A6^
MO*"NNH6=Z[2KKKED>"M+^K?2/-GZJ J4GKW.,[<+<95^[9FK/V[<Z&H;8YA/
M8QK8D#U[3'J.*F7[V^L0;'TD!3;N":=M*UV!K8^>=)YPV+JKV+=I,!J%_O-O
MW8-KR0L#W=[=*Y9V;^G^/32 L@'[]Z&$:# V<*E/H!7FZ9*L^!Z&5PO#.]G#
M\#8-AO=L&.,?!S_=7/WRZ>+K;]?O;XA[??$0UG(X5@Y/QED'6"OY0^^$=$Z>
MI+E'I=:4&/DS#Q+,AJ@:60/X>S'$"KW.>:_G6HD4\03NPPF X5LO<Q#6#$A@
M+XTCQ$^2?".>>."'@7_GJT].?1]@QX!%'I?' ;RI8RH78FW'Y7PWAQW$(L.+
M1KG0FT,O3_W1HOH^>CM6C9&F!+CRP+_UPC%<?/!N9$&A#[A$WIQ'XEOX B_/
M;N-$++CX$Y<<7@(]#U!AY%$TO_-"W]7=CB^!=#I.(B@X-Z"!A<#H\XG5DX"L
MC^E.4M0 ID:L![$*%0@,,'_[KON=(W06_;M3O"&.N;'"SU>?+R^NWUU=N'!4
M633$[Z\^ 2]S==,&^0A\AERDI2:-^6+[2Q6?ZK<;?>P)0_AY_D/5@VE[#ZGT
M0:SU[)N3QF$P<I+)H-5V'?C/@=H*&N:;](W%L.$Z7VZ/WAV]Z-(]A\E5-64Z
M*\]B[Z58?D747+>!/Q;VGB3N_2R)>Q>9KLOWX@$6WE-K7YI=86LJT.)KS5G)
MO59_>\!-@X4Z?('PE3&.PS"^APMJ)JX.J)WCRV'H@3)513,Q_1:82N C(^Q:
M/?IAN^Z!C2MHZ GQ=YIIO3570@N[49:C&V9C0[^S4![86:PJEWR[OT%K\C7(
MPI=>C\[9YJS'.VQ57[4<CPQC]I9<JVN7M!=[>>?L05;(BK1(=4WP VRH9]B0
M=<IP(\N%*;^IW<4+G_SO?BJX7BLY<"M>XB5!B7I;]:7NE_4*6>M+$D3#8.:%
M9=EZ8$1WDU7.7F]O@MXND #NW&$B'?TAB#QQI,2):N1=[M5R [5<D)S7H9"U
M(,$E;[#L[9Y^KN-_V>OLE]39CV&6VO3SM;>55Z:4+Z)1(A[W<^A%?[RX3MZ-
MX[K7>7N=M]=Y&ZSS_CN8.A=AZ$=[A;=7>)NRB'N%MU=XZU)X/P>A\$2]8>9[
M^5[G[77>IBSB7N?M==ZZ=-YU,+SUDI'SC\1+HWA3TD"[<6[WRJ_!(C;4;8^+
MJNZ5WU[Y+?)PO;GSZY'S:SSWT[W.V^N\O<[;Z[S%6[S.29;TZ4K!?,^K66^"
M*;05$+_/_NTGKM"R>ZOR:6#ZYZH(6SF<7F@D$SP_*W;?>H$!O=A*_#S_@=[M
M\! :=\\N8D%52^OGG8/Z;^=L6;W+2PWIQ^"G"Q:MPR 2;QUF/[X)7J;BDHMB
M/U[<?#W4-;Z5!<;UA<.G-66SXA^L.VZS:?C3_P=02P,$%     @ /# =64>L
M4BYT P  !PT   T   !E>%\W,3@W-C(N:'1M[5=M;]LX#/Z\_ HN!W1?XB1V
MMS6+70/I*PY]0=#F<!\/LLW$PLF2)\EK<K]^E.*L398-PP%==\!]22Q2Y$,^
MHB@I*6TETJ1$5J2=5XGE5F"*R[^.PM'1^ZA/VF2P%G9>D?YU$, E2M3,8@'9
M"F9E(PO49ZI"F"IMF8  1H/HPR :1F_A<!R.QN_>P^0&@B!-*K0,\I)I@_:X
MV]AY,.JV4LDJ/.[.E:Z8#0JTF%NN9!=R)2U*FFU18%TJB<=2==-.,EC'G&2J
M6(&Q*^'-I0T,_P?'X;"VL1_.6<7%:OQFQBLT<(L/<*<J)M_$-2L*+A?C(9?0
M#[F,G==ZR]4W;?<!?6*:,VG'TN4@XHKI!9=CI^ZF!S(S=9P,ZK3S#8P=B!]!
ML+BT 1-\(<>:+TJ[#9EDZ?FRY!FW$!WVPV20I=_#_QDY_OH\YE1JJ+\B\E1)
M0QI0<_B=RKU&^J'A'2ZXH?FT%:9-)G@.DSQ7C;145G#!=?4KD/XO"-E"F)4(
M)XKIPF5_QC5M3*5-DNFT<\+5*2DXZQ$M>7_\TJG"P<=&V7@':2V,X1$//"!L
M(4(+"2TFK$'_1->!_.);!9:XX#)7NE;4 :D_N1:H<4XE('.G\C,F%=5'Y4QN
M51_"C:'VU=+:&4L=U,^AP05!PWT0]AS%.Z0ZD6HT61.FA<(WWANF\Q*BHQZX
M+MN#AY+3F"(334&I,PFXK 63C)9J!373;*%970(SFV!.554SN3KX;12%1S&9
M9%QPNW)JUW&Y;-#-9K!0KIA)EJ.6A,1M2;&8FLI@X\L1I 1?AY8QPB4N3(EH
MS;Z$F)>>88Y5AAH.0Y_%(45=N(^HU[(EO+\MYU]8\RY4C6LV38\T*O^[5(+.
M(M,F!?BQH91ZWG'.3 ESH1X,+;OV""ND<PC<5BZ^&XW[>AJ15!;-AO-V65A=
M>V]M!>QS)QLZ&]OIFS4/A\'5/HJHZI@P:K?T'BN-!(T!?_1ZC3L+W3JYU*-A
M?+XD:JPG(@IC%Y5I?+#[*K#_TMOV?XR?U\T'9C"]NH![:A%G'!>J!]?7TY=.
MZK] W!/&3NFN0$U$<O:<@)-FT1BZNWU8-_GGA'I^]K80"OX)<L&,.>Y>3^YG
MP71R>1Z<W)U/KMP-_(EV>GDQN]N1E?- JX>OA3D* =/+VS]N'M%HAGLH[/FC
M* ;NX4"W,_\ ^@Q02P,$%     @ /# =699 6WA;"0  VWH   T   !E>%\W
M,3@W-C,N:'1M[5WK4^,X$O^\_!6]+#,;JI*0%WE#%<O"U-;=L!0P=1^O%%M)
M5.O72#*/^^NO6[;S)H09B)-@"DCBR%*K7_JU+*F[0^TZI]TA9_;IWB]=+;3#
M3_GC?QOE9J->+>*WW:/HXMXO^/VOA0)\X1Z73',;>D]P-PP]F\L_?9?#M2\U
M<Z  S:,*_I8J-6BT2ZUVM05G7Z%0..VZ7#.PADPJKD_V0]TO-/?CJQYS^<E^
MWY<NTP6;:VYIX7O[8/F>YAZ6UMSAP=#W^(GG[Y_N=8\BFKL]WWX"I9\<<[NG
M"TK\C[>A7 IT!\R%/G.%\]2&S]]#7W?NA,L57/$'N/%=YD47.Q PVQ;>H TE
MX4&I6!9>!ZQ0*E^V@87:[U";P51#<;TS%7;&1!@:S,=[)@7S=-NC_CD=S1]U
M@3EBX+6E& QUQV5R(+PVE4>&]$XO'H>B)S3VHM$]ZIUVCX+3O6>:_WVF_=]7
M(6"JO<]>3P6=96W\7!<ME!^7<WT\9XX5.HS$#'X?+H6#_(=+SN&.]1S^4K_?
MA:;+OV^^PFVAO+-,O^$#H;2,N'ZKT8Q=+ C?R(A!#SG<<M1ZH04V?69I$DRY
M5:U"*M+(76))N'L*^.'."N0/X9\S:0N6A[\\JY@2HR\>&0K["GTP29ST(%$4
M5 ZFX#;@EN@+]/GH'856<(Y.'&M:MUPT>0;H^1+5]62_A,,#=YS8=8\^JX!9
MR>?7<_!!V'J(;TN?8CH*#N_KMAD#X@O&9[>340''11PX);ZA5QM'+*+ .]EO
MC9J/""Y$54,Y>.S$?2B8 FU0OB/LT46L@8:=GL.L?^+_<M#+E?) OX<=N.=2
M"XLYL51!^T$'XMIK]6+UDZ$+R5F?"AF?#>4VU>L\16K<BYF2N!TN48'&#F:D
M.U3F2!, H5=STR1#IYG8\[7V7</%B&VOX4WQ^-.(RT:L$]481D\H7$30&U 0
ME1\142U6QD1$JC1'Q4LTKEFXL<R>QM:^9N7"(6"1MCPOG(A=Q+C?2N:G,R.5
M6"B13!HDDM2X"N<.4PI28R[!^]=Q]T=5OU:L;YOJ$QY-2S(3"#DM$F["U^K&
MZRROEHKEG;E^Z.G4>#H:#-=E=>5ML[IKZ0>^0K20EHR^LD?AAFY:S?_=[W.)
M&#:M]J^EL#A<<YD6 =\\H=]WQ&^FX'<FM6H,CME@(/D 0_&TF.U/:MN8KH"4
M@*[ERH?K\%*U;?-2A UN)N7VK@RJKQ WI#22TJ1!6LHK)V>TTB*BSQ<JP=M'
MLW-&LT) NTY>H$DH#+FAAZ,'$_;[6\6V1=,7WT,32.],('ONNRY:GM*^]4\>
M B;AGCDAAX-2L50J0\ EJ"&3''*??VM6*J5.?,,MW6 NE3MK&5ZV*_2DP MJ
MQXV<_PKF;'SL5<G7JJU\J5+;AJ@')CH#<6_V3P\JQ5I]!^#HP7&^U6K17[%4
MRU4RA#?'(7)@I7*M42]]1'!WT&P>%^>[_D$AS;7D]\(/E?.4X9H/A6L,3,G@
M27KPY+T?Q[W%[.BJ-&X^**CGD2KZRQ!!A@AV Q$L7_<W9LODDL&$,1!S!F)&
M@"FR,"[819BP)M:EC!W6U$O4C<(EK9:UX3],TLHJ,U,6A-(:,L7!]W@\4^+W
M81)]C&9.%M203*#DJH>YVF'N>.MG4M8DC!%^&:0WO;*FKI**E"N=;9AQV49N
MO3&FV]1N;B;$VS5N_2SH2Y<?&1+,D&"&!%_NY22XRR<++H12H5E#'0;X'2W!
MYX]<6D*-EN0O I 9Z/L1T)?B,[5=&[$RT)>!O@ST9: O WT9Z,M WY)>_N"<
MW^Q$'R&^#.YE<WP9W,O@WN8H10;W,KCW\>#>[JQSSY!>^M-["=++U3. E\WG
MS71UJQ;.;P"_#BK%1GG7 =Y!/5\OM?*-X^/=6,*_)K9MTRJ^=6E2JY$M[<OF
M]C+$ER&^C5:G#X3XLBF];9K2>X?5]M5L*\82]FP3B'L'Y:C5*L7F2GAM=!SE
M\>QQE*_ERN1)BI4J6<1:%6+NW#J?3IM.3DJ"Z"22A8=*OH%&N,*V'9YM&ENH
MC.5*'(?6BJ7F.IC_\Z[JO7<5;J#+*.>;]7*QDCD-!Q8'=)GC6+=*MA*(DSF-
MC74:U4JS6,N<AG$:A#84_Y @(Z9MRE>\N3UD-OL6-DNAT8>VURNNC;7^&;[7
MT8R9I6:6^@:6>EQ=$L7OX2O-'V]Z;HTDJP5ES(@FYX1G<YJ^*P6/G7&"C*3\
M(N>Q/RORI-*FH7/)].(<$_)@KN1!<2GZ$RR!U7CRPF&W,6&CY!_K(^PZE"JD
M?"S:AV@>O%S/TW,$R8%6$#-'T7HDF@N1XW0;S ,2!WYPA6<D[(5NCTMZ!D&R
MI6-3$=RH<=H?IL!E3[2RB9Y@8!6T8!EC)<H39 LG- >M2JY"1U-;?>F[8$Y_
M!!4X0E,'S2=;W O4 UN!C[(7R!4F@3+**&9R>ZGBDD%J6Y1E^=1L>LIRH;1P
M39(V=&\<0]R^'^5W"D)))ZN3^*TDO0!*D;Z:.DFWSTW9&8TS3UX@?"%;5)YT
MB+G<;%7,4;EX,?MT\61)^R[H075#]>".1)X<IN]&QX_#Z,!Q2$[^!G/6=_)<
MTNQ(4'-;$D;U1.L>4;%,.BBZ8U3/@W <^A)=3VAA4;R9@>T[:/L%5,%"]!9Z
M3 E%_Z,B5,5+1"W:_6I*&B=G+R8G%SBAFJE^]!1VE3Y//\1=84?N8=Y0@P:@
M0FL8F5S"MS$-B21>Q7^J=^$>8.%93DC#]%OV0N#XX#WAJX+QJ6"[8*K+]\^D
M9ZI7/MX9,$JM.>^*)?\>"E+UA3YY\+Q/W@6)+=_@GJYSE>,\>82:#&1::*63
MV[Z>,]-I[U6$NVC CFX:N0C.T+',-Q'Y7M03A'.1VZ'RX_.W&988"KSU.?>"
M92+X:%PITAOAA9XCK(@TH4:TY3$"]-"U1J=\Y^.:+41U6NA0<Q63P O]B,C
METFFSZFE,(;*R&=&&,1EPB,B0B]@&)<M]M:+&#S1_;FSQV?ZN@M&L7S-T&88
MQ<A]H>8D:#/*(<DL"P--YJ%('X0>K@0O\V/ @%$-CQ%NHA(KHYP\DH>*J3">
M29 O0ZMU^5C9HKAX2N-F#)4&7#["&U/]54E6U>>T;-V!_3K:P& /+$IC=[+_
M[[/;N\+UV9>+PA\W%V?_HKS)$]]>?[F\NYFY-NP7I/\P?Y$F'.#ZR]6WK^/6
ML 0E?U[P@E0<43+HT^Z126K]?U!+ P04    "  \,!U9$%?S0IL[  !'>P$
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M*VE@&5E$5-7R!A<GSR<1J&*3)LO"%U_ 4F&:..?V.T=-'>5%C9,K%<USB)0
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M,90)#$W2LC(Y/S;3!=2ZIM*"ARPSK!)%XR?M,-?3BKV]64H7*PR.0H]34.+
M=N?IC-+$C>0%[],.9[+.@:?_W:A*PF7\AUPAA]:.(P)7.@C]%N(M\'(WUYMX
MKX-A>T1I?RW;G*K,?GA\?R^*>_._@(\?/-X[Z$^3&PPC] 0!B=]<G/R_8YP/
M_O"/MF_+I24;U#UD))%"5O,:M M&]1R&,+5Q[^Y+15X'(6DK9=(=(Z!'8\*<
M4)EM]]X><PE#;O<#_H1BY"W8&=&;.?Q%MGF;8K]5"F<QQLST:9Q+KC6%'J<J
M'U/ZV5B)[ZJ@RLQ)DX]KG?O%@^!?>4X#)O&LH'17- H=UK4E?4$&0%059KH4
M<]E.!B2;,;&5;DW,F*N&DI^5EFC"X!*X8I NV^X7D_O0/<.4A)>HN2(I@?M5
MQFE%!9X9B$N^5Z9%D> X<!W(L7]KBZMHM%G\6U$B'V+\!RU?9:6"<U701A1-
M[<3!$HF] H^8C#S43?P NBP5Y3U^1;V'"4M2,Q]-$VEQH]8Z=?K.RWH\XE^B
MF$]BH%5T563-##5*]%N@< 5+ X[CB@O@1I+K[DG]3T#4S76PN0XVU\'7Z!&_
M?TL>\?L;C_AGYQ&_-?7FQB6-^IX/,O&&/7ETZ-*;Q;44.-JTOJNTP\7B1?ON
MGK=A*=Z SIM+EB7ROE)P@^3B"CJU3L#FZ\-"6T8[HE4'LV^GRXAG*J#:KM^?
MT<?KH3CTUA1**5O;DV?+%6WV*.<(4R&WE/1[^7N,_HBU6>2/0^R-BQ*+/O60
M]27(U.DEZ4SR$*HV6'B/M=\QH@%$)_"-(@$R1M4"-,&9FYKQ_)>C$Q_XR(>[
MT5IZS(Y/S -AIS;IL/(^TAXD@>5H8#,I8<25F912!;MV(N60<YJK..M[9N37
M7:.F=SR(PG*$P#7:+8^X'M"F0<)VZ&IMB]S0.8NAZZ:5U&>AJ<EM86U2/Z>?
MPDH7/QE&HU<E2I?=::6\/U11M-,H'4@K3\[Z$0?AOSA)2J2$K>SW<]AELMWH
M!"9'1*>$X0>, ,$:;#\$A,6\Z@?&Z!Y8LJQT;:Z7?D)O#3>LM[8RU)(%ET(R
M9SX:D^(CUAAM&]-Q*<B47\S9!<U! BVD2!=1G3TW=WJ"A;UL1I+$$^@N9>M;
M84&2RS]&U%I\R:7P\D2*O'M.;U@&K=G8.;UMB()AE);R'10UA9^FM.JD?OH*
MW.L/ T;Y??C/.IY6[[]FEY?^K0!F:U:%91^VI#NXQ+JB6DY5Q1(ALH2IN6 >
MS%X]*"NO?AE_SRE"'X&;2^87HC&;S^-%%.322P)GF*&8R9N<&Q#VE@O<@%.S
M]-]-RLA;23R+IV)MDT\)\^3 Z(ZS>L%"7<7 ['_:1Q2&#JD>UKX;H6T]8TM#
M$3?-]P/"_&E_C\CEBE-,:,0]%W_-GP[:CVB\Q,L46+ MBE?L[<#2HOW=5:7K
M#CR*<[;:W](J@(.F4&J.A;^.07.L C(;5<(4>;OW:!P=-XN=EWE/RB*"#5WI
MM,4ED5CXDH'#B(W6!"-[^ SB:F7\GZ,I@3WIV[:EJ^'#+X[.+U#23<MXAJZP
M#!'?XBH*0$]PZ*KE31(*()OHF1\)YITNL+$W4;_H:3G/:6:5?KZRS\_I>2PH
M1  O :&)>V2?L4E#!0L$XBPFG=GS28=73-N]6>%P4I47')HU9.;&U")3:VU;
M"Z=E4A9Z+:V70:Z,@Z78QBNB\J6>U!L/JW6RZB(P8A_K.D5]C5U #$K_L<A'
M84J/8-6.&5W$+T%;I9AT7Z=P#"S!(H6J2S[6][X W_GV X),:3@+_+C)K2T:
MR$1TTXAJ%P#F:8 8=W#> \^)+N>JHA0I9 @REH3X3CWKQGW\L>[C![?D/GZP
M<1_?0??QND)_J=0_0[VJ0HR?Z(P$54O AS8&B"[K4/,5'A*+XCE;;7'T*V6#
MM:R-F@MIS1#7J8OD2Q*!RU))<_05QXU&P,QQM8PW<-]57K%_$.\?T:;AMQ?
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M/.$X5T53@0Z*Y=P>K4VMF%/![;<F/"'02!2I5! .?R<8R$<[?]MMP[9S:FO
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M@^5NU.&O8;URFK^%?]$9O,DZ_[BL\P>WE77^8)-UOC3KG+Y?8%Y8C=F[R.O
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M%V#1>S2&H,BL6?P^G36S_KF)4 SZ:TF?H1 2@0N?$\PO6S;'.RM^[H/XR1A
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M2?Q$H[("^?O#K0,0E2K/18R9O^M%,M9_=_'@6KJWENPR2YL9_G'P5Y2'<"+
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MY26H*0\E3(:F;Z'\.!;P!E/U]N+M0U .<XSX_]<!_8/[8"--*V"K=,__JK4
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M0_. S8+ Q/-.R6:LXG&2CQ$K52SP'D GEDZR/C!%L,VG"L&<C,5;+7-ADLJ
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M1V./B 2<)V^S^7+>/S<1L4$;"T'P#TL%N00HQ;CLNCE^L<+L#@BSG+$6".Z
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M0\^O39[C-[2PW<)1BUU]5YMKT!)R6&_X:U$VT>]E5C3Y*M;/MKLCFE7E0C<
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M=GAY.,+)*5 -JBHXQ @<5"91XT78%?_11FD0:T$4.E)'),T<I*=S\TTREVC
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MFQ*:U$(S:E%R4:5W-Y-LQ!E#"DN\RS$X!&E>EE>!3DK\ X9JT>;SA-E"A3;
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M&AX,E\_+Q(^R)TI+M>A5 <\$N3DQ0H9OH&@UGJ.=:=R=8%_="3:;W8<3;/
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M%1*:K#I5&X>G++[=G%FS*ZF5T1=;: D^S\E@US4YAH8:WF5_E 0E#]F@WO"
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MTK_NU!4UDL[ 'T3:2X3)RLMNYD5G-LL))8LPN5/*C>VDA71)2J-E256@;)F
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M;H$':[: 6A1$B/K<(1B>@#8UH06^&ML<F!DJ9J^_CWQV,<L@C&96.)6VQ)(
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M<)7HM:I$_?A25:U9HFQO= %2+(M"%;]9$X4.W;%N?B\ #]_=%>#ANQW@8>L
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M'VY0'SN*$PX/D1P]6,AC# 3AKD?2&^!F#B[CB*4J<6VALW8.T'"&)^E/5-<
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M[5^\/WP;QA]6 L#"H=U.<U,W6YLQQME*JTV?H?OC@\&#FGF_;MQOQ[>*P6<
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M^?*_;7(?+M?8(-TT?$*MA46WC:A.)Y$Q#@8'F*XX5U?4N4RQ\T!()Y$5<PP
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M.IJ8(&H#<0DXQN)((,? C0/:K(DXTI.5FL&FLQV<6Y@%H6^\MQXF!F>83\S
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M(!*].GY_.#Q[?3SL*3)Q\I+&+X]/L"+=^$LJG_?T=R/YZ'/*04_W_HAR4+N
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M5//]D=?9DL.G:<6HS*_<6? 'JTG'8Y7[7EBF96JF_P&F4+(^+D"H7*(S"V9
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M'A>X?%E^VN'2I0>9!3OC<YR1I7&E+!D(SE(O4MX75<7+MU;8SUEH/O'"B].
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MIYUN\$+Z%($V^S\ 4$L! A0#%     @ /# =64-P'\EF P  ;@T  !$
M         ( !     &)C9&$M,C R-# X,CDN>'-D4$L! A0#%     @ /# =
M6?3C_E$;!   :B$  !4              ( !E0,  &)C9&$M,C R-# X,CE?
M9&5F+GAM;%!+ 0(4 Q0    ( #PP'5D>JV3GR00  $8L   5
M  "  >,'  !B8V1A+3(P,C0P.#(Y7VQA8BYX;6Q02P$"% ,4    "  \,!U9
MC-?,MK4#  !*(   %0              @ '?#   8F-D82TR,#(T,#@R.5]P
M<F4N>&UL4$L! A0#%     @ /# =67/#D?-1T   )(L& !0
M ( !QQ   &)C9&$R,#(T,#@R-U]S,6$N:'1M4$L! A0#%     @ /# =64>L
M4BYT P  !PT   T              ( !2N$  &5X7S<Q.#<V,BYH=&U02P$"
M% ,4    "  \,!U9ED!;>%L)  #;>@  #0              @ 'IY   97A?
M-S$X-S8S+FAT;5!+ 0(4 Q0    ( #PP'5D05_-"FSL  $=[ 0 -
M      "  6_N  !E>%\W,3@W-C@N:'1M4$L! A0#%     @ /# =665^B5K5
M00  4X8!  T              ( !-2H! &5X7S<Q.#<V.2YH=&U02P$"% ,4
M    "  \,!U9>#\N6VB1   WK , #0              @ $U; $ 97A?-S$X
M-S<P+FAT;5!+ 0(4 Q0    ( #PP'5F20MB$D"T  'GR   -
M  "  <C] 0!E>%\W,3DP-C8N:'1M4$L! A0#%     @ /# =65.4'"3##
MJST   T              ( !@RL" &5X7S<Q.3(W,RYH=&U02P$"% ,4
M"  \,!U9B"N(R;,;  !W'   "@              @ %Q. ( ;&]G;S Q+FIP
79U!+!08     #0 - !\#  !,5 (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>bcda20240827_s1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcda-20240829.xsd" xlink:type="simple"/>
    <context id="d2024S1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d2024S1A" id="ixv-3822">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d2024S1A" id="ixv-3823">0000925741</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d2024S1A" id="DT">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="d2024S1A" id="ixv-42">BioCardia, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d2024S1A" id="ixv-53">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d2024S1A" id="ixv-60">23-2753988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d2024S1A" id="ixv-85">320 Soquel Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d2024S1A" id="ixv-89">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d2024S1A" id="ixv-91">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d2024S1A" id="ixv-93">94085</dei:EntityAddressPostalZipCode>
    <dei:EntityFilerCategory contextRef="d2024S1A" id="ixv-3834">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d2024S1A" id="ixv-3835">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d2024S1A" id="ixv-3836">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="d2024S1A" id="ixv-208">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140495715844976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">BioCardia, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">23-2753988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">320 Soquel Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity, Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity, Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000925741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>14</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bcda20240827_s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bcda.com/20240829/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcda-20240829.xsd</File>
    <File>bcda-20240829_def.xml</File>
    <File>bcda-20240829_lab.xml</File>
    <File>bcda-20240829_pre.xml</File>
    <File doctype="S-1/A" isOnlyDei="true" original="bcda20240827_s1a.htm">bcda20240827_s1a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>32
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcda20240827_s1a.htm": {
   "nsprefix": "bcda",
   "nsuri": "http://www.bcda.com/20240829",
   "dts": {
    "schema": {
     "local": [
      "bcda-20240829.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bcda-20240829_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcda-20240829_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcda-20240829_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "bcda20240827_s1a.htm"
     ]
    }
   },
   "keyStandard": 14,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 18,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 14
   },
   "report": {
    "R1": {
     "role": "http://www.bcda.com/20240829/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d2024S1A",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20240827_s1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d2024S1A",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20240827_s1a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.bcda.com/20240829/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
